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Abstract
Synthetic xenoestrogens have differential estrogenic properties. Research has shown that
exposures to xenoestrogens could promote breast cancer by disrupting normal function of
the human epidermal growth factor receptor 2 (Her2) gene. Although animal models
demonstrated a connection between xenoestrogen exposure and Her2 activity, no study
using human cells has systematically examined their carcinogenic potential influencing
the Her2 gene expression. Furthermore, breast cancer cells are phenotypically disparate
(ER+, Her2+), with some phenotypes (Her2+), leading to more aggressive disease. This
study aimed to dosimetrically assess the carcinogenic potential of commonly used
xenoestrogens influencing Her2 gene expression, and delineate cellular phenotypes at
greater risk of more aggressive disease. The study assessed whether the composition,
concentrations, and exposure duration of BPA, EE, NPH, and DDT significantly altered
Her2 copy numbers in estrogen and Her2 receptor positive or negative breast cancer
lines. Each line was randomly assigned to cases (exposed) and control (unexposed)
groups using a randomized block design. Fluorescent in-situ hybridization measured
Her2 gene copies. Mann Whitney, Kruskal Wallis, and Incidence Rate Ratios revealed
Her2 copy gains in all 4 xenoestrogens and receptor types with persistent exposures. A
44% increase in Her2 was observed in the normal ER and Her2 line, marking a shift in its
Her2 status, and a 30-times greater risk was noted in the Her2+ lines. These findings
promote positive social change by revealing all 4 xenoestrogens as risk factors for breast
cancer. This information can be used by breast cancer advocacy groups, health educators,
and steering committees to educate women and formulating policies.
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Chapter 1: Introduction to the Study
Introduction and Epidemiology
In 2011, the incidence and mortality for breast cancer in the United States were
220,097 and 40,931 women respectively (Centers for Disease Control and Prevention
[CDC], 2014). For 2015, is the American Cancer Society [ACS], (2015) estimated that
231,840 cases of invasive and 60,290 cases of in situ breast cancer would be diagnosed.
Regardless of race and ethnicity, breast cancer is the most common type of cancer found
in American women (CDC, 2014). In the United States, breast cancer is the leading cause
of death in Hispanic women and the second leading cause of death in women of all other
ethnicities. Currently, almost 2.9 million women are living with a history of breast cancer
in the United States (ACS, 2015; Surveillance, Epidemiology, and End Results Program
[SEER], n.d.). Breast cancer cases are further estimated to increase by 50% in the next 15
years in America (American Association for Cancer Research [AACR], 2015).
The global incidence rate of breast cancer was 1.7 million cases in 2012 (Ferlay,
Soerjometram, Dikshit, Eser, Mathers, ... Bray, 2014). Breast cancer is also the main
cause of death for women globally, with its worldwide mortality rates reaching 522,000
women in 2012 (Ferlay et al., 2014; International Agency for Research on Cancer
[IARC], 2013). In 2012, the global incidence and mortality for breast cancer rose
dramatically by more than 20% and 14% respectively compared to 2008 (IARC, 2013).
Additionally, 6.3 million women worldwide were found to be living with a history of
breast cancer diagnosed in the past five years (Ferlay et al., 2014; IARC, 2013). A
woman’s lifetime risk of breast cancer today has increased, from 1 out of every 11 found
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in the 1970s to 1 in every 8 women (ACS, 2013; Valeron, Pestano, Luzardo, Zumbado, &
Boada, 2009).
Financially, breast cancer accounted for $18.1 billion of annual health care
expenditures in the United States alone, ranking highest amongst all cancer care
expenditure for 2014 (National Cancer Institute [NCI], 2015a). Projections on the overall
cost of breast cancer care using current statistics, have suggested that they will rise from
$16.5 billion in 2010 to $23.24 billion in 2020, with the largest increments (40.9%) found
to be in breast cancer (NCI, 2015b). Furthermore, a trend analysis of indirect costs of
breast cancer, such as loss in time and economic productivity due to illness and mortality
are projected to rise from $52.4 billion in 2010 to $102.26 billion by 2023, a 95.2%
increase (Milken Institute, n.d.). Together, these statistics indicated that the breast cancer
incidence, mortality, risk, and financial burden worldwide are on the rise, making breast
cancer a public health concern.
Major risk factors known for breast cancer (e.g., genetic predisposition of BRCA1
and 2, parity, reproductive history, lactation, age at menarche) and the increased usage of
screening mammography only account for a third of all breast cancer cases (Aube,
Larochelle, & Ayotte, 2011; Buteau-Lozano, Velasco, Cristofari, Balaguer, & PerrotApplanat, 2008; Davis & Sieber, 1997). Lifestyle factors account for remainder (Aube,
Larochelle, & Ayotte, 2011). Current researchers have considered exposure to
environmental toxins as a lifestyle factor, and they have studied it as a potential risk
factor for breast cancer (Aube, Larochelle, & Ayotte, 2011; Rudel, Attfield, Schifano, &
Brody, 2007). Environmental toxins, such as xenoestrogens, have been partially blamed
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for the increase in breast cancer incidence (Aube, Larochelle, & Ayotte, 2011; ButeauLozano, Velasco, Cristofari, Balaguer, & Perrot-Applanat, 2008; Davis et al., 1997).
Estrogen and progesterone are two hormones that are required for normal breast
development and function, but their unregulated stimulation by extrinsic estrogen such as
xenoestrogens can de-regulate the cell-cycle and result in breast cell proliferation,
inducing carcinogenicity (Brown & Lamartinere, 1995; Murray, Maffini, Ucci,
Sonnenschein, & Soto, 2007; Recchia et al., 2004). Estrogen receptors (ERs) are
activated by ligands (e.g., estrogen, xenoestrogens), and with the help of many cofactors
and growth factors can regulate estrogen responsive genes (Arpino, Wiechmann,
Osborne, & Schiff, 2008; McKenna & O’Malley, 2002). Also, required for normal breast
development is human epidermal growth factor receptor 2 (Her2), a proto-oncogene,
which can mutate into its oncogenic state causing breast carcinogenesis. The Her2 protooncogene is found in two copies in the normal breast tissue, but in its mutated form there
is an increase in the gene copy numbers, also known as Her2 gene amplification or overactivation. In its mutated (amplified/overactive) form, it becomes into an oncogene (i.e.,
cancer-causing gene) inducing carcinogenicity of the breast tissue. These tumors present
an aggressive phenotype encompassing high tumor proliferation rates, metastasis, and
mortality (Gutierrez & Schiff, 2011; Slamon, Eiermann, Robert, Pienkowski, Martin,
Press, … Crown, 2011). Importantly, the estrogen receptor (ER) cross communicates
with the Her2 receptors at the cellular surface for normal function of the cell, these
signaling processes further activate Her2 gene within the nucleus of the cell (Her2 gene
expression) and the phosphorylation of the nuclear ER (Jung, Park, Jun, Kong, Kim,
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Kim, … Im, 2010; Stoica, Franke, Wellstein, Czubayko, List, Reiter, ...Stoica, 2003;
Yang, Barnes, & Kumar, 2004).
Biologically, estrogen signaling can occur by distinct pathways: genomic or
nongenomic. In the genomic pathway, the ligand activated ER binds to the DNA, which
further activates protein kinase (i.e., mitogen activated protein kinase [MAPK]) and
modulates genes that regulate cellular functions. On the other hand, the nongenomic
activity occurs within minutes after the formation of ligand (i.e., estrogen and
xenoestrogens) receptor complex. In the nongenomic pathway, ligand-activated ER with
the help of coactivators activates Her2, which then increases the phosphorylation of
MAPK and modulates the nuclear ER. This Her2-dependant kinase activity of the nuclear
ER is an important and essential component of normal regulation and function of nuclear
ER. However, unregulated stimulation of ER causes an increase in Her2 expression,
which then increases expression of coactivators, the MAPK kinase activity, and
phosphorylation of nuclear ER (Jung et al., 2010; Montemurro, Cosimo, & Arpino,
2013).
How the xenoestrogens act in biological systems was a conundrum for many
years. Only in the past decade or so has the research on their mechanistic properties
gained some momentum. It has been observed that upon xenoestrogenic exposures,
cellular ER gets activated within minutes, suggesting that xenoestrogens activate the
nongenomic response of the ER (Bulaveya & Watson, 2004). Research done on their
cellular membrane activity indicated that some xenoestrogens are slow-activators while
others react quickly and are fast-activators (Bulaveya & Watson, 2004; Payne, Rajapakse,
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Wilkins, & Kortenkamp, 2000). Similarly, nuclear transcriptional assays performed to
assess their potency showed that some xenoestrogens are very weak (e.g., DDE), while
others are somewhat weak (e.g., Bisphenol-A [BPA]), yet others are quite strong (e.g.,
Diethylstilbestrol [DES]) in their estrogenic activity (Silva et al., 2007). A couple of
studies indicated that exposures with two xenoestrogens or multiple derivatives of a
single xenoestrogen for a short time period (24 hours to 1 week) produce an additive
effect on cellular membrane activity (Aube, Larochelle, & Ayotte, 2008; Rajapakse, Ong,
& Kortenkamp, 2001). Together, these studies provided the insights that although
xenoestrogens are categorically grouped under one umbrella, their biochemical properties
are disparate and that react and interact differentially in biological systems.
Reporter gene assays conducted to study carcinogenicity of organochlorines
(OCs) indicated that 1-day exposure of normal mammary cells using nanomolar (nM)
concentrations increases the expression of a number of protein kinase genes, including
the Her3/ERRB3 kinase (Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009).
Interestingly, the structure of Her3 shows that Her3 itself does not have a protein kinase
domain and it has to bond with other Her family members, especially Her2 for its kinase
activity (Ross et al., 2009). A recent study showed that for a breast cancer cell line
(MCF7) that had only ERs, the proliferative effect of xenoestrogens (OC mixture) was
purely because of the estrogenic potential of the cells; whereas in another cell line
(CAMA-1) with equal numbers of estrogen and androgen receptors (ARs), the cellular
proliferation occurred due to the inhibition of androgenic receptors (Aube, Larochelle, &
Ayotte, 2011). This suggested that xenoestrogens respond and interact differentially to
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estrogen and androgen receptors. Studies conducted on xenoestrogens to assess their
carcinogenicity have been performed using short-term exposures (up to 1 week) mainly
with OCs and their derivatives (Aube, Larochelle, & Ayotte, 2011; Boada et al., 2009).
However, because the biochemical nature of xenoestrogens is disparate, it follows that
the carcinogenicity of xenoestrogens other than OCs, such as those commonly found in
household products (e.g., BPA, NPH, and EE), used individually as well as in
combination may be quite different from that of OCs. Additionally, breast cancer has
been observed to have a long latency period (Marsden, Wright, Carrier, Moroz, &
Rowan, 2012; Nadler & Zurbenko, 2013; Olsson, Baldetorp, Ferno, & Perfekt, 2003;
Paez, Labonte, Bohanes, Zhang, Benhanim, Ning, … Lenz, 2011), whereas the
aforementioned studies have only studied short-term exposures (24 hours to 8 days).
Furthermore, breast cancer cells have been found to be phenotypically different
(e.g., ER+, ER-, Her2+, and Her2-) making breast cancer a heterogeneous disease
(Montemurro, Di Cosimo, & Arpino, 2013). It has also been observed that for ERpositive breast cancers, specifically those with increased Her2 gene copies, the ERs
activate Her2 signaling and vice-versa (Montemurro, Di Cosimo, & Arpino, 2013;
Osborne, Zhao, & Fuqua, 2005). In Her2 and ER-positive (i.e., Her2+/ER+) breast
cancer cells; either Her2 or ER can function as the promoter of cellular proliferation and
survival (Wang, Morrison, Gillihan, Guo, Ward, Fu, ... Schiff, 2011). In this case, it is
biologically plausible that some breast cancer cell-types (e.g., ER+/Her2+) may have a
greater risk of breast carcinogenesis than others (e.g., ER-/Her2- or normal expression of
ER and Her2) when exposed to xenoestrogens.
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Some epidemiologic studies conducted on xenoestrogenic exposures suggested
that the risk of having a more aggressive type of breast cancer is to those women that are
ER negative, indicating that xenoestrogens are not only a risk factor for women that have
an ER-positive status, but also to those with an ER-negative status. In fact, women with
an ER-negative status had worse survival outcomes, and were resistant to therapy
(Gammon, Wolff, Neugut, Eng, Teitelbaum, Brinton, ... Santella, 1999; Rosenberg,
Zhang, Coogan, Strom, & Palmer, 2008). Importantly, Gammon et al. (1999) assessed the
Her2 status in women that were using over-the-counter contraceptive pills and the
researchers found that breast cancer aggressiveness and prognosis in these women were
positively associated with the overexpression of Her2 oncogene. These findings were
further supported by animal studies connecting an increase in Her2 and 3 expression
levels with exposure to OCs (Jenkins, Raghuraman, Eltoum, Carpenter, Russo, &
Lamartiniere, 2009). Another study found that increased Her2 gene expression causes
shorter breast cancer latency period and faster progression rates when the mice were
exposed with derivatives of DDT (o’ p’ Dichlorodiphenyltrichloroethane [DDT], and p’
p’ DDT) (Johnson, Ho, Cline, Hughe, Foster, & Davis, 2012). Collectively, these data
suggested that the mechanism underlying breast carcinogenesis with xenoestrogen
exposure observed in animal models may also correspond to that found in humans and
the critical assessment of Her2 is warranted.
Because breast cancer is a heterogeneous disease with a long latency period,
assessing the carcinogenic potential of the commonly used synthetic xenoestrogens in
relation to the Her2 gene, with multiple and prolonged exposures using different breast
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cancer cellular phenotypes, is important. In this exploratory research project, I aimed to
do exactly that. This study was intended to provide a model for gene-environment
interaction (GEI) that will aid in predicting the carcinogenic potential of four
xenoestrogens (BPA, Nonylphenol [NP or NPH], ethinyl estradiol [EE], and DDT)
commonly used in household products (e.g., plastics, oral contraceptives, pesticides) in
relation to the Her2 gene, as well as discern cellular phenotypes (i.e., ER+/- and Her2+/-)
that may be more susceptible to aggressive disease upon prolonged exposures (7 to 8
weeks), individually and in combination. The results from this research may impact
breast cancer risk factor assessment with xenoestrogen exposure/s, useful in decisionmaking for policy-level changes as well as advocacy purposes for its primary prevention
and discerning cellular phenotypes that may be at a greater risk of breast cancer
progression, which could be monitored for early intervention using biologically targeted
therapies for its secondary prevention.
Background
Historically, cancer has been known primarily as a genetic disease with a long
latency period (Barrett, 1993, Knudson, 2001; Pitot & Dragon, 1991). Both nonhereditary
(i.e., somatic cell) and hereditary (i.e., germ cell) cancers are caused by genetic accidents
(e.g., mutations) that disturb the cellular proliferation systems. However, a vast majority
of cancers (>70%) occur due to somatic cell mutations and are not inherited (Cornelisse
& Devilee, 1997; Knudson, 2001, Lee & Muller, 2010). Models of breast carcinogenesis
provide evidence that carcinogenesis is a multistage process, accompanied either by the
mutation/amplification of a proto-oncogene into its oncogenic form, or inactivation of a
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tumor suppressor gene [TSG] (Barrett, 1993; Lee & Muller, 2010; Leedham &
Tomilinson, 2012; Pitot et al., 1993). Her2 is a proto-oncogene that has been implicated
in breast carcinogenesis (Dressman, Baras, Malinowski, Alvis, Kwon, Walz, &
Polymeropoulas, 2003; Hynes & Stern, 1994; Jung et al., 2010; Slamon et al., 1989).
As a proto-oncogene, Her2 plays a pivotal role in cell-signaling processes for the
normal growth and development of the mammary epithelia (Akiyama, Ogawara,
Toyoshima, & Yamamoto, 1986; Slamon et al., 2011; Yardin & Sliwkowski, 2001).
When the Her2 proto-oncogene mutates (i.e., oncogenic form), it deregulates the cellcycle; which then initiates uncontrolled cellular proliferation of the mammary cells
(Gutierrez & Schiff, 2011; Slamon et al., 1989; Slamon et al., 2011). Her2 gene is a
member of the epidermal growth factor receptor (EGFR), encoding for a transmembrane
tyrosine kinase (TK), which is an enzyme that is important for cellular signal
transduction. This enzyme is a key regulator of normal mammary cell growth, but also
plays a critical role in the development and progression of cancer (Gutierrez & Schiff,
2011; Hynes et al., 1994). Mutation of the Her2 gene increases its gene copy numbers
with in the nucleus, also known as Her2 gene amplification. The gene amplification (i.e.,
increase in gene copy numbers) results in an increased production of Her2 receptors on
the cellular surface for which the gene encodes. Because amplification of the Her2 gene
(nucleus) directly results in the overexpression of the Her2 receptors (cell surface), the
gene amplification observed at the genomic level can thus be used as a proxy for the
overexpression of its protein product (Her2 receptors) at the cellular surface (Gutierrez &
Schiff, 2011; Slamon et al., 1989; Slamon et al., 2011). Additionally, the terms gene
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amplification, or the increase in gene copy numbers, and gene overexpression can be
used interchangeably in the case of breast carcinogenesis (Dressman et al., 2003;
Gutierrez & Schiff, 2011; McCormick, Lillemoe, Beneke, Schrauth, & Reinartz, 2002;
Meng, Tripathy, Shete, Ashfaq, Haley, Perkins, …Uhr, 2004; Slamon et al., 1989).
Empirical data revealed that Her2 is overexpressed in up to a third (30%) of
incident breast cancer patients (Bertucci, Borie, Ginestier, Groulet, Charafe-Jauffret,
Adelaide, …Birnbaum, 2004; Korkaya, Paulson, Iovino, & Wicha, 2008 Slamon et al.,
1989;; Slamon et al., 2011). The percentage of patients with Her2 overexpression has
been found to increase (by 40%) with higher disease stage and progression (Meng et al.,
2004). It has been widely demonstrated that when there is amplification or
overexpression of the Her2 oncogene, then the patient prognosis relates to a more
aggressive type of breast cancer with disease progression, tumor invasion, fewer diseasefree days, and worse survival outcomes lending to its poor prognostic value (Baselga &
Swain, 2009; Gutierrez & Schiff, 2011; Johnson et al., 2012; Lindemann, Resau, Nahrig,
Kort, Leeser, Annecke, …Harbeck. 2007; Slamon et al., 2011).
In vitro and vivo studies clearly showed that these exposures to xenoestrogens
promote (a) mitosis and changes in breast tissue morphology (Brown & Lamartinere,
1995), (b) nuclear activity (Murray, Maffini, Ucci, Sonnenschein, & Soto, 2007; Recchia
et al., 2004), and (c) cellular proliferation (Bulaveya et al., 2004; Mercado-Feliciano &
Bigsby, 2008; Recchia et al., 2004). Additionally, the kinases used in bringing about
these changes are estrogen receptor kinases 1 and 2 [ERK1/2] (Bulaveya & Watson,
2004). Interestingly, these cellular end-points and kinases overlap those when Her2 is
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amplified, inducing breast carcinogenicity (Ellsworth, Ellsworth, Patney, Deyarmin,
Love, Hooke, ... Shriver, 2008; Zhang, Wolf-Yadlin, Ross, Pappin, Rush, Laufenburger,
& White, 2005; Yang et al., 2004). Cross-talk between ER and Her2 receptors exists,
especially during breast carcinogenesis, and the cellular end-points with xenoestrogenic
exposures overlap those when Her2 is amplified. Hence, it is plausible that perturbing the
normal levels of estrogens with xenoestrogenic exposures further heightens this chemical
cross-communication between ER and Her2 thereby leading to Her2 mutation and its
oncogenic activation, inducing breast carcinogenicity.
Population-based studies assessing the risk of breast cancer with xenoestrogenic
exposures have employed methods susceptible to recall and other systemic biases. The
exposure assessment was conducted using interviews or self-reports and women may not
be able to identify these xenoestrogens correctly, thus leading to misclassification (Van
Hoften, Burger, Peeters, Grobbee, Van Noord, & Leufkens, 2000). Some studies have
used controlled that were suffering from benign breast disease or mammomegaly
(Stellman, Djordevic, Britton, Muscat, Citron, Kemney, …Gong, 2000; Zheng, Holford,
Mayne, Ward, Carter, Owens, … Tessari, 1999; Zheng, Holford, Mayne, Tessari, Ward,
Carter, … Hoarzham, 2000). Whereas some other studies used small (≤20) sample sizes
(Djorveck, Hoffmann, Fan, Prokopczyk, Citron, & Stellman, 1994; Falck, Ricci, Wolff,
Godbold, & Deckers, 1992). Furthermore, the unknown and the variables cannot be
controlled in epidemiological studies, thus making it hard to establish direct correlation
or causality between various xenoestrogenic exposures and mammary tumor outcomes.
Keeping these in mind, a more sensitive approach to assessing the carcinogenic potential
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of the xenoestrogens is necessary. Molecular genetics technologies, such as fluorescent
in-situ hybridization (FISH), provide a sensitive tool to observe and assess gene level
changes after xenoestrogenic exposures (Johnson et al., 2012; Press, Slamon, Flom, Park,
Zhou, & Bernstein, 2002).
Statement of the Problem
Synthetic xenoestrogens and their repeated exposure could chemically modulate
the promotion and progression of breast cancer (Aube, Larochelle, & Ayotte, 2013;
Brody & Rudel, 2003; Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). Breast
carcinogenesis is known to occur by the activation of oncogenes, or inactivation of TSGs
(Barrett, 1993; Lee & Muller, 2010; Pitot & Dragon, 1993). Patient data showed that the
Her2 oncogene is amplified (increased gene copy numbers) and overexpressed in almost
a third (20% to 30%) of incident breast cancer patients (Korkaya, Paulson, Iovino, &
Wicha,, 2008, Lee & Muller, 2010; Slamon et al., 1989; Slamon et al., 2011).
Additionally, a few population-based studies indicated that some xenoestrogenic
exposures leading to aggressive breast cancer were found in women with ER-negative
and Her2-positive status (Gammon et al., 1999; Rosenberg, Zhang, Coogan, Strom, &
Palmer, 2008). Because breast cancer cells possess differential cellular receptor
phenotypes, such as ER and Her2 (positive or negative) (Gutierrez & Schiff, 2011;
Slamon et al., 2011), it is possible that the carcinogenic potential influencing the Her2
oncogene may differ for various xenoestrogens within these receptor types, rendering
some phenotypes more susceptible to aggressive disease over others, and this also has not
yet been assessed.
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Furthermore, studies showed that xenoestrogens had an additive effect, but these
studies only used binary exposures at a single time-point for a few hours (48 hours) or
exposures to mixtures of OCs for a short time period (9 days) (Aube, Larochelle, &
Ayotte, 2008; Rajapakse, Ong, & Kortenkamp, 2001). However, cancer is a disease that
has a long latency period (Barrett et al., 1993; Marlow, Honeth, Lombardt, Cariatti,
Hessey, Piplli, … Dontu, 2013; Nadler & Zurbenko, 2013; Pitot & Dragon, 1993). Also,
most women are exposed daily to various xenoestrogens commonly used in household
products. However, no study to date has critically examined how the concentration,
duration, and type of xenoestrogen exposure influence the Her2 gene and, in turn, cancer
cell growth and proliferation in human cells. Additionally, prolonged, continuous (7 to 8
weeks) and multiple (3 to 4 xenoestrogens) exposures of commonly used household
xenoestrogens, such as BPA, NPH, estrogen and DDT, have not yet been studied using
human cells or cell lines.
Purpose and Objectives of the Study
Using an experimental case-control study design nested with in a randomized
block design (RBD), this research study quantitatively assessed Her2 copy numbers with
FISH technology on four phenotypically disparate human breast cancer cell-lines (ER
and Her2 positive or negative lines) after exposing them to differential exposures with
four commonly used xenoestrogens (i.e., BPA, NPH, DDT, and EE). Controls remained
unexposed to any xenoestrogen. Her2 gene copy numbers for the cases and controls were
counted and differences evaluated for statistical significance. The study determined the
relationship between Her2 copy numbers with increasing exposure concentrations and
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durations to various xenoestrogens applied individually or in combination to the celllines. This research produced molecular data that provide mechanistic insights on the
workings of this oncogene with differential xenoestrogenic exposures further assisting in
the evaluation of their carcinogenic potential and breast cancer risk assessment with the
various breast cell phenotypes.
The main objectives of this case-control study were to
assess the carcinogenic potential of commonly used xenoestrogens influencing
the Her2 oncogene and
to discern cellular phenotypes that maybe more susceptible to more aggressive
disease with xenoestrogenic exposures.
Theoretical Construct
Breast carcinogenesis occurs with the activation of oncogenes or the inactivation
of TSGs (Lee & Muller, 2010; Pitot & Dragon, 1993). Exposures to chemicals and
hormones, including xenoestrogens, can trigger the activation of oncogenes (Brody,
Tickner, & Rudel, 2005; Davis, Bradlow, Wolf, Woodruff, Hoet, & Anton-Culver, 1997;
Montemurro, DiCasimo, & Arpino, 2013). Her2 is a proto-oncogene, needed for normal
mammary cell development and function, but it can mutate and become oncogenic. Her2
oncogenic overexpression is noted in up to 30% of incident breast cancer patients
(Korkaya, Paulson, Iovino, & Wicha, 2008; Slamon et al., 1989; Slamon et al., 2011),
with the number of patients increasing by 40% with disease progression (Meng et al.,
2004). Mammary carcinogenesis is controlled by cross-talk that occurs between ERs and
Her2, forming a positive feedback loop for cellular proliferation, survival tactics used by
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tumor cells, and their invasion and migratory activities (Montemurro, DiCasimo, &
Arpino 2013; Osborne & Schiff, 2005; Wang, Morrison, Gillihan, Guo, Ward, Fu,
…Schiff, 2011). Her2 can interact with ER once the estrogen receptor ligand complex is
formed activating the Phosphoinositide 3-kinase (PI-3K) pathways (Jung et al., 2010;
Montemurro, DiCosimo, & Arpino, 2013; Stoica et al., 2003). Its increased expression
initializes the mitogen activated protein kinase (MAPK) pathway, which then relocalizes
more ER from the nucleus to the cellular cytoplasm, thus forming a positive feedback
loop for the Her2 amplification (Jung et al., 2010; Montemurro, DiCosimo, & Arpino,
2013; Yang, Barnes, & Kumar, 2004). Once activated, Her2 can take over this pathway
by homo-dimers or hetero-dimers with its other family members thereby activating an
autocrine loop, in which case Her2 becomes self-sufficient for its renewal (Fiszman &
Jasnis, 2011; Pinkas-Kramarski et al., 1998; Witsch, 2010).
The MAPK, also known as estrogen receptor kinase (ERK), is a protein found in a
cell that communicates a signal from the cell surface receptor to the DNA found within
the cell’s nucleus. The cell’s signaling is initiated when a ligand (e.g., growth factor,
hormone, or xenoestrogen) binds to the receptor and ends when the DNA in the nucleus
initiates transcription of a protein and produces a change in the cell, such as cellular
growth. Thus, it is a signaling pathway governing some of the key cellular processes,
such as proliferation, differentiation, and cell-survival (Duronio & Xiong, 2013; Fiszman
& Jasnis, 2011; Witsch & Yarden, 2010). The MAPK/ERK pathway includes many
proteins that communicate. When the proteins involved in the pathway have a mutation,
the signals sent to the nucleus go awry, which is a necessary step for carcinogenesis.

16
MAPK/ERK pathway is found to be de-regulated in various diseases, including breast
cancer (Duronio & Xiong, 2013; Orton, Sturm, Vyshemirsky, Calder, Gilbert, & Kolch,
2005).
Several pathways leading to breast cancer (e.g., radiation, estrogens, alcohol, and
diet) were initially hypothesized by Davis, Bradlow, Wolf, Woodruff, Hoe, Anton-Culver
(1993), one of these pathways also showed that xenoestrogens increase the estrogenicity
of a cell above normal levels and this leads to the mutation of genes found in the 17q loci.
Interestingly, the Her2 gene maps to this area (17q11.2-17q12) of the human genome,
and this pathway provided the theoretical construct for this exploratory research project.
The nongenomic and genomic action of ER and its cross-talk with Her2 buttress this
construct (Jung et al., 2010; Montemurro et al., 2013).
Xenoestrogens for the Study
Xenoestrogen selection criteria were geared towards products found in almost
every household across the globe or those that bio-accumulate.
Using the aforementioned criteria, the following xenoestrogens were selected:
•

DDT is an insecticide that was produced in large quantities (approx. 22
million pounds) in the United States in the mid-1900s. One of its important
properties is that it bio-accumulates. Due to this, even though DDT was
banned in the United States in 1972, it still persists in the environment. More
so, DDT is still being used as malarial vector control by many countries (e.g.,
India, Africa), and it can transported to other parts of the world from these
countries (Agency for Toxic Substances & Disease Registry [ATSDR], n.d.).
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•

EE is an estrogen used in almost all formulations of present-day combined
contraceptive pills. In the past few decades, the EE part of the pill has been
reduced from 100ug to 20ug. Small amounts (6ug) of EE are also converted
from 1 mg of norethindron acetate (NETA), which is a formulation used in
hormone therapy (Chu, Zhang, Gentzschein, Stanczyk, & Lobo, 2007).

•

BPA is a chemical used in making plastics and resins. Some of its mainstream
products that are used every day are plastic containers for storage, baby
formula bottles, soda bottles, plastic tubing used for various purposes, and
dental sealants. The chemical bonds that form BPA are highly unstable and
can degrade with normal use. Factors such as increase in temperature, pH, and
even time can break these bonds. When these bonds break, BPA can easily
enter the human body (Jenkins et al., 2009).

•

NPH or NP is a subset of alkyl phenols. It is widely used in industrial
detergents and surfactants, and is added to many consumer products like
pesticides, paper manufacturing, dry-cleaning, paints, household cleaners, and
cosmetics (Calafat, Kuklenyik, Reidy, Caudill, Ekong, & Needham, 2005).
Research Questions, Variables, and Hypotheses

Research Question 1: Do increasing concentrations of synthetic xenoestrogens
significantly increase the Her2 copy numbers?
Outcome/dependent variable: Her2 gene copy numbers
Predictor/independent variable: Concentrations of xenoestrogens (0.000nM or
unexposed control, .1nM, .01nM, .001nM) and Receptor types (ER and Her2 positive and
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negative).
Null (H01): There will be no significant increase in Her2 copy numbers with
application with increasing concentrations of xenoestrogens.
Alternate (H11): There will be a significant increase in Her2 copy observed with
the application of xenoestrogens with increasing concentrations.
Hypothesis 1: It is hypothesized that increasing the concentrations of the
xenoestrogens will increase Her2 copy numbers. It will also do so for each cell line or
receptor type.
Research Question 2: Do the concentration at which the increments in Her2 copy
numbers become significant vary between the four xenoestrogens?
Outcome/dependent variable: Her2 gene copy numbers
Predictor/independent variable: Xenoestrogenic exposures of BPA, NPH, DDT,
and EE using .1nM, .01nM, .001nM concentrations.
Null (H02): A significant increase in Her2 copy numbers occurred at similar
concentration levels for all four xenoestrogens (BPA, NPH, DDT, and Estrogen).
Alternate (H12): A significant increase in Her2 copy numbers occurred at
different concentration levels for all xenoestrogens.
Hypothesis 2: It is hypothesized that Her2 expressions will significantly increase
for the four different xenoestrogens at different concentrations.
Research Question 3: Overall, is there a significant increase in the Her2 gene
copies between short-term (5 days) and persistent/long-term (50 days) exposures to the
xenoestrogens?
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Outcome/dependent variable: Her2 gene copy numbers
Predictor/independent variable: Exposure duration (short-term: single, short-term
vs. multiple, persistent), and Xenoestrogen (BPA, DDT, EE, NPH).
Null (H03): No significant increase will be found in Her2 copy numbers between
the short and long term applications of xenoestrogens.
Alternate (H13): A significant difference in Her2 copy numbers will be found
between short and long term xenoestrogenic exposures.
Hypothesis 3: It is hypothesized that increasing the duration of xenoestrogenic
exposures will significantly increase Her2 copy numbers overall and for each categorical
xenoestrogen.
Research Question 4: Overall, does Her2 expression vary significantly with each
specific receptor type (i.e., cell line) upon exposure to xenoestrogens?
Outcome/dependent variable: Her2 gene copy numbers
Predictor/independent variable: Receptor types/Cell lines (ER+/Her2+, ER/Her2-, ER+/Her2-, and ER-/Her2+) and Exposure durations (single, short-term vs.
multiple, long-term).
Null (H04): Her2 copy numbers will not vary significantly between the different
receptor types/cell lines upon exposure to xenoestrogens.
Alternate (H14): A significant difference will be found in the Her2 copy numbers
between the different receptor types/cell lines upon exposure to xenoestrogens.
Hypothesis 4: It is hypothesized that differential Her2 copy number increase will
be noted between the different receptor types/cell lines when they are exposed to
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xenoestrogens. However, each cell line would show significant Her2 copy number gains
with multiple, persistent exposures compared to single, short-term exposures.
Operational Definition
Measuring the Dependent Variable
The dependent variable in this study was Her2 gene copy numbers. They were
measured after conducting FISH experiments by counting the number of orange signals
of the Her2 gene probe because each orange signal denotes a copy of the Her2 gene. The
Her2 gene copy number was quantified in its absolute value, that is, total Her2 copies
observed per nuclei (McCormick, Lillemoe, Beneke, Schrauth, & Reinartz, 2002). As
humans are diploid (i.e., have two homologous chromosomes in normal individuals;
Bilous, Morey, Armes, Cummings, & Francis, 2006), the increase of Her2 in its absolute
value will be greater than 2 copies of the gene.
Measuring the Independent Variables
•

Concentrations of the xenoestrogen/s were measured by their molar
concentration, diluted to nanomolar (nM) concentrations. The specific
concentrations used were .001nM, .01nM, and .1nM (Payne, Rajapakse,
Wilkins, & Kortenkamp, 2000; Rajapakse, Ong, & Kortenkamp, 2001).

•

Duration of application (one time application cultured for 5 days vs. daily
application for 50 days (Jenkins et al., 2009).

•

Number of xenoestrogens that were applied (exposed to1 xenoestrogen vs.
exposed to all 4 xenoestrogens) (Payne, Rajapakse, Wilkins, & Kortenkamp,
2000; Rajapakse, Ong, & Kortenkamp, 2001).
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Strengths
FISH technology was used to assess Her2 gene copy numbers, which provided
high-test sensitivity (95% to 97%) and specificity (97% to 100%) (Press et al., 2002),
thereby yielding a high predictive value (Mass et al., 2005; Olsson, Jansson, Holmund, &
Gunnarson, 2013; Sauter, Lee, Bartlett, Slamon, & Press, 2007). Specifically, in the case
of breast cancer, researchers have observed that the Her2 gene amplification or increased
copy numbers found at the level of the gene directly corresponded to its transcribed
mRNA and its protein overexpression (Dressman et al., 2003; Slamon et al., 1989;
Slamon et al., 2011). Thus, these study data cut across two biologic processes (i.e., Her2
oncogenic amplification and hence its protein overexpression). Because Her2
measurements are not hindered by the number of xenoestrogens used, it did not
overestimate or underestimate true values of xenoestrogenic exposures (Rajapakse, Ong,
& Kortenkamp, 2001).
This work was conducted in a laboratory, where the exposure types, amounts, and
durations were measured precisely, controlled, and monitored. In the realm of the
laboratory, this study was performed ethically using human cell-lines, whereas it would
be unethical to do so in human populations (Brody, Tickner, & Rudel, 2005).
Additionally, the Her2 probe-set is FDA-approved, which helped in the IRB approval.
Furthermore, the experimental design (Trochim & Donnelly, 2007, p. 158) increased the
validity of this study, because random assignment of the flasks was performed for the test
and control groups for each line.
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Lastly, this exploratory research was conducted in a laboratory using breast
cancer cell-lines. However, FISH experiments can be performed with fresh or archived
tissue samples (Garimberti & Tosi, 2010; Schruter, LeBrun, & Harrison, 2002) and FISH
reproducibility is high (Garimberti & Tosi, 2010; Press et al., 2002), making further
research possible using either prospective or retrospective study design to gather data at
the population level.
Limitations
Conducting experiments with cell-lines required extreme caution with respect to
how long the cell-lines had already been cultured and passaged in the bio-repository
before their receipt in the laboratory, as cell-lines with high passage numbers (> 40) can
easily change their genetic conformation in response to stress produced by the culturing
environment (American Type Culture Collection [ATCC], 2007). Due to this reason,
extra precaution was used when ordering the cell lines to make sure that the ordered lines
had a low passage number (< 40).
The cell repository had limited data on the lines, thus matching of data was not an
option for other breast cancer risk factors (e.g., age, parity, breast-feeding, diet, smoking,
and alcohol history). Another potential weakness could have been low yield of cells to
work with after treatment with various xenoestrogens, which would be technically
challenging. To combat this challenge FISH experiments were conducted using
interphase nuclei. Interphase FISH is performed without a high yield of actively dividing
cells (Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2012; Ohlschlegel, Zahel,
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Kradolfer, Hell, & Jochum, 2013; Olsson, Jansson, Holmund, & Gunnarson, 2013; Press
et al., 2002; Schruter, LeBrun, & Harrison, 2002).
Generalizability
Each normal healthy breast cell does have two copies of the Her2 proto-oncogene
(Akiyama et al., 1986; Slamon et al., 2011). However, because this research was
conducted using breast cancer cell-lines, the data were limited to cell-lines. Even so, the
lines themselves were derived from humans. Breast cancer cell lines selected were ERand Her2-positive or -negative because of the following reasons: (a) ER and Her2 are the
main drivers of breast carcinogenesis (Gutierrez & Stoica, 2011), (b) xenoestrogens
mediate their effects via ERs (Mercado-Feliciano & Bigsby, 2008; Stoica et al., 2003),
and (c) ER cross-communicates with Her2 receptors in breast carcinogenesis (Jung et al.,
2010; Stoica et al., 2003). Different combinations of these two receptor types (e.g.,
Her2+/ER- and Her2-/ER+) were taken into consideration in the selection of these breast
cancer cell-lines.
The four cell-lines used were MCF7, BT474, MDA-MB-231, and SKBR3, and
they had already been categorized as ER and Her2 positive or negative. The specific
classification for each line was as follows: MCF7 (ER+/Her2-) BT474 (ER+/Her2+),
SKBR3 (ER-/Her2+), and MDA-MB-231 (ER-/Her2-) (Chang, Chiu, Tseng, Chang,
Chien, Wu, & Lui, 2006; Johnson et al., 2010; Wang, LiU, Wu, Hong, Yang, Liu, ... Gu,
2010). The generalizability was limited beyond those receptors (e.g., insulin-growth
factor receptors, progesterone receptors, androgenic receptors) that are also found on the
cellular surface of a mammary cell.
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Significance and Social Change
Breast cancer still remains a public health concern (Aube, Larochelle, & Ayotte,
2011; Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). Synthetic xenoestrogens
are found in varying quantities in commercial products that are available quite easily
(e.g., herbicides, plastics, pesticides, contraceptives) to which women in all societies and
all over the world are constantly exposed (Cohn, 2011; Darbre & Charles, 2010; InifoNunez, Herreros, Eucinas, & Gonzalez-Bulnes, 2010; Kuch, Metzer, & von der Trenck,
2010; Qui, Suri, Bi, Sheng, & Fu, 2010; Vogel, 2009). If commonly available synthetic
xenoestrogens do increase the risk of breast cancer, their ease of availability needs to be
curtailed. Studying the risk associated with these compounds in relation to breast cancer
can provide clues that could lead to its primary prevention (Aube, Larochelle, & Ayotte,
2011; Boada, Zumbado, Henriquez-Hernandez, Almeida-Gonzalez, Alvarez-Leon, SerraMajem, & Luzardo 2012; Buteau-Lozano, Velasco, Cristofari, Balaguer, & PerrotApplanat, 2008; Davis et al., 1997). Thus, reducing the risk factors of breast cancer
would not only affect women, but also many families whose support structures they are.
This would not only translate in financial terms, but also emotional terms for many
children and husbands, who will not lose their mothers or spouses to breast cancer
mortality. Furthermore, as synthetic xenoestrogens are found all over the world, this
research would be far reaching, helping not only the immediate community in the fight
against breast cancer, but also the global community.
As cancer is primarily a multistage genetic disease (Croce, 2008; Hanahan &
Weinberg, 2011; Knudson, 2001; Vogelstein & Kinzler, 2004), integrating molecular
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technologies into risk assessment methodologies can provide a powerful tool for gaining
insights into oncogenic alterations that occur in response to xenoestrogenic exposures
(Bishop, 2010). Such oncogenic alterations offer the potential to understand the nature of
the deregulated oncogene leading to carcinogenesis, thereby improving understanding of
the molecular mechanisms underlying breast cancer pathogenesis and progression.
This research provides a model for GEI that will aid in predicting the
carcinogenic potential of four commonly used synthetic xenoestrogens influencing the
Her2 oncogene, a biomarker of breast carcinogenesis. Additionally, the study discerned
cellular phenotypes that are more susceptible to aggressive disease with these exposures.
Taken together, these results impact breast cancer risk assessment with xenoestrogenic
exposures and provide mechanistic insights useful in decision-making for policy-level
changes for its primary prevention and advocacy against the usage of xenoestrogens,
especially for those women that are at an increased risk of disease progression.
Definitions of Terms Used
Allele is one member of a pair of genes. It is located on a specific position of a
specific chromosome (Ellsworth et al., 2008).
Androgen receptors are responsible for the male phenotype. This nuclear receptor
is activated by the binding of testosterone and Dihydrotestoterone (i.e., androgenic
hormones) (Walters, Simanainen, & Handelsmann, 2010).
Bioaccumulate is defined as the increase in concentration of contaminated air,
water, or food in living things due to their slow metabolism or excretion (Environmental
Protection Agency [EPA], 2012).
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Carcinogenesis is the process of malignant transformation leading to the creation
of cancer (Barrett, 1993).
Catenin is a class of proteins that play an important role in cellular adhesion
(Zhang et al., 2005).
Chromosome carries hereditary information, is formed of condensed chromatin,
and is located in the nucleus of a cell (Akiyama, Sudo, Ogawara, Toyoshima, &
Yamamoto,1986).
Dimerization is the process when two molecules link via covalent bonding
(Tzahar & Yarden, 1997).
Endocytosis is the dissociation of dimers within the cell (Lenferink, PinkasKramarski, Van de Poll, Van Vugt, Klapper, Tzahar, …Yarden, 1998).
Estrogen (E2) is a female sex-steroid hormone (Tora, White, Brou, Tasset,
Webster, Scheer, & Chambon 1989).
Estrogen receptor (ER) is the receptor found in the cell through which estrogen
(ligand) mediates its effect (Tora et al., 1989).
Enzyme-linked immunosorbent assay (ELISA) is a colorimetric assay that uses
antibodies to identify the presence or absence of a protein (Engvall & Pearlmann, 1971;
Konecny, Meng, Untch, Wang, Bauerfeind, Epstein, …Pegram, 2004)
Fluorochromes are specific DNA sequences that are labeled with fluorescent
probe (Nitta, Hauss-Wegrzyniak, Lehrkamp, Murillo, Gaire, Farrell, …Grogen, 2008).
Immunohistochemistry is an assay that localizes antigens in cells of tissue-sections
using antibodies that specifically bind to the antigens (Press et al., 2002).
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Fluorochromes are specific DNA sequences that are labeled with fluorescent
probe (Nitta et al., 2008).
Immunohistochemistry is an assay that localizes antigens in cells of tissue-sections
using antibodies that specifically bind to the antigens (Press et al., 2002).
Isoform is when a protein exists in different configurations. They can be quite
similar to each other, but are not exactly alike, and can perform different functions
(Stoica et al., 2003).
Ligand is a molecule (e.g., hormone or growth factor) that binds to a specific
receptor forming a ligand-receptor complex? These ligand-receptor complexes are
important as they can modulate signal transduction and gene transcriptional activities of a
cell (Akiyama, Sudo, Ogawara, Toyoshima, & Yamamoto, 1986).
Homodimer is when the dimerization occurs with like molecules (Her2-Her2)
(Tzahar & Yarden, 1997).
Homologs are DNA sequences that have similarity, and share a common ancestry
(Vennstrom & Bishop, 1982).
Heterodimer is when the dimerization occurs with two disparate molecules (Her2Her3) (Tzahar & Yarden, 1997).
Molarity (M) is defined as the concentration of a solution expressed as moles of
solute per liter of solution (Brown, Le May, & Burstein, 2002, p. G-9).
Oncogene is a gene that causes cancer when it is mutated or over-expressed
(Barrett, 1993).
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p-arm is the short arm of the chromosome (Akiyama, Sudo, Ogawara,
Toyoshima, & Yamamoto, 1986).
Phosphorylation activates an effector molecule from its inactive state in order to
convert one form of signal (i.e., stimulus) into another (e.g., cellular growth) (Tzahar &
Yarden, 1989).
Proto-oncogenes are genes that are required for the normal growth and
development of cells and tissues (Barett, 1993).
Sensitivity measures the proportion of true positives that are correctly identified
by a test (Press et al., 2002).
q-arm is the long arm of the chromosome (Akiyama et al., 1986).
Specificity measures the proportion of true negatives correctly identified by a test
(Press et al., 2002).
Southern blot is an electrophoretic technique used in genetic testing. It is used to
separate sequences of DNA that have been digested with enzymes which breaks the DNA
into fragments. These fragments are then blotted onto a membrane and hybridized with
labeled probe to detect the fragment containing the gene of interest (NCBI, 04).
Tumor Suppressor Genes (TSGs) are required for the cell-death (apoptotic)
processes of a normal cell (Barrett, 1993).
Ubiquitinization is a process that modifies and degrades proteins (Zhang et al.,
2005).
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Summary
Research data from in vivo, in vitro and some population-based studies have
established that xenoestrogens are a risk factor for breast cancer (Bulaveya & Watson,
2004; Charlier, Albert, Herman, Hamoir, Gaspard, Mevrisse, & Plomterix, 2003;
Gammon et al., 1999; Johnson et al., 2012; Maras et al. 2005; Recchia, Vivacqua,
Gabriele, Carpino, Fasanella, Rago, ...Maggiolini, 2004; Warner, Eskenazi, Mocarelli,
Gerthoux, Samuels, Needham, ...Brambila, 2002).
The designs of population-based studies pose technical challenges for exposure
measurements as they are riddled with recall bias and misclassification, the variables
cannot be controlled to establish causality or direct correlation between exposure and
tumorigenesis, and conducting randomized trials to gather population-level information
with xenoestrogen exposures is not an ethical option, but a costly one to detect low-level
risk (i.e., less than twice) incurred by xenoestrogens. However, because most women
around the globe are exposed to xenoestrogens, studying the risk that they pose and
modifying these risk factors will have a great public health impact even though they only
account for low levels of relative risk (Aube, Larochelle, & Ayotte, 2011; Brody,
Tickner, & Rudel, 2005; Johnson et al., 2012).
The carcinogenic process occurs primarily due to activation of an oncogene or
turning off a tumor suppressor gene. In the case of breast cancer, empirical patient data
provide evidence that the Her2 oncogene is activated in up to 30% of breast cancer
patients (Gutierrez & Schiff, 2011; Slamon et al., 1999; Slamon et al., 2011).
Additionally, the percentage of patients with Her2 oncogenic activation grows by an
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additional 40% as the cancer progresses to the next stage (Meng et al., 2002). Current
reviews for xenoestrogenic exposures-related breast cancer have now marked the
epidermal growth family and its receptors (HER) as one of the risk factors for breast
carcinogenesis (Fucic, Gamulin, Ferencic, Katic, & von Krauss, 2012).
Further, a population-based study strongly suggested that the Her2 oncogene is
activated with xenoestrogenic exposures and these patients mostly are ER negative, but
their breast cancer was more aggressive with a shorter latency period (Gammon et al.,
1999). Studies using mouse models showed that Her2 gene is activated upon
xenoestrogenic exposures (Aube, Larochelle, & Ayotte, 2011; Jenkins et al., 2009), and
the activation of the Her2 gene causes accelerated tumor progression (Jenkins et al.,
2009; Johnson et al., 2011). These studies further buttressed the hypothesis that similar
processes of carcinogenesis maybe are occurring in both humans and mice, making it
imperative to study the carcinogenetic potential of xenoestrogens for breast
carcinogenesis in relation to the Her2 gene using human cell with different phenotypes.
This research project determined that significant (p = .000) increase in the Her2
copy numbers did occur with persistent xenoestrogenic exposures, occur in all receptor
types (ER and Her2 positive or negative), and with all four categorical xenoestrogens
(BPA, DDT, EE, and NPH) in individual and combined exposures. These gains in Her2
copies occurred at nanomolar concentrations (.001nM) for all four xenoestrogens.
Chapter 2 reviewed existing literature and discussed how some research has suggested
an association between Her2 overexpression with xenoestrogen exposure. The chapter
began with a description of models and theory of carcinogenesis that provided the
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foundation and the theoretical framework for this study. A brief overview of estrogen, its
receptors, and Her2 family of receptors is provided. A detailed discussion of the Her2
oncogene itself and its oncogenic potential specifically for breast carcinogenesis, as well
as the chemical connections found between ER and Her2, which play a pivotal role in
breast carcinogenesis followed. The chapter also discussed the sensitivity and specificity
of different technologies used in the assessment of Her2 gene. Finally, the chapter ended
with an in-depth discussion of the research performed (laboratory and population-based)
on xenoestrogens and breast cancer along with their outcomes, and discussed
implications of past research for future work.
Chapter 3 described the methodology used in this project to answer the research
questions. Further, it discussed the use of nonparametric analysis as a means to analyze
the relationship between the dependent variable (Her2 oncogene) and the independent
variables (differential concentration and durations of exposures with individual
xenoestrogen as well as a combined exposure of all four xenoestrogens). The chapter also
included a description of the cell-lines, experimental protocols, ethical considerations,
measures, and analysis of the data.
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Chapter 2: Literature Review
Introduction
This literature review established the need for research in the area of
xenoestrogenic exposures, especially with respect to how persistent and combinatorial
exposure influence oncogenic expression of Her2 in relation to breast cancer. The review
encompassed the current knowledge of the carcinogenesis process and Her2 as an
oncogene for breast cancer, which provided the theoretical construct of this proposal.
Because xenoestrogens have estrogenic properties, the review provided a broad overview
of the ER and the cross-communication between Her2 and ER. I discuss the properties of
xenoestrogens, especially the research done using animal models that has shown Her2
gene activity upon xenoestrogenic exposures. The review then ends with the main focus
on the epidemiologic studies conducted using xenoestrogens, mainly organochlorines and
pharmaceutical estrogens, and a summary providing the existent gaps that need to be
filled by continued research such as this one.
The papers and some books used for this review were either accessed
electronically through databases such as Pubmed Central, Medline, Google Scholar,
Partners Healthcare Library, and Academic Search Premier (Walden University), or they
were obtained from various books and journals that the Cytogenetics Core Laboratory at
Brigham and Women’s Hospital (BWH) subscribes to. The terms used in the various
databases were xenoestrogens, breast cancer, estrogen receptor, EGFR2, Her2-neu or
Her2/neu, Her2, and Her2 oncogene. The search was conducted in English. Primary
articles were also obtained from review articles found using the above terms.
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Carcinogenesis
The Process
Cell-division is a process by which normal cells reproduce in tissues. Under
normal circumstances, this process is tightly controlled by genes and chemical
messengers, such as growth factors and hormones that relay messages to specific genes
(Duronio & Xiong, 2013; Park & Lee, 2003; Sherr, 1996). When genes guarding the celldivision processes undergo genetic changes either by mutation, amplification/increase in
gene copy numbers, or chromosomal translocations, genetically aberrant cells are formed
and the cell-division process is perturbed, which leads to uncontrolled cellular
proliferation and differentiation resulting in carcinogenesis (Collins, Jacks, & Pavletich,
1997; Knudson, 2001; Sher, 1996; Valente, Gray, Michalak, Pinon-Hofbauer, & Scott,
2013; Vogelstein & Kinzler., 2004). Cancer is principally a genetic disease of somatic
mutations with a latent phase of up to 30 years (Anderson et al., 1992; Barrett, 1993;
Knudson, 2001; Nadler & Zurbenko, 2012; Vogelstein & Kinzler., 2004).
Models and Mechanisms
Carcinogenesis occurs in multiple steps (Barcellos-Hoff, Lyden, & Wang, 2013).
Cancer initiation occurs when genes controlling either normal cellular growth and/or
death (i.e., apoptosis) undergo genetic changes (i.e., mutation) forming genetically
aberrant cells and its progression occurs when the genetically aberrant cell multiplies and
further undergoes a series of genetic changes (Armitage & Doll, 1954; Fearon &
Vogelstein, 1990; Lee & Muller, 2010; Moolgavaskar & Knudson, 1981). Carcinogenesis
occurs due to an accumulation of genetically altered clones arising from a single
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transformed cell that undergoes secondary and/or tertiary changes (Croce, 2008; Hanahan
& Weinberg, 2011).
Mechanisms for carcinogenesis are characterized by three stages. First, initiation
is an irreversible change in a cell, usually genetic. Genetic changes can be amplification,
mutations, chromosomal rearrangement, or aneuploidy. Second, promotion is the process
by which the initiated neoplastic cell divides resulting in its clonal expansion. Third,
progression marks the irreversible onset from benign to malignant form (Barrett, 1993;
Hilton, Graham, & Clarke, 2013; Pitot & Dragon, 1991). Figure 1 depicts the steps of the
carcinogenic process.

CARCINOGENESIS PROCESS

INITIATION

PROMOTION

PROGRESSION

Carcinogen
Genetic
mutation

Normal
Cell

Aberrant Cell
Formation &
Division

Another
mutation

Another
mutation

Malignant Cell
Malignant
Tumor
(after 3-6
mutations)

Figure 1. The process of carcinogenesis. The illustration shows the genetic events
occurring with exposures to carcinogen/s leading to the conversion of a normal cell into a
malignant one.
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Histopathology on breast tumor sections bears evidence to the multistep processes
of carcinogenesis (Xu et al., 2002). For example, dysplasia occurs during the initial
stages of breast cancer in which only the cellular morphology changes without
metastasis, and carcinoma marks its later stages; here the cancer has metastasized to other
organs (Barett, 1993; Hartmann et al., 2014; Pitot et al., 1993; Virnig, Tuttle, Shamliyan,
& Kane, 2010; Xu et al., 2002). Ductal hyperplasia is when the cells of the mammary
duct are proliferating at a faster rate than normal, but the cellular structure and form (i.e.,
cellular morphology) remains normal (Wagoner, Laronga, & Acs, 2009; Xu et al., 2002).
Atypical hyperplasia occurs when the cellular proliferation and morphology become
deviant from the norm and this is a precursor of carcinoma in situ (Hartmann et al., 2014;
Virnig, Tuttle, Shamliyan, & Kane, 2010). Carcinoma in-situ occurs when there is
uncontrolled cellular proliferation and the cellular morphology is abnormal, but these
cells are still within the tissue itself. Invasive carcinoma occurs when the cells from the
carcinoma in-situ have starting invading other tissues or have now metastasized to the
surrounding tissue/s. In this specific case the abnormal/cancerous cells are now not only
in the mammary duct but have also metastasized to other parts of the breast and lymph
nodes (Virnig, Tuttle, Shamliyan, & Kane, 2010; Xu et al, 2002).
Two classes of genes are involved in the process of carcinogenesis: oncogenes
and tumor-suppressor genes (TSGs). Both these types of genes provide different cellular
responses (Gutierrez & Schiff, 2011; Lee & Muller, 2010). Proto-oncogenes are the
normal counterparts of an oncogene and are required for normal growth and development
(e.g., the Her2 proto-oncogene is necessary for normal breast growth and development;
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Slamon et al., 2011). Proto-oncogenes promote normal cellular growth in numerous
ways. Some proto-oncogenes produce hormones or mitogens effecting signal
transduction, whereas others produce cellular receptors and are sensitive to hormones
(Anderson, Reynolds, You, & Maronpot, 1992; Croce, 2008; Gutierrez & Schiff, 2011).
The proto-oncogene can mutate into its oncogenic form with excessive or continued
exposure to chemicals or ligands, such as hormones and xenoestrogens (Barrett, 1993;
Davis et al., 1999; Montemurro, Di Cosimo, & Arpino, 2013). The transformation of a
proto-oncogene into its oncogenic (e.g., Her2) form confers a growth and survival
advantage to the cells that carry the mutated gene. Due to this growth advantage, the
mutated cells accumulate over time leading to tumor formation (Bishop, 1991; Croce,
2008; Gutierrez & Schiff, 2011; Lee & Muller, 2010).
Contrastingly, TSGs control the cell-death processes of an abnormal or mutated
cell, and when TSGs become dysfunctional they cannot block the cancerous cells from
growing, thus the cancerous cell loses its capacity to senesce and keeps on proliferating
(Lee & Muller, 2010; Valente et al., 2013). Usually, both oncogenes and TSGs are
required in tumorigenesis (Barrett, 1993; Croce, 2008, Lee & Muller, 2010; Vogelstein et
al., 2004). This has been observed in the case of breast cancer where p53, a TSG is
deleted, and Her2 an oncogene is overexpressed simultaneously in patients suffering with
the disease (Ismail, Aly, Khaled, & Mohamed, 2009). TSGs are also known as anticancer
genes, because inserting TSGs suppresses uncontrolled cellular growth and induces
normal morphological characteristics in neoplastic (i.e., cancerous) cells (Huang et al.,
1988; Valente & Strasser, 2013).
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Another contrasting feature of TSGs when compared to oncogenes is that while
oncogenes are dominant, meaning a single mutational event can activate them; the TSGs
are functionally recessive requiring a “two-hit” inactivation process, meaning that genes
found in both of the chromosome homologs must undergo a mutational event in order for
the TSGs to become inactivated. This process is known as the Loss of Heterozygosity
(LOH). In the case of oncogenes, the mutation is a somatic event; whereas in TSGs this
event can either be somatic or inherited or both (Knudson, 1971; Knudson, 1973; Lee &
Muller, 2010). The proteins coded by the TSGs suppress the cell cycle and/or promote
cell senescence or both by deregulating the signaling pathways. The diverse functions of
the TSG proteins can be categorized as follows:
1. Repress gene expression required for cell division when a cell’s DNA is
damaged and cannot be repaired (Lee and Muller, 2010).
2. When DNA damage occurs and cannot be repaired, TSGs then initiate
processes of programmed cell death (apoptosis and autophagy, a type of cell
death were cytoplasmic processes engulf a cell is found to be controlled by
p53, a TSG) (Sherr, 2004; Maiuri, Malik, Morselli, Kepp, Criollo, Mouchel, ...
Kroemer, 2009; White & DiPaola, 2009; Hotchkiss, Strasser, McDunn, &
Swanson, 2009).
3. Some TSG proteins maintain contact inhibition and thereby suppress
metastasis. Contact inhibition is a process by which normal cell arrest their
cellular growth and proliferation when they come in contact with other cells.
These processes are found to be lost in cancerous cells (Partanen, Nieminen,
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& Klefstrom, 2009; Hirohashi & Kanai, 2005; Beltrami, Kim, & Gordon,
2013).
4. Mutations in the DNA repair proteins are also categorized as tumor
suppressors because mutations in the DNA repair genes increases cancer risk
(Brady, Jiang, Johnson, Jarvis, Kozak, … Attardi, 2011; Valente & Strasser,
2013). It has also been observed that mutation rates increase with decrease in
DNA repair genes, this further leads to inactivation of additional TSGs and
the activation of oncogenes (Markowitz, 2000; Saal, Gruvberger-Saal,
Pearson, Lovgren, Jumppanen, Staaf, … Borg, 2008; Valente & Strasser,
2013).
Presented below are the main features of oncogenes and tumor suppressor genes in a
tabular format.
Table 1
Main Attributes of Oncogenes and TSGs
Oncogenes

Tumor Suppressor Genes (TSGs)

Dominant

Recessive, Loss Of Heterozygosity (LOH)

Gain of cellular function (e.g., proliferation)

Loss of function (e.g., programmed cell death)

Somatic origin

Somatic or inherited or both in origin

Note: Self-made on Microsoft Word, 2007, using cited information on Oncogenes and
TSGs.
Loss of TSGs increases chromosomal instability and the life of a cell in normal and
transformed human cells (Dalton, Yu, &Yang, 2010). Some oncogenic mutations may
also disrupt the normal apoptotic processes of a cell, thereby leading to initiation,
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progression, and metastasis (Angelini, Fluck, Pedersen, Parra-Palau, Guiu, … Arribas,
2013; Shortt & Johnstone, 2012). Contrastingly, other oncogenic changes promote
apoptotic processes hence promoting selective proliferation and survival of certain cells
by blocking programmed cell senescence of these cells thus immortalizing specific clones
of cells that have the growth advantage (Lowe, 2000; McDonnell, Deanne, Platt, Nunez,
Jaeger, McKearn, … Korsmeyer, 1989; Vaux, Cory, & Adams, 1988). Comparative
genomic technologies have also revealed genes are duplicated or deleted in cancers
corresponding to the amplifications found in oncogenes and deletions of TSGs in the
human genome (Bell, 2010)
Cancer is also a latent disease. Cancer latency has been studied in mouse and
human models. Marsden, Wright, Carrier, Moroz, & Rowan (2012) injected tumor cells
from bone marrows of mice with breast cancer into mammary fat pads of normal mice;
which resulted in tumor formation in the disease-free mice in two months after injection.
These tumors were found to be highly metastatic as tumors were also observed in
kidneys, lungs, and livers of the normal mice. Olsson, Jansson, Holmund, & Gunnarson
(2013) had performed DNA analysis on 17 women suffering with breast cancer, who had
undergone radiation therapy. Studying the S-phase (Synthesis phase of the DNA
replication cycle), they found that the median S-phase index for radiation induced tumors
was 14%, corresponding to a median latency period of approximately 22 years. The
researchers found that a high S-phase index correlated to a shorter latency period and
vice-versa for a low S-phase index.
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Nadler & Zurbenko (2012) developed a model called the Weibull Model
Extension to study cancer latency. This model uses survival analysis curves to estimate
cancer latency. This model is assumption free and relies only on the hazard distribution
of cancer development, thus making it a flexible model to study cancer latency. Using
this model for various cancers, they found that pancreatic, lung and liver cancers have
short latency period (range: 8.5-13.5 years), whereas other cancers such as myeloid
leukemia, stomach, melanoma, and breast have the longest latency period (range: 22.8-30
years).
Human Epidermal Growth Factor Receptor 2 (Her2)
Attributes, Role in Development, & Interactions with Her Family of Receptors
Human epidermal growth factor 2, also known as Her2, Her2-neu, or ErbB2 is a
proto-oncogene, and that plays a critical role in signal transduction for the normal growth
and development of the breast tissue. The Her2 gene encodes for the Her2 receptor
protein. It belongs to human epidermal receptor (Her) family. The Her2 protein is one
member of a family of closely related proteins, composed of Her1, 2, 3, and 4 (Lupu, R.,
Cardillo, Harris, Hijazi, & Rosenberg, 1995; Slamon et al., 2011; Yardin & Sliwkowski,
2001). After a ligand binds to the Her receptor, the receptor binds to another receptor
closely related or similar in structure, a process called dimerization initializing
phosphorylation, activating signal transduction processes, resulting in various cellular
processes such as cellular growth and proliferation. When the receptor binds to a similar
receptor, it is called homodimerization; and when it binds with a closely related receptor,
it is heterodimerization (Ghosh, Narasanna, Wang, Liu, Chakrabarty, Balko, … Arteaga,
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2011; Tzahar, Waterman, Chen, Levkowitz, Karunagaran, Lavi, … Yarden, 1996).
Biochemical research showed that these receptors interact with a wide-range of growth
factor ligands. The ligand and the receptor form ligand-receptor complexes and modulate
signal transduction and gene transcriptional activities of a cell (Akiyama, Sudo, Ogawara,
Toyoshima, & Yamamoto, 1986; Gutierrez & Schiff, 2011).
Ligands of the EGF family of growth factors binding to the various Her family of
receptors fall into the following 3 categories: a) EGF and heparin-binding (EGF-HB)
bind only to Her1/EGFR (Aceto, Duss, MacDonald, Meyer, Roloff, Hynes, & Alj, 2012;
Higashiyami, Abraham, Miller, & Klagsburn, 1991), b) Betacellulin (BTC) binds to Her1
and 4 (Riese et al., 1996; Emede, Kostler, & Yarden, 2010), and c) Neu differentiation
factors (NDFs), like Heregulin bind to Her3 and 4 (Aceto et al., 2012; Plowman et al.,
1993; Witsch, Sela, & Yarden, 2011). Although Her2 itself does not have a ligandbinding site, but it alone can partner with all of the other receptors of the Her family (i.e.,
Her1, 3, or 4) forming dimers and inducing receptor tyrosine phosphorylation (DeFazioEli, Strommen, Dao-Pick, Parry, Goodman, & Winslow, 2011; Emede, Kostler, &
Yarden, 2012). Further, Her3 does not have a kinase site, and requires Her2 to activate
the phosphorylation process in order to achieve its cellular end-point (Emede, Kostler, &
Yarden, 2012; Fisman & Jasnis, 2011; Tzahar & Yarden, 1998). In fact, Her2 is the most
preferred co-receptor for dimerization found in Her receptor family (Graus-Porta, Beerli,
Daly, & Hynes, 1997; Fiszman & Jasnis, 2011; Emede, Kostler, & Yarden, 2012). Her1,
3, and 4; especially Her1 and 3 compete to dimerize with Her2 (Aceto et al., 2012;
Pinkas-Kramarski et al., 1998). By way of its association with different Her family
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receptors and dimerizing with them, the Her2 molecule has achieved a wide array of
signals transmitted into the cell. Her2’s fluid dynamics have achieved many more cellular
processes (e.g., proliferation, invasion, migration) compared to any of the other Her
molecules (Emede, Kostler, and Yarden, 2012; Fiszman & Jasnis, 2011; Tzahar et al.,
1997; Witsch et al., 2010). In fact, heterodimers formed with Her2 are more stable and its
signaling is more potent compared to any other homodimers or heterodimers formed
within the Her family of receptors (Emede, Kostler, & Yarden, 2012; Fiszman & Jasnis,
2011; Karunagaran, Tzahar, Beerli, Graus-Porta, Ratzkin, …Yarden, 1996).
Another important characteristic of the Her2 molecule is its slow rate of
endocytosis, and furthermore they are recycled to the cellular surface where they become
active all over again, resulting in increased activity sustained over a much longer timeperiod and is proposed to play a role in breast tumorigenesis (Lenferink et al., 1998). Her
family receptors’ mitogenic index examined by its proliferative capacity has shown that
Her2-Her3 heterodimers have the highest mitogenic potential followed closely by Her1Her2 (proliferative index of 10.5 and 9.6 respectively), when compared to all of the other
Her family homo and heterodimers (proliferative index ranging from 0-5). Further, these
hetero-dimers (i.e., Her2-with 1 and 3) have been found mostly in breast carcinomas.
Interestingly, it was also observed that Her2-Her2 homodimers do possess some
mitogenic potential (proliferative index of 3.5) even though they do not have any ligandbinding domain (Ghosh et al., 2011; Pinkas-Kramarski et al., 1998). This property of
Her2 may have important implications, especially in the case of breast cancer where
these ligandless receptors could induce a positive feedback loop for phosphorylation
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resulting in cellular proliferation without any outside stimuli also known as the autocrine
loop (Aceto et al., 2012; Witsch, Sela, & Yarden, 2010). Proximity Ligation Assays
(PLAs) detects the formation of protein-protein complexes in a single molecule. PLAs
performed on 321 patient tumors detected Her2-Her2 and Her2-Her3 complexes
allowing for the in vivo detection of these molecules, a significant association (p =
<.00001) was noted between homodimerization (Her2-Her2 complex) and gene
amplification of Her2 (Spears, Taylor, Munro, Cunningham, Mallon, Twelves, …
Bartlett, 2012).
Aceto et al. (2012) studied the role of Her2/Her3 activation as a unit in breast
cancer. They induced normal mammary cells with Her2 and Her3 vectors, Her2, and
Her3 vectors. Normal mammary cells with empty vehicle were used as the control. After
culturing the cells for two weeks they performed a3D morphological analysis of the
culture revealed that the normal cells formed small round structures and so did the cells
that only had Her3. But, most of the cells (~70%) with Her2 alone became larger
structures, and almost all of the cells (~90%) that were co-expressing Her2 and Her3
showed complete lack of polarity; which characterizes highly invasive cellular structures.
Because the Neu gene was initially found in rat neuroblastoma, and later, its
normal counterpart was discovered in rats and humans, thus, work done in rat models
could bear important implications for the human (Hung, Schechter, Chevray, Stern, &
Weinberg, 1986; Witsch, Sela, & Yarden, 2010; Yamamoto et al., 1986). Her2 homologs
are also involved in the origin and development of erythroblastoma in chickens (ErbB)
(Vennstrom & Bishop, 1982; Witsch, Sela, & Yarden, 2010).
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Her2 gene and protein
The Her2 proto-oncogene spans a 190 Kilobase (Kb) region mapped to
chromosome 17q11.2 - q12, encoding a 185 kilo Dalton (kDa) trans-membrane
glycoprotein (Emede, Kostler, & Yarden, 2012). A healthy breast cell has two copies of
this gene (Akiyama, Sudo, Ogawara, Toyoshima, & Yamamoto, 1986; Witsch, Sela, &
Yarden, 2010). When activated, Her2 initiates the tyrosine kinase activity which results
in a signal that is sent from the membrane of the cell where these receptors (i.e., Her2
protein product) are located to its nucleus. This signal transduction ultimately leads to
gene activation and various other cellular processes depending on the dimerization
molecule involved with Her2 (Fiszman & Jasnis, 2011). Basically, Her2 sends control
signals to the nucleus from the membrane, thereby instructing them to grow, divide, and
make repairs. It has great networking capabilities and kinase capacity, which makes it a
potent activator of cellular functions (Fiszman & Jasnis, 2011).
An initial correlation study on the Her2 gene and its protein product was
performed by Slamon et al. (1989) on 51 samples breast cancer that over-expressed Her2
using Southern, Western, Northern blots and IHC to assess the gene amplification, RNA,
and the protein status respectively. The correlation between gene amplification and its
over expression was found to be significant (p = <.0001). In all 51samples (100%), two
of the three measures (i.e., Western blot, Northern blot, and IHC) used to assess the
protein product showed concordance with its gene amplification. Complete concordance
was observed in 46 samples (90%) by all three measures. The discordance in the
remaining four samples occurred due to a dilution factor in Western blot; where the
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tumor sample is mixed with normal stroma. Another study by Dressman et al. (2003) also
performed expression profile analysis of Her2 amplification in primary breast tumors
which showed a significant correlation between gene amplification and its protein
expression (r = 0.76, p = .005), further validating that the high expression levels is
occurring due the amplification of the Her2 gene in breast cancer.
Her2 Oncogene and Breast Carcinogenesis
Amplification or copy number increase of the Her2 oncogene in breast cancer
leads to genomic instability (Ellsworth et al., 2008; Szasz, Li, Eklund, Sztupinzki,
Rowan, Tokos … Kulka, 2013). Genomic instability leads to increased cellular
proliferation, and motility/migration (Asrani, Keri, Galisto, Brown, Morgan, Ghosh, …
Winkles, 2013). These factors further translate in to tumor invasiveness and metastases
(Laurin, Huber, Pelletier, Houalla, Park, Fukui, … Cote, 2013; Johnson, Seachrist,
DeLeon-Roderiguez, Lozada, Miedler, Abdul-Karim, & Keri, 2010), as well as increased
angiogenesis and decreased cell death (Konecny et al., 2004; Ye & Lu (2010).
Her2 Amplification and Genomic Instability
Amplification of the Her2 can be used as a proxy for the lack of stability in the
entire genome. Ellsworth et al. (2008) investigated the changes found in the entire
genome in relationship to the Her2 copy number status in patients suffering from
invasive breast cancer.
Her2 copy number changes were assessed by FISH in 181 patients (n = 181). The
FISH uses the centromeric as well as the Her2 gene probe. The number of signals of the
centromeric (CEP), and the Her2 probe were analyzed and compared. An amplification
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was defined when the ratio of the Her2 vs. CEP was >2 signals. For allelic imbalances
spanning the entire genome micro satellite markers (two markers per chromosome) were
used. Allelic imbalance (AI) was determined using the following criteria: when a given
marker showed less than or equal to 0.35 allelic ratios. Co-relation between Her2 status
and AI was done non-parametrically. Non-parametric assessment does not confer to any
assumptions (Cubash, Hanish, Schuz, Neugut, Karsdaedt, … Jacobson, 2013; Paxton,
Chang, Courneya, & Pierce, 2012; Siegel & Castellan, 1988, p.34) thus making them less
stringent, however, since they digress from tight associations or assumptions they are
more flexible to accommodate complex data-sets as they can grow along with its
complexity. Mean allelic levels for Her2 positive patients were significantly more when
compared to patients that were Her2 negative (27% vs. 19% respectively, p = <.005).
Also, stratifying by chromosome regions, Her2 positive tumors had more AIs.
Additionally, AI patterns downstream of the Her2 gene (i.e., 17q12 to q21) using markers
D17S250 and D17S579 found in this area showed that half of all Her2-positive tumors
had allelic imbalances for both markers. This area has other genes of importance in breast
cancer (e.g., TPO2A, BRAC1, and BRCA2). This indicates that many genes from the 17q
area of the genome are altered in Her2 positive tumors.
Amplification of the Her2 can be used as a proxy for the lack of stability in the
entire genome. Ellsworth et al. (2008) investigated the changes found in the entire
genome in relationship to the Her2 copy number status in patients suffering from
invasive breast cancer. Her2 copy number changes were assessed by FISH in 181 patients
(n = 181). The FISH uses the centromeric as well as the Her2 gene probe. The number of
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signals of the centromeric (CEP), and the Her2 probe were analyzed and compared. An
amplification was defined when the ratio of the Her2 vs. CEP was >2 signals. For allelic
imbalances spanning the entire genome micro satellite markers (two markers per
chromosome) were used. Allelic imbalance (AI) was determined using the following
criteria: when a given marker showed less than or equal to 0.35 allelic ratios. Co-relation
between Her2 status and AI was done non-parametrically. Non-parametric assessment
does not confer to any assumptions (Cubash et al., 2013; Siegel & Castellan, 1988, p.34;
Paxton, Chang, Courneya, & Pierce, 2012) thus making them less stringent, however,
since they digress from tight associations or assumptions they are more flexible to
accommodate complex data-sets as they can grow along with its complexity. Mean allelic
levels for Her2 positive patients were significantly more when compared to patients that
were Her2 negative (27% vs. 19% respectively, p = <.005). Also, stratifying by
chromosome regions, Her2 positive tumors had more AIs. Additionally, AI patterns
downstream of the Her2 gene (i.e., 17q12 to q21) using markers D17S250 and D17S579
found in this area showed that half of all Her2-positive tumors had allelic imbalances for
both markers. This area has other genes of importance in breast cancer (e.g., TPO2A,
BRAC1, and BRCA2). This indicates that many genes from the 17q area of the genome
are altered in Her2 positive tumors.
Szasz, Qiyuan, Sztupinszki, Rowan, Tokes, Szekely, ... Kulka, J. (2013)
conducted another correlation study using ER+, PR+, and Her2+ tumors to evaluate the
correlation between genomic instability with respect to receptor status. The researchers
assessed chromosome instability in 4 genes (FOXM1, TOP2A, TPX2, AURKA) also
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known as CIN4, using gene expression arrays in 186 tumor samples. Receptor positive
cells were defined using IHC for ER and PR positive status, and Her2 was measured
using FISH. The level of CIN was defined by the patient’s clinical outcomes (size,
vascular invasion, necrosis, disease-free survival). It was observed that ER+ and PR+
tumors had an inverse relationship with CIN4 expression (p=.001 and .017 respectively);
whereas the Her2 expression and amplification correlated inversely with the CIN4
expression (p =.001 and .013 respectively). These results show that ER-negative and
Her2-positive expressions are associated with increase in CIN4 expression and worse
clinical outcomes.
Cellular Proliferation, Migration, Invasion, & Directional Persistence
Her2 amplification can induce cellular growth and migratory activities.
Dimerization activated via ligands recruits different partnering molecules in a signaling
cascade which relay different types of messages to produce various cellular responses,
and each message is specific for a particular response.
In a large study, Zhang et al. (2005) ingeniously provided for the cause and effect
relationship in biological systems using mass spectrometry (MS) together with woundhealing assays plus fluorescent imaging to decipher phosphorylation of effector
molecules, cellular proliferation and migratory response. First, to determine the activation
or deactivation of effector molecules (clusters of peptides) a Human Mammary Epithelial
Cell (HMEC) line with normal Her2 expression, a Her2 over expressed line, and serafree control were used. All were stimulated with EGF (100ng/ml) or HRG (80ng/ml) (i.e.,
ligands), and their phosphorylation sites compared with MS. The MS data-set projected
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different molecules with increased or decreased phosphorylation levels. When Her2 is
amplified it activates and deactivates various effector molecules providing regulatory
functions for the internalization, degradation, and recycling of the receptor. Decreased
phosphorylation leads to decreased ubiquitinization of the receptor. Ubiquitinization is a
process that modifies and degrades proteins; its decreased activity marks an increase in
time before the receptor is degraded.
Second, cellular proliferation was quantified in all three lines using tritiated
thymidine uptake after the stimulation with ligands. Only the Her2 over-expressed was
noted with significant increase in cellular growth compared to the control (30,000 &
40,000 CPM with HRG and EGF treatments respectively vs. 15,000 CPM in control, p =
<.05). Third, quantification of cellular migration models by wound healing projected that
cellular migration is highest with EGF stimulus when Her2 is over-expressed.
Interestingly, the Her2 over-expressed line always showed increased migratory activity
(0.3 inches in 6 hours) when compared to the parent line (0.1 inch in 6 hours). The results
of this study provide evidence that increased expression of Her2 is the driving force for
cellular proliferation and migratory response. Hence, Her2 may not only be involved in
the cancer initiation, but also its progression.
Aceto et al. (2012) performed migration assays using normal mammary cell line
(MCF-10A) induced with Her2, Her3, or Her2 and Her3 vectors. Control had empty
vehicle as vector. These assays showed that a significant number of cells migrated with
Her2 alone (three and a half times more than the control, p = <.003), but a much greater
number of cells migrated when Her2 and 3 co-expressed (5 times more than the control, p
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= <.002). Another recent study by Asrani et al. (2013) found that the fibroblast growth
factor-inducible 14 (Fn14) , a member of the Tumor Necrosis Factor (TNF) receptor
super family is also over expressed in breast cancers that over express Her2. This growth
factor increases the migratory and invasive capacity of Her2 over expressed tumors. In
transgenic mice, Her2 directly induces the expression of Fn14. Carrying this forward on
human breast cancer cell line (MCF7) transfected with Her2; the researchers found that
the human line also has increased Fn14 and MMP9 expression. Ablation of Fn14
expression with siRNA (RNA sequences that silence the expression of specific genes)
decreased the migratory and invasion response even when Her2 was being over
expressed and suggested that Fn14 is an important downstream effector molecule for
Her2 in its migratory and invasive cellular response.
Tumor metastasis is a two-way process requiring not only cell movement, but also
cellular invasion. Her2 has shown to play a pivotal role in the invasion processes of
breast carcinogenesis. Kumar et al. (2000) investigated Her2 mediated cellular migration
and invasion using cell-lines with or without Her2 receptor. Using time-lapse
photography the researchers examined cellular processes produced by cell-lines in the
presence and absence of Her2 receptors when exposed to EGF family peptides (i.e.,
NDF, BTC, and EGF). It was observed that in the absence of Her2, the cellular migration
was comparable to the control. Exposing the cells with Her2 not only increased the
tyrosine kinase activity compared to the control, but the increment was much more
prolonged (>2 hours) when compared to a transient peak (30-40 minutes) found in the
cells without Her2. Also, the migratory response started almost immediately (~5 minutes)
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in lines with Her2 receptors. A reduction in cell-to-cell contact was noted within a halfhour, leading to tissue breakdown and hap-hazard cellular movement; whereas cells
without Her2 receptors failed to participate in migratory processes, maintaining their
original cell-to-cell contact. The cells without Her2 did not invade the basement
membrane at all with any of the treatments.
Johnson et al. (2010) highlighted one such mechanism is the activation p120
Catenin, which further induces activation of Rac1. The expression of p120 mRNA was
found to be four times more in Her2/Neu-positive mice mammary tumors compared to
the wild type tumors (p = <.001). Performing migration and invasion assays using Her2
over expressing human breast cancer lines and the same lines were silenced for p120
Catenin using shRNA (silences target genes by RNA interference) showed that both
cellular migration and invasion was significantly reduced (80% reduction, p = <.05) in
the silenced lines even though these lines over expressed Her2. The Rac1 expression was
also reduced by half (p = <.05) in the p120 Catenin silenced lines. These experiments
indicated that Rac1 activated metastatic response of Her2 positive breast cancer required
for the activation of p120 Catenin, and that p120 Catenin is the mediated the Rac1
metastatic response when Her2 was over expressed.
Catenin using shRNA (silences target genes by RNA interference) showed that
both cellular migration and invasion was significantly reduced (80% reduction, p = <.05)
in the silenced lines even though these lines over expressed Her2. The Rac1 expressed
was also reduced by half (p = <.05) in the p120 Catenin silenced lines. These experiments
indicated that Rac1 activated metastatic response of Her2 positive breast cancer requires
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activation of p120 Catenin, and that p120 Catenin is the mediator of the Rac1 metastatic
response when Her2 is over expressed.
Aceto et al. (2012) studied the effects of Her2 and Her3 co-expression and
cellular invasion in breast cancer. Their research revealed that when Her2 and Her3 coexpress, this increases the expression of IL-8; a critical factor that is involved in the
invasion, migration, and proliferative processes of Her2 over expression. They performed
invasion assays using normal mammary cell line (MCF-10A) and induced it with Her2,
Her3, or Her2 and Her3 vectors. Control was induced with empty vehicle. Although
Her2 alone showed an upward trend for the invasion assays, but it did not reach
significance. The invasion assays only reached significance when Her2 and 3 coexpressed (three fold more than control, p = <.002). Furthermore, gene expression
profiling of Her2 and Her3 co-expression using an Affymetrix array platform identified
80 genes that were up-regulated forming the Her2/Her3 unit gene signature. Of special
mention here is the increased expression of IL-8, which was up-regulated the most (11
fold). Gene ontology analysis using Ingenuity® software showed that Her2/Her3 gene
signatures are enriched with pathways involved in cellular motility, invasion, migration,
proliferation, apoptosis, and signaling. Interestingly, IL-8 was found to be involved in all
of the aforementioned processes. To further confirm this finding whether IL-8 induces
cellular invasion, they treated normal mammary cells (MCF-10A) with increasing
concentrations (10ng/ml to 50ng/ml) of IL-8. Control was unexposed. Results revealed a
positive linear relationship between increasing concentrations of IL-8 and induced
invasiveness in the normal mammary cells. Twenty percent cells were found to be
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invasive at 10ng/ml of exposure of IL-8, reaching 50% cells that were invasive with
50ng/ml of IL-8 exposure compared to the control (p = <.05). However, these invasive
structures were not greater in numbers than those found with the co-expression of Her2
and 3 (90% invasive structures, p = <.05). Also, analysis of 1,881 primary breast cancers
(public dataset) showed that the Her2 over expressed tumors always had increased IL-8
expression.
Her2 Over-expression and Vascular Endothelial Growth Factor (VEGF):
VEGF plays an important role in disease progression by aiding in the infusion of
blood vessels to other tissues (angiogenesis) in the metastatic process of breast cancer
cells. In a clinical cohort (N = 603) of primary breast cancer patients, Konecny et al.
(2004) evaluated the association between Her2 and VEGF expression, and the clinical
outcomes with their expression levels. ELSA was performed using antibodies for VEGF
isoforms and Her2, and the patients were divided according to their Her2 and VEGF
status into: a) normal Her2 expression with no VEGF in low-risk group, b) Her2 over
expressed with no VEGF; and c) normal Her2 expression with VEGF were both in the
intermediate risk, and d) Her2 over expressed plus VEGF constituted high risk group. A
significant association (p = <.001) was noted between Her2 over-expression and VEGF
expression, with almost 80% (463/603) of the patients that over expressed Her2 also had
detectable VEGF expression profiles. Survival analysis showed significant differences
between the four groups, with increased mortality for those in the high risk group and the
most favorable survival indices found in the low risk group (log rank test p = <.0092).
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Thus, Her2 over expression is not only associated with VEGF expression, but in
conjunction with VEGF results in high mortality rates.
Ye & Lu (2010) also found similar results on their assessment of the expression of
Her2 and VEGF on 117 post-operative breast cancer patients using IHC. Fifty patients
with mammary gland hyperplasia were used as controls. Positive expression of Her2 and
VEGF was noted in the sample compared to the controls (p = <.05). A positive
correlation was found between Her2 and VEGF expressions (p = <.05, r = 373).
Pathologically, both Her2 and VEGF correlated to lymph node metastasis (p = <.05),
however, no correlation was found with age, histological type, grade, and stage (p =
>.05).
Schoppmann, Tamandl, Roberts, Jomrich, Schoppmann, Zwrtek, ... Birner (2010)
further validated that Her2 over expression is associated with an increase in VEGF.
Using IHC, they studied the expression of VEGF (factor C), lymphatic microvessel
density, lymphovascular invasion and Her2 over expression on 150 randomly selected,
node-positive breast cancer patients. Mann Whitney U test results showed that the cases
that over expressed Her2 (3+ IHC score) also expressed significantly greater (p = .0006)
amounts of VEGF compared to those patients that did not over express Her2.
Additionally, the lymphatic microvessel density showed a significant (p=.012) correlation
with VEGF expression. This data suggests that Her2 protein over expression influences
tumor metastasis by increasing the production of VEGF factor C.
The aforementioned studies (Aceto et al., 2012; Asrani et al., 2013; Johnson,
Seachrist, DeLeon-Roderiguez, Lozada, Miedler, Abdul-Karim, & Keri, 2010; Konecny
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et al., 2004; Lauren et al., 2013; Schoppmann et al., 2010; Ye & Lu, 2010) performed on
the mechanistic insights of how Her2 mediated its carcinogenic potential have now
elucidated how Her2 effectively used many effectors (downstream elements) and
mediated diverse singular effects―metastasis via migration, invasion, proliferation, and
angiogenesis.
Accruing Her2 Amplification with Disease Progression
Historically, clinical data has shown that Her2 gene amplification occurs in
approximately a third (30%) of patients suffering from breast cancer (Slamon et al., 1989;
Emede, Kostler, & Yarden, 2012). However, this diagnosis of Her2 over-expression has
been done only on primary tumors, whereas the remainders of the patients who do not
show Her2 gene amplification initially have not re-assessed for Her2 amplification
during their later stages. However, as the disease progresses it there could be more
patients with Her2 amplification.
Indeed, this is the case as many studies have shown that Her2 over expression is a
dynamic process, and it can be acquired over a period of time with disease progression.
Meng et al. (2004) followed 24 breast cancer patients who were Her2 negative for it’s
over expression. Their Her2 amplification status was assessed prospectively before,
during, and after treatment, or when the patient became chemo- refractory (i.e., the
chemotherapy stops working on the tumor cells and the disease progressed to the next
stage) using FISH probes (Her2 and CEP17) on their circulating tumor cells (CTCs) in
their blood. A total of 9 patients of the 24 (37.5%) did end-up with a Her2 overexpression in their CTCs during disease progression. Another study by Hayes et al.
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(2002), also using FISH techniques to quantify Her2 levels in the CTCs evaluated 19
patients for their Her2 over expression levels with disease progression that were initially
Her2 amplification negative. It was observed that in 7 of the 19 patients (i.e., 40% of the
patients) a rapid rise in Her2 gene copies did precede disease progression.
Genomic instability and acquisition of Her2 amplification with disease
progression has been corroborated by Ismail, Aly, Khaled, & Mohammed (2009) where
they evaluated the correlation p53, a tumor suppressor gene (TSG), and Her2 and myc
oncogene expression levels on breast tumor samples (n = 34) using FISH technology.
Increase in copies or amplification of Her2 and myc oncogenes, and deletions in the
copies of p53 gene (TSG positivity rates) were assessed by scoring signals for each with
respect to the centromeric signals. All three of these genes showed a significant
correlation with each other, more so with regards to Her2 over-expression (Her2 and myc
r = .511, p = .002; Her2 and p53 r = .432, p = .01; myc and p53 r = .356, p = .03).
Additionally, the frequency of the number of patients with Her2 oncogene amplification
or increase in its copy numbers did increase with advancement of the disease. Using
tumor size, disease stage, and lymph node status as parameters of disease advancement, it
was observed that 70%, 40%, and 50% of the patients showed positivity for Her2, myc,
and p53 genes respectively when the size of the tumor was small (<3 cm) which
ballooned-up to 92% (Her2, p = .005), 87% (myc, p = .0006), and 71% (p53, p = .01)
with a larger tumor size (>3 cm). Similarly, for disease stage, the Her2, myc, and p53
expressions jumped from 75%, 56% (for both myc and p53) of the patients in early stages
(I & II) to 95%, 89%, and 72% of the patients respectively for later stages of the disease
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(III & IV). Noteworthy here is that only Her2 over expression levels increased
significantly between the early and the late stages (p = .008). For lymph node status from
negative to positive, once again statistically significant increase only in Her2 overexpression were noted (node negative mean = 1.69 ±0.25, node positive mean=2.49
±0.22, p = .038), although the number of patients with a p53 deletion did increase
tremendously from 42% in the node negative to 77% for the node positive category, but it
still not statistically significant (p = .05).
Measuring Her2 Using FISH Technology
This molecular technique is DNA based and detects targeted gene sequences.
(Garimberti & Tosi, 2010). It is a DNA based technology which makes use of the fact
that a DNA molecule consisting of two homologous strands, and can be denatured to
single strands. The denatured DNA strand can only be re-natured with its homolog, thus
remaking an exact replica of the initial double strand (Liehr, 2009, p.26-28; Garimberti &
Tosi, 2010; Gasparini & Malazzi, 2006). A FISH probe is made of specific DNA
sequences that renature to the gene in question. The target DNA is fixed on a glass-slide,
and the probe DNA is tagged with a fluorescent reporter molecule. Then, both these
single-strands are unified in a hybridization reaction and visualized under a fluorescent
microscope (Liehr, 2009, p.26-28; Varga, Noske, Ramach, Padberg, & Moch 2013).
Detection of the exact in-situ chromosomal location of a gene and its copy number
changes can be delineated, quantified, and assessed (Liehr, 2009, p.26-28; Varga, Noske,
Ramach, Padberg, & Moch, 2013). FISH can be studied in metaphase spreads or
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interphase nuclei (Bishop, Garimberti & Tosi 2010; Gozetti & Le Beau, 2000; Pinhel et
al., 2012).
Press et al. (2002) compared the accuracy between FISH and IHC tests employed
for testing Her2 levels. Gene amplification was first assessed using Southern blots
(NCBI, 04) in 117 (n) breast cancer samples. FISH (Her2/CEP17 probe set, Vysis) and
IHC (DAKO Hercep), sensitivity and specificity was evaluated compared to Southern
blotting. Three or more signals marked amplification. Forty-two samples (36%) were
amplified. FISH sensitivity was 95.4% (42/43 samples) and specificity 98.6% (72/73
samples). One hundred and fourteen samples were correctly identified by FISH for
accuracy of 97.4%. Concordance (κ) with Southern blotting was 0.945 (CI=0.88-1.0).
With IHC, only 30 of the 43 samples were identified for over expression of the protein,
making its sensitivity 69.8%, however, all of the cancers that showed low expression
were accurately categorized with this test yielding a specificity of 100%, and accuracy of
88.9%. Concordance (κ) values between IHC and Southern blots was only at 0.745 (95%
CI=0.618-0.871). Other studies (Mass et al., 2005; Olsson, Jansson, Holmlund, &
Gunnarson, 2013; Sauter et al., 2007) have also yielded very high predictive values
(sensitivity: 95% to 97%, and specificity: 97% to100%) for the assessment of Her2 with
FISH.
FISH is the preferred technology over IHC is partly due to the fact that while IHC
is subjective, FISH is quantitative (Bartlett et al., 2001; Jacobs, Gown, Yaziji, Barnes, &
Schnitt, 1999; Thomson et al., 2001). A proficiency test conducted in 146 clinical
laboratories, using Her2 amplified / over expressed and low Her2 amplification / low
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expression showed that all laboratories using FISH were in 100% agreement; whereas
those using IHC only 72% agreed (Pinkel et al., 1986). Due to these discrepancies
between the two tests, American Society of Clinical Pathologists (ASCO) reviewed and
changed its guidelines in 2011 for IHC scoring of Her2 from 2+ and 3+ staining to be
observed in 30% of the cells instead of 10% cells that was done previously (2005-2010).
These changes in IHC scoring criteria has lowered its false-positive rates considerably,
and increased the positive concordance rates between IHC and FISH from 72% to 95%
(1083/1118 cases retrospectively analyzed using IHC and FISH). However, the cases
where discrepancy still exists between the IHC and FISH results, the confirmatory
analysis is still done using FISH technology, and the FISH results for Her2 are
considered definitive. Importantly, the guidelines for FISH analysis of Her2 have
remained constant over the past 12 years, and so has its specificity, sensitivity, and
accuracy (Varga, Noske, Ramach, Padberg, & Moch, 2013). Another advantage with
FISH technology is that besides interphase nuclei, it can be performed on metaphase also
which allows a researcher to pin-point the exact chromosomal location of the aberration
(Bishop, 2010; Gozetti & Le Beau, 2000).
The probe-set used for Her2 testing is FDA approved (Park, Park, Koo, Yang,
Kim, & Park, 2010; Wulfkuhle, Berg, Wolff, Langer, Tran, Illi, … Petrcoin, 2013), and is
currently being used for clinical diagnosis, prognosis, and management of breast cancer
patients (Burris, Rugo, Vukelja, Vogel, Borson, Limentani, … O’Shaughnessy, 2011;
Fleming, Sill, Darcy, McMeekin, Thigpen, Adler, … Fiorica, 2010; Ohlschlegel, Zahel,
Kradolfer, Hell, & Jochum, 2011; Slamon et al., 2011). Specifically, in this kit the probe
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sequences are tagged by fluorescently labeled probes which recognize both the genetic
sequences for the Her2 gene and chromosome 17 centromeric regions. The Her2 gene
and the centromeric regions are labeled with different colored fluorochromes for an easy
scoring of disparate signals (e.g., orange and green respectively) (Olsson, Jansson,
Holmlund, & Gunnarson, 2013). The Her2 amplification can be quantified using a
fluorescent microscope by counting the Her2 gene copies, and the CEP17 is used as an
internal control to check for aneusomy (i.e., increase of the entire chromosome) of
chromosome 17 (Nitta et al., 2008; Gutierrez & Schiff, 2011).
Estrogen and Its Receptor: An Overview
Human estrogen (E2) is synthesized in 3 forms by the ovary: a) estrone (E1),
produced during menopause, b) estradiol (E2) predominantly found in non-pregnant
women, and c) estriol (E3) produced during pregnancy. E2 mediates its effect via its
receptors, estrogen receptor alpha (ERα) and beta (ERβ). ERs are nuclear receptors
(NRs), meaning that it is found in the nucleus of a cell (Tora, White, Brou, Tasset,
Webster, Scheer, & Chambon, 1998). Biologically, the function of ERα has been
extensively studied in the case of breast cancer (Jung, Park, Jun, Kong, Kim, Kim, ... Im,
2010; Palmieri, Cheng, Saji, Zelda-Hedman, Srri, Weihua, ... Gustafsson, 2002). Both
ERα and β are found in the normal mammary epithelium, but an increased level of ERα is
noted in breast cancer. Almost 70% of breast cancers with ER-positive status expressed
ERα (Renoir, Marsand, & Lazennec; 2013). Basically, E2 forms a complex with its
receptor, known as a ligand-receptor complex. When ER is unbound to a ligand, it is
found as a monomer bound to a protein called the heat-shock protein. Upon binding with
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a ligand, hsp gets disrupted producing conformational changes of the receptor molecule,
which induces receptor activation (Gutierrez & Schiff; 2011; Le Goff, Montano, Schodin,
& Katzenellenbogen, 1994; Montemurro, Cosimo, & Arpino, 2013).
Classically, when activated, they form a homodimer with other co-regulatory
agents. Together, they bind to the estrogen response element (ERE) contained in the
promoter region of specific genes, and have the capacity to modulate the transcriptional
activity of those genes (Kumar & Chambon, 1988; Montemurro, Cosimo, & Arpino,
2013). Besides the classical pathway of the ER functioning as transcriptional regulator, it
is also proposed that E2 exerts its effect non-genomically (non-classical pathway) by
interacting with growth factor receptors [e.g., epidermal growth factor (EGF), and insulin
growth factor (IGF)], and cell signaling molecules (Kahlert et al., 2000). Furthermore,
different ligands can change the conformation of the ER in differential ways
(Montemurro, Cosimo, & Arpino, 2013; Osborne et al., 2003). Thus, ER transcriptional
activity is controlled by specific ligand, co-regulatory molecules, their phosphorylation
(i.e., activation), and promoter sequences present in distinct set of genes.
A study by Grober, Mutarelli, Giurato, Ravo, Cicatiello, DeFillppo, …Weisz
(2011) was conducted using ERα positive cell line (MCF7). The researchers found that
this line co-expressed ERβ. Analysis of their transcriptomes with CHIP-Sequencing
(CHIP-Seq) technology for the entire genome surprisingly showed that there are 9702
ERβ sites vs. only 6402 ERα binding sites in the MCF7 line when it is stimulated with
estrogen (E2). Further analysis of the binding sites by sequencing showed the presence of
estrogen receptor elements (EREs) in ERα and ERβ. Additionally, ERα and β share
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similar genomic targets, and in co-existence they compete for these genomic targets.
However, the cellular response is opposite for ERβ vs. ERα. Cell proliferation assays for
the MCF7 using miRNA line show that ERβ down regulates cell growth, unlike ERα
which promotes cell growth. Thus, the ERβ receptors were able to modulate the effects of
ERα receptors on gene transcription and cellular growth as was noted in the MCF7 cell
line.
Signaling Pathways: Cross-Talk between ER and Her2
Phosphotidyl Inositol 3-Kinase/Akt Pathway (PI3-K/AKT Pathway)
Cellular signaling for the activation and control of gene expression by estrogen
was found to be complex as well as multifaceted to say the least. Two major pathways of
ER signal transduction were: a) phosphotidylinositol 3-kinase [PI 3-K/Akt], and b)
MAPK pathways. Estradiol was able to bind to ERα directly. The estradiol bound to ERα
interacted with Her2 followed by the activation of the PI 3-K/Akt was indicative of the
cross-communication that occurred between ERα and Her2.
An extensive research by Stoica et al. (2003) examined the activation of various
signaling molecules, and their pathways upon stimulation by exogenous estradiol in ERα
positive (MCF-7), and ER-negative (MCF-7/ADR) breast cancer lines. They determined
the requirement of ERα itself, by exposing MCF7/ADR cells to17β estradiol, and
immunoblots probed them with anti-phospho-Akt. A nine-fold increase in Akt activity
was noted in the ER-positive line. No Akt activity was observed in the ER-negative line,
and transfection with ERα restored the Akt activity. Further, the MCF-7 cells treated with
the two isoforms of estradiol (α and β), only the β isoform showed a nine-fold in Akt
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activity.
The researchers elucidated the mechanism and the kinase responsible for Akt
activity, by treating MCF-7 cells with 17β estradiol that had been exposed to AG825
which selectively blocks Her2, and AG30 an EGFR inhibitor. The cells treated with Her2
inhibitor did not induce any Akt activity; however, this response was not inhibited by the
EGFR inhibitor, suggesting that Her2 is a critical element for Akt pathway activation. As
Akt also exists in three isoforms (1, 2, and 3), treatment with antibodies specific to each
showed that ERα positive line (MCF-7) Akt 1 is expressed, and ER negative line (MDAMB-231) produced activity with Akt 3, this indicated that different isoforms of Akt can
be selectively activated depending on the ER availability, thus involving two distinct
mechanisms for protein and gene expression. It can also be inferred from this data that in
cells where Her2 co-exist with ER (e.g., breast cells), exposure of the cells to estrogen
itself or estrogen-like compounds (xenoestrogens) can activate their cellular growth and
survival via these pathways.
Mitogen Activated Protein Kinase Pathway (MAPK Pathway/ERK)
Jung et al. (2010) found that co-activators, such as Matrix metalloproteinase-1
(MMP-1) expression increases when crosstalk occurs between the ER and Her2 receptors
via the MAPK pathway. These co-activators act as molecules that relay the message from
the ER to the Her2 receptors.
ER is mainly found in the nucleus of an ER-positive cell. However, when
stimulated with estrogen, the ER interacts with Her2 and initializes the MAPK pathway
by inducing extra cellular signal regulated kinase 1 and 2 (ERK 1/2) activity (Lemmon &
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Schlessinger, 2010). This further prompts re-localization of the ER from the cell’s
nucleus into its cytoplasm, increases Her2 expression, aids in the progression of breast
cancer, and makes the cancer resistant to therapy. Yang, Barnes, & Kumar (2004) had
investigated the communications that occurred between Her2 and ER, the signaling
cascade in breast cancer cells, and the indispensable role that Her2 plays in breast cancer
pathogenesis. Breast cancer cells that did not express any Her2, as well as those that
over-expressed Her2 were used to perform confocal microscopy using
immunofluorescence after their exposure to 17β estradiol. It was observed that upon Her2
amplification there was physical movement of the ER from the nucleus into the
cytoplasm. Vice-versa effects occurred when Her2 expression was de-regulated with
anti-Her2 antibody, which is that ER, moved back into the nucleus from the cell’s
cytoplasm. Western blots plus confocal immunofluorescence with anti-ERK 1/2 showed
that ERK 1/2 increased (8 fold) with the increase in Her2. This data shows that ER
relocation from its primary position; the nucleus to the cellular cytoplasm is a
downstream effect of increased Her2 expression, and Her2 interacts with the ER to
produce this effect. Also, ERK 1/2 activity provides the fuel for the relocation of ER.
Jung et al. (2010) found that co-activators, such as Matrix metalloproteinase-1 (MMP-1)
expression increased when crosstalk occurred between the ER and Her2 receptors via the
MAPK pathway. These co-activators acted as molecules that relayed messages from the
ER to the Her2 receptors.
PI-3K, MAPK, and Her2 Over Expression
How the PI-3K and MAPK pathways interacted withHer2 over expression was
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further detailed by Serra, Scaltriti, Prudkin, Eichhorn, Ibrahim, Chandarlapaty, …
Baselga (2011). Using PI-3K inhibitors (BEZ235) on Her2 over expressing cell lines
(BT474 and SKBR3) resulted in a dose-dependent inhibition of PI-3K catalytic activity
(i.e., phosphorylation) within 24 hours (p = <.05). In addition, a simultaneous increase
was noted of a downstream effector (P90RSK) of the MAPK/ERK pathway. When
similar tests were performed using Her2-negative lines (MCF7 and MDA-MB-468),
activation of ERK/MAPK was not pronounced. To confirm the involvement of Her2,
both BT474 and SKBR3 (Her2+ lines) were treated with anti-Her2 agents; this prevented
the phosphorylation of the ERK/MAPK pathway to occur.
Unique Properties of Xenoestrogens: Insights from Animal Models, Lines and
Assays
Activate Protein Kinase Genes
Valeron, Pestano, Luzardo, Zumbado, & Boada (2009) used RNA arrays and
studied the expression of protein kinase genes after they exposed human mammary cell
line with DDT analogs, alderin and dieldrin at 0.18, 90, and 180 nM concentrations for a
period of 96 hours (4 days). Their arrays results showed a sharp increase in the
expression of protein kinase genes; such as KIT, ALK-1, and ERRB3/Her3. Noteworthy,
is the finding of an increase in ERRB3/Her3 kinase, but an inherent physical property of
the ERRB3/Her3 receptor is that the receptor itself does not have a kinase site, so it
dimerizes with Her2 for kinase activity in order to reach the cellular proliferative end
point (Aceto et al., 2013; Fiszman & Jasnis, 2011; Ross et al., 2005; Tzahar et al., 1998).
Thus, it may be that here also Her2 mediated the kinase activity for Her3 since Her2 is its
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preferential dimerization partner, and Her3 cannot possibly activate the kinase on its own
since it is physiologically incapable to do so on its own.
Estrogen Receptor Agonist that Activates Cellular Signaling
Xenoestrogens are estrogen receptor (ER) agonist. Exposure to small amounts of
xenoestrogens leads to receptor (estrogen receptor) binding with the ligand
(xenoestrogenic compound) forming a receptor-ligand complex. This receptor-ligand
binding rapidly initiated activation of cell signaling molecules (ERKs). Bulaveya &
Watson (2004) demonstrated the rapid changes that occur in cell signaling pathways
specifically when xenoestrogens, such as DDE, bisphenol A (BPA), endosulfan,
nonylphenol (NPH), coumestral, and dieldrin bind to estrogen receptors (ERs). Changes
that had occurred during intracellular signaling were measured by performing ELISA for
dose-dependent phosphorylation using prolactinoma lines. Time-periods used were
between three to thirty minutes after exposure with concentrations from 10-8 to 10-10 M.
Administration of an agonist at different concentrations in a dose-response experiment
exhibited an uphill curve as one proceeds from the left to the right of the graph. Any
activity of ≥120% compared to the control (ethanol) was considered statistically
significant (p = <.05). Each xenoestrogen, except BPA produced rapid phosphorylation
of the estrogen receptor kinases (ERKs) within 30 minutes after application reached
statistically significant levels of response. Each xenoestrogen activated the ERKs in a
unique fashion. Some (e.g., NPH and coumestral) produced dual activity peaks; whereas
others (e.g., endosulfan) produced activity at all times with all concentrations tested, but
none of these compounds was able to exactly copy the phosphorylation patterns of
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estrogen (E2) itself. Nevertheless, they all initiated ERK activity in low dosage
concentrations (i.e., nanomolar and picomolar amounts).
Differential ERK activity patterns were observed. The time of activation for the
various xenoestrogens were divided into two groups: a) fast-phase responders with one
activity peak in the first half or 6-10 minutes (e.g., DDE), and b) slow-phase responders
that produced a single delayed peak in 30 minutes (e.g., endosulfan and nonylphenol).
However, E2 was different, as it produced a bimodal ERK phosphorylation response with
distinct periods of phosphorylation and deactivation; whereas all xenoestrogens produced
only a monophonic response. Importantly, the study found that although xenoestrogens
activated the ERK, but they had different dose-dependent patterns. Two basic patterns
had emerged:
1) Some compounds were active in nano-molar as well as sub-pico molar
concentrations (e.g., coumestral, E2, endosulfan, and nonylphenol), and
2) Others were active only at nano-molar concentration (e.g., DDE and dieldrin).
Since the ERK pathway is also activated by Her2overexpression (Fiszman & Jasnis,
2011), it is biologically plausible that in the above experiments Her2 is also being over
expressed with xenoestrogenic exposures.
Cellular Proliferation & Nuclear Compartmentalization
Xenoestrogens initiated cell growth. A study conducted by Mercado & Bigsby
(2008) examined the role of PBDEs found widely in the environment, and act as
endocrine disruptors. The study was conducted in vivo, and measured estrogenic activity
with response to different dosage with various time intervals in two strains of mice. They
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were either wild type (naturally occurring), or those in which the ERα gene had been
removed (knockout) mice. All mice were injected with 75, 150, and 300 mg/Kg of DE-71
for 3 and 34 (persistent exposure) days respectively, and then their reproductive tracts
were weighed as estrogen bioassays. An in-vitro assessment of the effect of these
treatments was also done using MCF-7 breast cancer cell line and conducting cell
proliferation assays. Cell proliferation assays found a significant increase in cell counts.
A three-fold increase of DE-71 treated cells was obtained at 10uM concentration
compared to DMSO control (p = <.01). Albeit, the cellular growth observed in the E2
treated cells was much higher (five-fold increase) with a much lower concentration
(0.01nM). A noteworthy observation was that treatment with >2.5 x 10-5M concentration
of DE-71 results in a sudden drop in the cell growth, indicative of its noxious effect to the
cells beyond this strength. The estrogen assays revealed that only persistent treatment of
34 days increased the uterine weight substantially with estradiol treatment (8-12 times
compared to the control, p = <.001), and with DE-71 (23% more than control, p = <.05).
The knocked out mice had not produced any effect, which suggested that ERα is the
receptor that got actively recruited.
Recchia et al. (2004) also examined the estrogenic nature of xenoestrogens,
specifically BPA and 4-Nonylphenol (NPH). To assess this, the investigators created an
estrogen response element (ERE) in MCF7 and T47D breast cancer cell-lines. An ERE is
the promoter that initiated gene transcription when an estrogen agonist (ligand) binds to
the ER (Klinge, 2000). Both lines were treated with 10 μM of BPA and NPH for 5
consecutive days, and then cell proliferative and transcriptional assays were performed.
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Both BPA and NPH transactivated ERα. Nuclear compartmentalization had occurred
when BPA and NPH were added to MCF7 cells. Furthermore, proliferative activity
induced by BPA and NPH was observed for both MCF7 and T47D cell-lines were
assessed by cell-proliferative assays. It was noted that similar amounts (i.e.,
concentration) of xenoestrogens induced transcriptional and proliferative response in the
lines. However, when compared to the natural estrogen hormone, the proliferative
activity of both xenoestrogens was reduced. It is noteworthy here that cellular
proliferation were also induced and promoted with the over expression of Her2
(Ellsworth et al., 2008; Szasz et al., 2013). Hence, the overlapping cellular growth and
proliferation further provided biological plausibility that the Her2 gene is also involved in
the circuit of molecules when the xenoestrogens are applied to reach the specific cellular
endpoints.
Induction of Cellular Growth at Low Concentrations
Cellular growth was characteristic of estrogenic effect. Xenoestrogens can induce
cellular growth at very low concentrations. Maras et al. (2005) investigated the estrogenic
properties of five perfluorinated compounds (xenoestrogens) by using a combination of
in vitro assays. The capacity of these compounds to induce cellular growth in growth
arrested MCF-7 breast cancer line was measured by E-screen assay, and the cell cycle
analysis was done by flow cytometry. The E-screen is based on the ability of MCF-7
growth arrested cells to initiate growth in the presence of estradiol, and this is compared
to the compound under scrutiny (Soto et al., 1995). De-regulated cellular cycle can lead
to tumorigenesis due to increased cellular growth or decreased cell-death. Normally,
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apoptosis occurs after a cell goes into its resting phase (Elledge, 1995). When the resting
MCF-7 cells were exposed to fluorotelomer alcohols as they re-entered the synthesis
phase (S-phase) within a day. A 35% increase was noted with exposure to estrogen, and
4-Nonylphenol (4-NP). There was a 31% and 29% increase in cells with 8:2 and 6:2
fluorotelomer alcohols respectively. Additionally, low concentrations (e.g., 10 μM) of the
fluorotelomer alcohols induced cellular growth.
Changes Mammary Tissue Morphology
Increased cellular activity due to chemical exposure increased cancer
susceptibility. It has now been known for more than a decade that some xenoestrogens
can change the morphology of the mammary tissue, and initiate the proliferation of its
cells in animal models. Brown & Lamatinere (1995) investigated these properties by
conducting a case-control study on Sprague-Dawley rats. The experimental group of rats
was subjected to acute exposures of 50ug/gm body weight of DES, DDT, genestin, and
25ug/gm body weight of TCDD, Arcolor 1221 and 1254. Controls were given sesame oil.
Each group was assigned equal number (6) of rats, and exposed to the xenoestrogen for a
week. Morphological changes were assessed on whole mount preparations of breast
tissue. Cell proliferation was quantified using proliferating cell nuclear antigen (PCNA)
an indicator of mitotic activity, and cell differentiation was analyzed using IHC.
Genestin and DES did significantly increased mammary cell growth as well as its
differentiation when compared to controls (cell growth observed: 149 ± 7 mm2 Genestin
vs. 122 ± 10 mm2 control, p = <.05, and gland differentiation observed: 43 ± 8 lobules
with genestin; 43 ± 6 lobules with DES; 10 ± 1 lobules in control, p = <.01 and <.001
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respectively). Although, not statistically significant, but, Arcolor 1221 and 1254 showed
cellular proliferation. This could be due to insufficient dosage of these chemicals due to
their weaker estrogenic properties. Interestingly, it was noted that TCDD inhibited the
cellular proliferation of the mammary cells (81 ± 9 TCDD vs. 132 ± 6 mm2 control, p =
<.01). This could have occurred because TCDD’s toxicity was killing the cells.
Latent Effects in Mammary Tumor Development
Exposure to xenoestrogen (e.g., BPA) during gestational age in minute amounts
resulted in carcinogenesis of the breast tissue during adulthood. Murray, Maffini, Ucci,
Sonnenschein, & Soto (2007) investigated the effects of prenatal exposure to BPA, and
whether BPA exposure independently resulted in breast carcinogenesis during adult life.
Sprague-Dawley rats were exposed to 2.5, 25, 250, or 1,000 micrograms (ug) of BPA per
body weight per day from embryonic day 6 until day the first day after delivery via
implanted pumps. Control rats were given a dose of 50% dimethyl sulfoxide. Female
mice were specifically sacrificed on the 50th day or the 95th day after delivery, because
mammary gland ductal growth and extension of the ducts into the fat pads is noticed on
these days respectively. IHC on whole sections showed ductal hyperplasia in all of the
animals. Three to four-fold increment was found in the formation of hyperplasic ducts in
the experimental animals compared to the controls. The ductal size had also increased
due to the active proliferation specifically of the luminal epithelial cells. H & E staining
suggested differences in chromatin pattern, presence of nucleoli, and secondary lumina.
A much larger study conducted by Jenkins et al. (2009) utilized rats and
investigated whether oral BPA exposure as a neonate could cause breast cancer with a
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single carcinogenic exposure in the adult life. They exposed 32, 34, and 24 female rats to
sesame (control), 25 ug/Kg body wt/day (25), and 250 ug/Kg body wt/day (250) of BPA
respectively. Totally, 15 treatments were given. Eight rats from each group were taken on
21st and 50th days, and their mammary gland was excised to examine tumor progression
in live tissue. On the 50th day, a rat from each litter was also exposed to a dose (30mg/Kg
body weight) of DMBA, a known cancer causing agent, and sacrificed for tumorigenesis
study. Mammary gland proteins were observed by immunoblots. Cell-death and growth
was assessed by IHC on terminal end buds (TEDs), and confirmed by Ki-67 analysis.
Tumorigenesis was measured in two ways: a) tumor latency, and b) tumor burden.
An increase in the tumor formation was noted with increasing doses of BPA (2.84, 3.82,
and 5 respectively). Rats given doses of BPA 250 had a tumor burden that was
statistically significant compared to control (p = .004). Additionally, tumor growth was
observed in 65, 53, and 36.5 days for BPA 25, BPA 250, and controls respectively (p =
.025) showcasing an inverse relationship that existed between tumor latency and BPA
dosage. Noteworthy here is that although BPA 25 did show an increased tumor burden
and decreased latency when compared to controls, it did not reach statistical significance
for either (p = .131 and .058 respectively). However, this does not mean that the tumors
were not forming at all or that they were forming earlier in rats that were not subjected to
this xenoestrogen at all. Hence, it is plausible that if these exposures were carried out for
a longer period of time (persistent exposures) the tumor burden and latency may have
reached levels of significance.
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Further, mammary terminal end buds (TEBs) were significantly more in the 50
day old rats when compared to the control (22% increase in cellular proliferation of
TEBs, p = <.001), and a decrease in apoptosis was observed for the 50 day old rats
compared to control (40% less apoptosis, p = .001). Apoptotic and proliferation proteins,
Akt and phosphorylated Akt (pAkt) for 50 day old rats showed significantly higher
expression levels (2- fold, p = .001; and ~ 2 fold, p = .050 increase in expression
respectively) compared to control. Analysis of Progesterone receptor A and B (PR-A and
PR-B), their co-activators (steroid receptor co-activator; SRC-1, 2, and 3), and Her
family of tyrosine kinases using Western blots showed a 54% increment in PR-A protein
expression in TEBs of 50 day old rats compared to controls. SRC-1, 2, and 3 were all
found to be significantly over-expressed compared to control (3.5 fold, p = .001; 1.5 fold,
p = .003; and 3.5 fold, p = <.001 increased expression respectively). Although there was
an increase in Her2-neu, PR-B (a third more for both), and Her3 (~2 fold increase), but
only Her3 reached significance (p=0.01). Once again, it is possible that Her2 over
expression could reach levels of significance once the exposures are persistent.
Interestingly, since the Her3 receptor itself does not have a kinase terminal required for
phosphorylation to induce cellular changes, and to bring about these cellular responses
Her3 partners with Her2 (Akiyama et al., 1986). Thus, the increase in Her3 and Her2
should be similar, but strangely enough only Her3 reached levels of significance and not
Her2. Further, the down regulation (a third) of ERα was observed which also occurs
when Her2 amplification reaches its autocrine potential.
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Although this study was done in a rat model, it was the first to prove how early
exposures to a xenoestrogen like BPA by lactation can have harmful effects during
adulthood for the offspring with only a single dose of carcinogenic exposure. This study
elucidates the manner in which BPA acts for breast tissue carcinogenesis. Further, the
increased cellular proliferation and decreased cellular death plays a crucial role in
tumorigenesis. Importantly, studies done in humans on breast cancer patients also showed
that an increased expression of the steroid receptor co-activator-3 (SRC-3/A1B1) is
linked to an increased expression of the Her2 oncogene. Thus, it is likely that this study
maybe carried over to the human model.
In a recent study, Johnson et al. (2012) had directly linked Her2 gene expression
with exposures to two metabolites of DDT (o’p’ DDE and p’p’ DDE) in a mouse model
with the Her2-Neu proto-oncogene. Of these two metabolites, one (o’p’ DDE) is an
estrogenic isomer; whereas the other (p’p’ DDE) is antiandrogenic. They locally injected
5 μg pellets of the DDT derivatives, individually and in combination for two months into
the mammary fat pads (total: 4) of prepubertal mice. These exposures were at
concentrations that have been found in the human mammary tissue. It was observed that
the control mice also developed mammary tumors, suggesting that the breast cancer
incidence was similar in all groups, but the p’p’ DDE antiandrogenic isomer significantly
increased the breast cancer progression rate (shorter latency period) compared to the
control mice (90 vs. 147 days respectively, p = <.02). Although the rate of tumor
progression was greater with o’p’ DDE as compared to the control, but it not found to be
significantly higher (126 days vs. 147 days respectively, p = >.05). These results
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indicated that p’p’ DDE accelerated breast cancer progression via hormonal and other
actions, and the DDT isomers aided in breast cancer progression not initiation.
Interestingly, the combinatorial exposures of both isomers had no affect on latency when
compared to the control, suggesting that the actions of these two isomers are not
synergistic.
Differential Estrogenic Strength of Different Xenoestrogens
Different xenoestrogens exhibited a diverse range of estrogenic activity. Some
were mildly estrogenic whereas others were far more effective at a similar dosage of
exposure. Due to this attribute, it is deemed important that each xenoestrogen be assessed
individually. Silva, Scholze, & Kortenkamp (2007) studied the low dose (nanomolar
dosage) responses in 24 known xenoestrogens using the E-screen assay. They found that
estriol (E2) produced the highest level of proliferative response with the lowest dose (4.0
X 10-4 nM). Coumestral, a phytoestrogen was a hundred times less effective compared to
estriol, and produced an effect at 0.55 nM. Surprisingly, in the case of β-endosulphan, it
was noted that the concentration at which it produced a 1% effect was lower (140 nM)
than its concentration required for no effect (150 nM). More so, many of the steroidal
estrogens (e.g., estrone, estriol, hexestrol, and dienestrol) produced shallow doseresponse curves, whereas many of the synthetic xenoestrogens did not.
Additive Effects in Combination
Xenoestrogens produced an additive effect when they were present in a
combination as mixtures of different estrogenic compounds. However, this effect
occurred only when each of the individual compounds formulating that mixture had equal
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strength. Payne, Rajapakse, Wilkins, & Kortenkamp (2000) investigated whether additive
effects of different estrogenic compounds could be calculated by individual doseresponse effects of each compound found in the mixture using YES assay.
Dose-response assays were performed using equal strength of various
xenoestrogens (e.g., o, p’DDT, genestin, 4-Nonylphenol (4-NPH), and n-4-octylphenol),
individually and in combinations, using E2 as a positive control. Best-fit model predicted
by absorbance readings for an individual chemical showed that 4-NPH produced a
maximum response, similar to E2 (control). Individually, the chemicals showed a widearray of effects. Even when the estrogenic compound showed the lowest maximal effect
individually, it produced a large additive effect when it was combined with other
estrogenic compound/s. A major drawback noted was that the best fit of the model and
the readings on combined effects were quite similar only for binary mixtures, but with
three compound mixtures the effects were a little under estimated; whereas it was viceversa for four compound mixtures. Nonetheless, additive effects were observed in all the
mixtures. This data could prove to be extremely important, especially in the case of
estrogenic compounds that barely produced any detectable effects individually, albeit
they could produce significant effects when applied in combination.
Following suite to this study, Rajapakse, Ong, & Kortenkamp (2001) used the
YES bioassay and tested whether BPA and o, p’DDT produced an additive impact when
each of these xenoestrogen is combined with the naturally occurring hormone 17 βestradiol (E2). The researchers hypothesized that even weakly estrogenic compounds;
such as BPA and DDT can affect the functioning of the steroid hormone based on their
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concentration and strength in relation to the hormone. Hence, the impact would be
dependent upon the potency of the xenoestrogen in comparison to the natural hormone.
Mathematical models of concentration addition (CA) and independent action (IA) for
fixed ratios of mixtures were used that predicted the dose-response relationship, and
synergy between the two compounds was assumed. Then, predictions made were tested
experimentally. The IA model defined the maximal effect of a xenoestrogen; whereas the
CA model estimated concentrations of 2 xenoestrogens combined to yield a
predetermined additive effect using regression analysis. According to the IA data, all 3
compounds activated human ERα in a dosimetric fashion, reaching maximal effects at
1.59, 1.65, and 0.45 for E2, BPA, and o, p’DDT respectively. This followed well with the
experimental data. The maximal effects of BPA and E2 matched well at 1.65 and 1.59,
the maximal effect obtained for o, p’DDT was low comparatively to the hormone at 0.45
and 1.59.
The predicted CA data for 2-compounds mix, regression yielded a shift in the
dose-response graphs to lower concentrations that becoming more and more pronounced
when the amount of E2 were consistently increased in the mix for both E2 and BPA as
well as E2 and o, p’DDT, until the hormone completely over-shadowed the effects in
each mixture. Then, changing gears by increasing the relative strength of each weak
estrogen in the 2-compound mix showed that their effects at low concentrations (1:5000
molar ratios of E2 vs. BPA or o, p’DDT) were almost negligible, but, when each of the
weak estrogenic compound was consistently increased while E2 was kept at a constant
concentration (1:20000 molar ratios of E2 vs. BPA and o, p’DDT). The prediction curves
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started to shift in favor of the weak estrogenic compound. The CA models were similar
for E2 and BPA, but only over-lapped in low level effects for E2 and o, p’DDT. Upon
testing this model experimentally, the E2: BPA mix corresponded completely with the
predictions made by the CA mathematical model. The response of the mix far exceeded
the 95% CI of the E2 regression line. In the case of E2: DDT mix the experimental
effects observed were well-matched with the predicted models only in the low effect
range (up to 0.45 absorbance levels), but neither model was accurately depicted for the
high effect range. The researchers owed this to the low solubility of o, p’DDT which
hindered its absorbance by the yeast cells. To further test this possibility, they added 2%
DMSO in the E2: DDT mixture; as DMSO had previously shown to increase
permeability of the yeast cell-wall, thereby increasing the solubility of o, p’DDT within
the yeast system. With this mix there was a 40% increase observed in the maximal effect
of o,p’DDT, and now the CA model prediction and the experimental were in sync until
1:50000 ratio of E2: o,p’DDT, or 1.2 absorbance levels after which the responses started
to plateau off.
In all, these studies provided support that weak estrogenic compounds were able
to add to the already strong effects of the endogenous sex steroid action. As this study
provided external validity to the study that was conducted by Payne, Rajapakse, Wilkins,
& Kortenkamp (2000), proposed that action of weak estrogens or xenoestrogens found in
combination were additive in nature. The health implications of these additive effects of
xenoestrogens should be seriously considered.
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Resistance to Chemotherapy
Chemotherapeutic resistance can play a crucial role in breast cancer therapy, and
thereby its survival. BPA has the property of being a chemo-resistant for breast cancer
therapeutic agents even when it occurred in low (nanomolar) concentrations. LaPensee
Tuttle, Fox, & Ben-Jonathon (2009) investigated this property of BPA with various
chemotherapeutic agents (e.g., cisplatin, vinplatin, and doxorubicin) used for breast
cancer by conducting cytotoxicity assays on ERα positive cell line T47D (estrogen
responsive), and ERα negative line MDA-MB-468 (estrogen non-responsive). MTT
cytotoxicity assay showed that the viability of ERα positive and ER negative cancer cells
increased in a dose-dependent manner. Even at low dosage BPA (range: 1nM to 10nM)
significantly (P=<0.05) protected both of the lines from the cytotoxicity mediated by
doxorubin. Additionally, when the lines were subjected to BPA in the presence of ICI and
PHTPP, blocking ERα and β receptors respectively, BPA still inhibited the action of the
chemotherapeutic agents, exhibiting that this action occurs via other pathways besides
just the classical ERα and β. Protein analysis by Western blots indicated an increased
expression of anti-cell death proteins such as BcL-2, Bc1-xL, and Survivin upon BPA
exposure indicative of an anti-apoptotic action.
Modulate VEGF
Experiments revealed that some xenoestrogens increased the production of
VEGF, more so in the presence of high levels of ERα, thus increasing the angiogenic
capabilities of the breast cells. Buteau-Lozano, Velasco, Cristofari, Balaguer, & PerrotApplanat (2008) assessed whether xenoestrogens incorporated ERs in their ability to
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regulate the secretion of this factor by performing dose-response experiments. The
researchers exposed two breast cancer lines (i.e., MELN which over-express ERα and
MELP with low levels of ERα) to various xenoestrogens (e.g., E2, BPA, DEHP, BBP,
genestin, OP, and various phthalates) for 24 hours, and then quantified VEGF using
immunoassay. Ethanol was used as the control.
For the MELN cells with high ERα expression, the VEGF expression patterns
showed that E2 is the most sensitive, inducing VEGF production (two and a half time
more, p = <.05) in extremely low amounts (10-10 M concentration). A similar induction
was observed in the case of genestin, but with increased concentration (10-7 M, p = <.05).
A significant increase (twice that of control, p = <.05) in VEGF secretion was also noted
with dieldrin, BBP, OP, DEHP, and BPA although they did so at even higher
concentrations ranging from 10-4 to 10-6 M. Contrastingly, some pesticides (e.g.,
vinclozin, atrazine, HCH), and phthalates (e.g., DIDP, DINP) did not produce any effect
even with increased concentration. Whereas, for the MELP cells with low ERα
expression, there was only a significant increase (twice that of control, p = <.05) with E2.
All other xenoestrogens, the amount of VEGF secreted did increase, but to a lesser
amount (one and a half times). Interestingly, Her2 amplification also increases VEGF
production, and once again it is possible that Her2 is involved in these processes
alongwith ER because it cross-communicates with it during tumorigenesis of the breast
tissue.
To ascertain whether VEGF increase had occurred in the presence of ER, the
different xenoestrogens were treated in the presence of ICI; which blocks ER. Results
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showed a 50% to 70% reduction in VEGF secretion (p = .05) between the various
xenoestrogens, suggesting that ERα is needed for its secretion. It was further determined
if this activity was mediated by ER regulated kinases, the MELN cells were treated with
various kinase inhibitors (e.g., SB2035580 inhibits MAPK, and Wortmannin inhibits PI3K/Akt pathway). It was observed that different xenoestrogens used different kinases for
modulating VEGF secretion in breast cancer. For example, for BBP, OP, and dieldrin, the
VEGF secretion was reduced by the MAPK inhibitor and the PI-3/Akt inhibitor; whereas
only MAPK inhibitor reduced VEGF in the case of genestin suggesting similar and
different pathways are involved for different xenoestrogens. Interestingly, VEGF also
modulated with the increase in Her2 expression/copy numbers (Konecny et al., 2004; Ye
& Lu, 2010), and once again the cellular endpoints reached with the applications of
xenoestrogens overlapped with those observed when Her2 is over expressed, thus,
making it biologically plausible that this oncogene was being activated in this process.
Mediate Cellular Proliferation by Other Pathways (Androgenic Pathway)
Xenoestrogens, such as DDE utilized various cellular pathways and augmented
breast cancer progression. Principally, it has been known that xenoestrogens used the
estrogenic signaling pathway to produce cellular proliferation. Another direction explored
by Aube, Larochelle, & Ayotte (2008) studied the effects of DDE on cellular growth by
opposing the androgenic pathway using CAMA-1 cell-lines that expressed both ERα as
well as androgen receptors (AR), and MCF-AR line that was genetically manipulated to
express AR. Cell proliferation assays captured cellular growth. The cells were grown in
DDE alone, or with E2 and Dihydrotestoterone (DHT). Steroid dependant gene
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expression; such as ESR1, CCND1 (Cyclin D1), and AR was studied using RT-PCR or
immunoblotting. Notably, an inverse concentration response relationship between
increasing DHT (androgen) concentration and cell growth (coefficient β=0.887, p=<
0.001) was observed. When combined with E2, DHT decreased the proliferation response
at 27% (p = <.05), 54% (p = <.001), and 60% (p = <.001) with 100, 500, and 1,000
picomolar concentrations of AR respectively. Additionally, DDE alone had the capacity
to induce cellular growth response (3 to 3.5 times at 5 and 10uM respectively, p = <.001).
Gene expression levels for E2 treated cells had up-regulated CCND1 mRNA (50%
increase, p = <.01), but adding DHT (androgen) in nanomolar quantity (1nM)
significantly decreased this expression (p = <.01). The CCND1 gene regulates the
passage of cells from G1 (resting phase) to S (synthesis phase) in breast cell growth. E2
plus DHT markedly decreased ERα (>50% decrease, p = <.05), and CCND1 (~60%
decrease, p = <.01) expression levels compared to adding E2 alone whereas AR
expression was significantly heightened (~50% increase, p = <.01). Adding E2 alone
decreased (28%) AR expression significantly (p = <.05). Results of this study bear
evidence that DDE can significantly increase cellular growth of breast cancer line by
modulating not only its estrogenic response, but also its anti-androgenic responses. Thus,
more than a single pathway could be used by various xenoestrogens to induce cell
growth.
A confirmatory study to this end was performed by Aube, Larochelle, & Ayotte
(2011), where they studied the androgenic and estrogenic effects of organochlorine (OC)
mixtures in human breast cancer lines using reporter gene assays. For the estrogenic
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assay, MCF7 line was exposed to various concentrations (0.05-5 µM) of OC mixture for
24 hours in the presence of 1 nM estrogen (E2), and for the androgenic assay, the
CAMA-1 line was exposed to various concentrations (0.01-10 µM) of OC mixture for 24
hours in the presence of testosterone (DHT). Receptor expression assays showed that
both of these lines had equal amounts of the estrogen receptors (ERs), but CAMA-1 line
had greater amount of the androgenic receptors (ARs) when compared to the MCF7 line.
The results of the gene reporter assays showed that the OC mixtures induced the
estrogenic pathway in the MCF7 line that had a lower expression of the androgenic
receptors, whereas the OCs inhibited the androgenic pathway in the CAMA-1 line which
had a higher expression of androgenic receptors compared to the MCF7 line.
Increase Intracellular ERα
La Rosa, Pellegrini, Totta, Acconcia, and Marino (2014) studied the effects of
BPA, a synthetic xenoestrogen vs. Naringinin (Nar), a plant derived xenoestrogen on
intracellular ERα levels when stimulated by estrogen (E2). Using MCF7 line, they
performed dosimetric analysis on the ERα protein (mRNA) expression after stimulating
the cells either with E2, BPA, and Nar for 48 hours. The mRNA expression on ERα was
then assessed by Western blots. The results showed that while Nar prevented intracellular
ERα from degradation, BPA promoted ERα degradation. Additionally, cell proliferation
assays performed on both xenoestrogens, it was observed that BPA increases cell growth
with highest proliferative index observed at 10-5 M concentration (p=<.001), whereas Nar
decreases cell growth which is dose-dependent with significant decreases (p=<.001)
occurring between 10-7 to 10-4 M concentrations compared to the control. Comparing the
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proliferation rates with E2, it was noted that E2 also increased cellular growth, and BPA
reached similar growth curves as E2 at 10-5 M concentration. Together, these experiments
elucidated how synthetic xenoestrogens and plant derived xenoestrogens had activated
and modulated ERα levels in opposing ways.
Xenoestrogens and Breast Cancer Risk: Population-based Studies
Population-based studies using Xenoestrogens have been conducted mainly on
organochlorines and their derivatives or pharmaceutical estrogens. The data is confusing
since most of these studies; especially with organochlorines have yielded negative results,
but a handful of these studies were showing positive results also and cannot be ignored.
In the following section, first, the studies performed using organochlorines and their
derivatives will be described and assessed for their strengths and limitations, followed by
the same for studies conducted using pharmaceutical estrogens.
Organochlorines
Demers, Ayotte, Brisson, Dodin, Robert, & Dowally (2000) assessed the risk of
breast cancer initiation as well as cancer progression in relation to various
organochlorines using case-control study design. Plasma concentrations of 11 chlorinated
and 14 polychlorinated biphenyl congeners was measured in 315 newly diagnosed cases,
and 526 controls matched on age and residence. Of the controls, 219 were gynecological
disease-free hospital-based, and 307 were randomly chosen. Cases were stratified mainly
by tumor-size and metastasis. Organochlorines levels were divided into tertiles, based
upon their distribution found in the controls. Mean concentrations of the organochlorines

85
between the cases and the controls were similar, showing no increase in risk of disease
initiation.
Statistical analysis was performed on cases classified by disease status to address
if potential risk of disease progression is present. After confounding (age, parity, body
mass index, residence, and breast feeding) adjustments, results indicate that the odds of
having a more aggressive tumor was significant in women with increased exposure of the
following: a) β-HCB (OR = 2.25, 95% CI = 1.12-4.51), b) trans-nonachlor (OR = 2.27,
95% CI = 1.11-4.65) showed an increased tumor size (≥2 cm) comparing the highest (4th)
to the lowest (1st) exposures; whereas c) p-p’DDE (OR = 2.9, 95% CI = 1.43-5.91), d)
oxychlordane (OR = 2.34, 95% CI = 1.10-4.97), and e) PCB congener 153 (OR=2.12,
95% CI=1.05-4.30) showed increased metastasis comparing 1st and 3rd exposure tertiles.
Relationship between cancer aggressiveness and p-p’DDE was further dissected for
dosimetric effects. Both, tumor progression characteristics increased in a dose-dependent
fashion. The OR for 2nd compared to 1st tertile was 2.23 (95% CI = 0.94-5.77), and
comparing the 3rd to the 1st generated an OR of 3.51 (95% CI = 1.41-8.73). Similarly, βHCB (OR = 3.91, 95% CI = 1.47-10.35), and oxychlordane (OR = 3.22, 95% CI = 1.188.80) also showed an increased risk for higher levels of exposure.
A prospective case-control study by Hoyer, Jorgensen, Grandjean, & Hartvig
(2000) suggested that repeat measurements of xenoestrogens like organochlorines
provided for a more accurate method of breast cancer risk assessment compared to a
single measure, and that multiple exposures to xenoestrogens can change the risk of
breast cancer over time. Totally, 155 cases and 274 matched controls from Denmark
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participated. Sera collected over a 5 year period was subjected to gas chromatography for
isomers of DDT, total DDT, and PCBs. Trend analyses with two measurements yielded a
significant dose-response relationship only with p, p’DDT and PCB138. More than a
three-fold increase in breast cancer risk was noted only for p,-p’DDT (OR (1st exam) =
1.9, 95% CI = 0.9-4.3; OR (2nd exam) = 3.6, 95% CI = 1.1-12.2, Ptrend = 0.02), and for
PCB congener 138 the risk for breast cancer increased by 2.5 times (OR (1st exam) = 1.4,
95% CI = 0.8-2.6; OR (2nd exam) = 2.1, 95% CI = 1.0-4.4, Ptrend = 0.04). No
associations were observed with any other isomer. A significant dose-response
relationship was noted only with p, p’DDT and PCB138.
Another study by Hoyer, Jorgensen, Rank, & Grandjean (2001) has shown that
exposure to xenoestrogens does not necessarily lead to ER positive breast cancer. To
evaluate the influence of organochlorines on breast cancer risk according the hormone
receptor status, a case only study (n=161) was done. Tumor characteristics were obtained
from the hospital. Paraffin-embedded sections showed 7:3 ratios of ER positive and
negative tumors. Interestingly, even though a vast majority of the tumors were ER
positive, but, a higher tumor stage (RR = 5.4, 95% CI = 1.8-15.9), size (RR = 4.6, 95%
CI = 1.7-12.3), and metastasis (RR = 6.0, 95% CI = 2.1-16.9) were found to be
significantly associated with ER negative tumors. For ER negative women, a 7-fold
increased risk of developing breast cancer was noted for the highest levels of dieldrin
exposure when compared to those with the lowest level (OR 1st vs. 4th quartile = 7.6, 95%
CI = 1.4-46.1, Ptrend = 0.01), and the risk was two and a half times more with PCBs (OR
1st vs. 4th quartile = 2.6, 95% CI = 1.1-5.7, Ptrend = 0.02). This study indicated that
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exposures to certain organochlorines increased the risk of developing ER negative
cancers which represent a poor prognosis for the patients, because these tumors are larger
and have a high metastatic grade. A limitation of this study was that the numbers of ER
negative patients (n = 45) was small leading to insufficient power, and should be
interpreted with caution.
Warner et al. (2002) used a historical cohort from the 1976 industrial accident in
Seveso, Italy and studied the association between TCDD and breast cancer risk. Archival
samples from 981 women between 11 to 40 years were studied. Cases were ascertained
by in-person interviews and medical records. Biopsies were reviewed by a pathologist,
and TCDD levels assessed by gas chromatography. A double-blinded study was
conducted which added to the validity due to lack of bias. Hazard modeling was done on:
a) categorical variables; where the categories of exposure were <20 parts per trillion
(ppt), 20.1 to 44 ppt, 44.1 to 100 ppt, and >100 ppt, and b) continuous variables as log10
TCDD. Fifteen of the 981 women (15/981) developed breast cancer. Three (3/981) died
due to it, and were not included. The average age at the time of explosion and diagnosis
was 30 years (range: 14 to 39 years), and 45 years (range: 31 to 57 years) respectively.
Therefore, it took almost 15 years for the disease to have occurred, thus marking its latent
period. Median TCDD levels observed in the cases vs. controls were much higher (71.8
ppt vs. 55.1 ppt respectively). The continuous variable projected doubling of hazard rates
for every 10 fold increment in exposure (e.g., from 10 ppt of exposure to 100 ppt of
exposure) in TCDD exposure levels (HR = 2.1, 95% CI = 1.0 to 4.6, p = 0.05).
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Again, a limiting factor of this study was the small number of cases present.
However, an important point raised by the researchers was that the expected age-specific
incidence rates for breast cancer for Seveso between 1988 through 1992 should be 11
cases, but they report 15, making the standardized incidence rates (SIR) higher than
expected (1.36). Furthermore, if the three women who died were included, the SIR would
be even greater than 1.36. Although, this study showed that acute xenoestrogen exposures
like TCDD were significantly associated with breast cancer incidence, but it cannot
provide for everyday low to moderate levels of exposures that most women are subjected
to.
Aschengrau, Rogers, & Ozonoff (2002) investigated the association between
perchloroethylene (PCE) found leaching from the drinking water-pipes into the water
system, and the risk of developing breast cancer. They hypothesized that PCE acts as a
genotoxic agent either directly or indirectly via metabolites, hence increased the risk of
breast cancer. Cases comprised of 672 women diagnosed with breast cancer, and 616
controls matched for location and age. Exposure was an estimated amount of PCE
entering residences by water-pipes. Measurements were based on a PCE leaching model;
which relies on the rate of water flow estimated by pipe attributes and the amount of
water that it can distribute called pipe-load. Geographic information systems (GIS)
mapped the participants thus aiding locating participants with different pipe-line
characteristics (e.g., diameter, composition, year installed). Only a small to moderate risk
was observed for women that were exposed between 75th percentile, and 90th percentile
exposure levels (OR (adjusted) = 1.3 to 2.8, and 1.5 to 1.9 respectively).
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In 2002, Gammon et al. conducted a case-control study to evaluate the risk of
breast cancer associated with various organochlorines with disparate estrogenic
properties (e.g., p, p’DDT, p, p’DDE, dieldrin, PCBs). Cases (n = 415) were newly
diagnosed with breast cancer, and controls (n = 406) were matched for age and residency.
Like the previous study, this study also found only a small increment in risk between the
highest vs. the lowest exposure groups for DDE (OR = 1.20, 95% CI = 0.76 to 1.90), and
dieldrin (OR = 1.37, 95% CI = 0.69 to 2.72). Effect modifications could not be
ascertained as the sample size became too small to investigate their effects.
Charlier et al. (2003) evaluated the risk of breast cancer with organochlorine
exposure by measuring blood levels of DDT and hexachlorobenzene (HCB). All
participants were White women. Cases (n = 159), and controls (n = 250) matched for
smoking, age, residence, breast-feeding, menopause, and reproduction history. Mean
DDT and HCB concentrations obtained by gas chromatography were significantly more
in cases compared to controls (3.94 vs. 1.83 parts per billion(ppb) for DDT, p = <.0001;
and 0.79 vs. 0.09 ppb for HCB, p = .0005 for cases and controls respectively). Notably,
the blood concentrations of DDT and HCB were independent of the smoking status (50%
vs. 44% respectively, p = .54), or residence (56% vs. 52% respectively, p = .66).
Surprisingly, the ER status did not co-relate with DDT (r = 0.02, p = 0.08) or HCB
concentrations (r = 0.09, p = .49). However, since all their data comes from White
women only, the generalizability of the research conducted was limited, especially since
another study (Rosenberg et al., 2008) indicated that interethnic variations can play an
important role in breast cancer.
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Another factor that played a role towards an increased susceptibility to breast
cancer with xenoestrogenic exposure is age at which the exposure occurred. Cohn, Wolff,
Cirillo, & Scholtz (2007) used a prospective case-control design and examined if p,
p’DDT exposure in early adolescence (<14 years of age) increased breast cancer risk later
during adult life. A 1:1 ratio of cases and controls (n = 258), were matched for age and
residence. Commercial grade DDT with p, p’DDT (active ingredient), o, p’DDT
(contaminant), and p, p’DDE (metabolite) were analyzed. A five-fold increased risk of
breast cancer was found only for women that were less than 14 years of age during
exposure (OR = 5.2, CI = 1.7 to 17.1, p = <.001). Further, only p, p’DDT showed an
increased risk for breast cancer (OR = 2.9, CI = 1.1 to 8.0, p = .04). Once again, the
possible mechanism indicated for p, p’DDT being associated with the increased risk is
genotoxicity.
Xenoestrogens affected the biological nature of the fat tissue found in the nearby
stroma to where the breast tumor occurs. This could bear important implications in the
progression of breast cancer. Using a case only design, Munoz-de-Toro et al. (2006)
examined the burden of organochlorines from various pesticides and PCBs in invasive
breast carcinomas (n = 55). Gas chromatography measured organochlorine content, and
IHC assessed biomarkers of breast cancer within the breast tumors plus the stroma
surrounding it. Results showed that all the patients had increased levels of organochlorine
residues with the highest values of DDE and β-HCH at 4,794 parts per billion (ppb), and
1,780 ppb respectively. Post-menopausal women had higher levels (≥2,600 ppb) of
organochlorine concentrations in the surrounding stroma; and vice-versa for the pre-
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menopausal women (<2600 ppb). A positive association between dietary fat intake and
tumor growth (Fischer’s exact, p = .025) was also revealed. As this study was performed
in vivo, it brings about a real-time facet of the diverse effects that organochlorines can
have on different cells that compose the breast tissue.
In a recent case-control study conducted by Boada et al. (2012), the researchers
assessed the association between exposures to mixtures of organochlorines and the risk of
developing breast cancer. The study was conducted in Spain (Gran Canaria Islands) using
103 healthy women and 121 women that were diagnosed with breast cancer. The
organochlorine pesticides (OCPs) examined were p,p´-DDT, o,p´-DDT (DDT isomers),
p,p´-DDE, o,p´-DDE, p,p´-DDD, and o,p´-DDD (DDT metabolites), aldrin, dieldrin,
endrin, cyclodienes, and lindane. There was a statistically significant difference in the
demographics of the study population, specifically, the mean age (58±11.7 vs. 45.3±13.8
years for controls, p = <.001), and the BMI of the cases as compared to the controls
(27.7±4.8 vs. 26.3±4.3 kg/m2 respectively, p = .031).
The results showed that median values of DDT were higher among the healthy
controls compared to the women with breast cancer (217 vs. 153 ng/g of lipid
respectively; p = < .001). But, vice-versa results were noted for DDE and DDD as their
levels were higher among breast cancer cases compared to the healthy controls (DDE:
300 vs. 167ng/g lipid; DDD: 0.0 vs. 551 ng/g lipid, respectively, p = <.001 for DDE &
DDD). Consequently, it follows that the body burden of total DDT residues were found
to be significantly greater in women with breast cancer when compared to the healthy
controls (979 vs. 665 ng/g lipid respectively, p = <.001). However, contrastingly, the total
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cyclodienes and lindane burden was found to more in the healthy controls compared to
the women suffering with breast cancer (91.4 vs. 80 ng/g lipid respectively, p = .027).
An interesting set of results were observed in this study, mainly, the two groups
had a differences that were statistically significant body burden for different sets of OCPs
between the case and the control groups, that is, none of the healthy controls had a
combination of aldrin and DDE and DDD, and none of the women with breast cancer had
a combination of lindane and endrin residues. Also, it was observed that the main
ingredient of DDT (i.e., p, p’DDT) was detected in the serum of more than 70% of both
the groups (cases and controls), but DDT has been banned in Spain since 1970s; similar
to the USA. This indicates that DDT residues still exists even though it has been almost
three decades since its effective ban.
Furthermore, their findings were comparable to those observed by Aube,
Larochelle, & Ayotte (2011), where the researcher performed gene reporter assays after
exposing MCF7 breast cancer cell line to mixtures of 15 different organochlorines; and
found that DDT and its analogs caused cellular growth and division of the MCF7 cells.
Besides these studies that have found positive associations between
organochlorine exposures and breast, there are others that have yielded a negative result.
A list of these studies appears in Table 2.
Table 2
Epidemiological Studies that Resulted in No Association of Breast Cancer Risk to
Organochlorine Exposures
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Reference
& Year

Type of
Study &
Cohort

Krieger et
al. (1994)

Nested Study,
San Francisco
multiphase
health exam
participants
(California)
Case-Control,
Hospital based
(multicenter,
Europe)
Case-Control,
Hospital Based
(Mexico City)
Nested, Nurses’
Health Study
(NHS), Boston,
Massachusetts

van’t Veer
et al.
(1997)
LopezCarillo et
al. (1997)
Hunter et
al. (1997)

Helzlsouer
et al.
(1999)

^Zheng et
al. (1999)

OCs

# of Cases
(Mean exposure)

# of Controls
(Mean
exposure)

OR
(95% CI)

DDE

150
(43.3 ppb ng/ml)

150
(43.1 ppb ng/ml)

DDE

374
(1.35 µg/g)

DDE

DDE &
PCBs

Nested,
Campaign
Against Cancer
& Stroke,
Washington
County,
Maryland.
Samples
assessed in
1974 and 1989

DDE
& 26
PCB
congen
ers
(PCBs)

Case-Control,
Hospital Based
(Connecticut)

DDE &
DDT

Exposure
Assessed

PValue

1.33
(0.68 -2.2)

4th vs. 1st
quartile

Ptrend 0.43

374
(1.51 µg/g)

0.73
(0.44 -1.2)

4th vs. 1st
quartile

Ptrend 0.02

141
(567.2 ppb)

141
(505.4 ppb)

0.69
(0.38 -1.2)

Ptrend ≥ .05
for both

DDE
236
(Median = 6.0
ppb)

DDE
236
(Median = 6.9
ppb)

DDE
0.72
(0.37 1.4)

3rd vs. 1st
2nd vs. 1st
quartiles
5th vs. 1st
Quintile
for DDE &
PCBs

PCBs
230
(Median = 5.0 ppb)

PCBs
230
(Median = 5.1
ppb)
346
(DDE, 1974
13.6 ng/ml)
(DDE, 1989
9.6 ng/ml)

PCBs
0.66
(0.32 1.37)

346
(DDE, 1974 11.5
ng/ml) (DDE, 1989
7.9 ng/ml)
(PCBs, 1974
4.9 ng/ml)
(PCBs, 1989
2.1 ng/ml)

(PCBs, 1974
4.7 ng/ml)
(PCBs, 1989
2.2 ng/ml)

DDE, 1974
0.5
(0.27-0.89)
DDE, 1989
0.53
(0.24-1.17)
PCBs, 1974
0.68
(0.36-1.29)
PCBs, 1989
0.73
(0.37-1.46)

304
(DDE:
736 ppb)

186 (w/BBD)
(DDE:
784 ppb)

DDE
0.9
(0.5-1.5)

(DDT:
51.8 ppb)

(DDT:
55.6 ppb)

DDT
0.8
(0.5-1.5)

RR
(95%
CI)

1974
5th vs. 1st
quintile for
DDE &
PCBs
1989
3rd vs. 1st
quintile for
DDE &
PCBs

4th vs. 1st
quartile for
DDE &
DDT

(table continues)

Ptrend 0.43
for DDE
and PCBs

DDE,
1974
Ptrend 0.02
DDE,
1989
Ptrend 0.08
PCBs,
1974
Ptrend 0.13
PCBs,
1989
Ptrend 0.15
DDE
Ptrend 0.41
DDT
Ptrend 0.22
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Reference
& Year

Type of Study
& Cohort

^Bagga et
al. (1999)

Unmatched
Case-Control
study, Hospital
Based, Kaiser
Permanente,
Woodland Hills
(California)

OCs

DDT,
DDE,
DDD,
& DDT
+ DDE
+ DDD

# of Cases
(Mean exposure)

# of Controls
(Mean exposure)

OR
(95% CI)

73
(Serum,
DDT:
197.6 ng/g
^^DDE:
642.0 ng/g
DDD:
21.7 ng/g
DDT + DDE +
DDD:
861.4 ng/g)

73
w/mammomegaly
(Serum,
DDT:
231 ng/g
^^DDE:
693.6 ng/g
DDD:
9.2 ng/g
DDT + DDE +
DDD:
934.3 ng/g)
(Lipid,
DDT:
261.3 ng/g
^^DDE:
800.0 ng/g
DDD:
9.8 ng/g
DDT + DDE +
DDD:
1,071 ng/g)

DDT
1.05
(0.93-1.1)

(Lipid,
DDT:
267.3 ng/g
^^DDE:
709.1 ng/g
DDD:
24.0 ng/g
DDT + DDE +
DDD:
861.4 ng/g)

^Zheng et
al. (2000)

^Stellman
et al.
(2000)

Ward et al.
(2000)

Case-Control,
Yale-New
Haven Hospital
(cases &
controls),
Tolland & New
Haven
(controls)
(Connecticut)
Case-Control,
Two hospital
based,
Long Island,
New York

Case-Control,
Farm workers,
(Norway)

502
(DDE:
457.2 ppb)

DDE
0.96
(0.67-1.36)

(PCBs:
733.1 ppb)

(PCBs:
747.1 ppb)

PCBs
0.95
(0.68-1.32)

7 OCPs
& 14
PCB
congen
ers
(PCBs)

232
(OCPs:
1080 ng/g, 75th
percentile)

323
w/BBD
(OCPs:
1094 ng/g, 75th
percentile)

71
OCs, &
26 PCB
congen
ers
(PCBs)

150
(∑PCBs, serum
4.76 ng/g
∑PCBs, lipid
776.1 ng/g)
(Range:
∑OCs, serum
0.5x10-3 to 7.9 ng/g
∑OCs, lipid
0.080 to 1230 ng/g)

150
(∑PCBs, serum
5.09 ng/g
∑PCBs, lipid
806.6 ng/g)

P - Value

Two-way ttest

DDT
P = 0.42
DDE
P = 0.50

DDT + DDE
+ DDD
0.90
(0.71–1.15)

475
(DDE:
460.1 ppb)

(PCBs:
382 ng/g, 75th
percentile)

Exposure
Assessed

DDE
1.13
(0.8-1.6)

DDE &
9 PCB
congen
ers
(PCBs)

(PCBs:
458 ng/g, 75th
percentile)

RR
(95%
CI)

OCPs
1.29
(0.8-2.0)

3rd vs. 1st
tertile for
DDE &
PCBs

DDE
Ptrend 0.58
PCBs
Ptrend 0.44

Highest
magnitude
of OR
(1.29)
observed in
the middle
tertile of
OCPs

Ptrend ≥ .05
for OCPs
& PCBs

Paired
t-tests for
∑PCBs &
∑OCs

∑PCBs =
0.47

∑PCBs:
Q4 = 0.5
(Range:
∑OCs, serum
0.5x10-3 to 8.23
ng/g
∑OCs, lipid
0.084 to
1260 ng/g)

∑OCs:
Range =
0.2 - 1.8

(table continues)

∑OCs =
≥0.05
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Reference
& Year

Type of Study
& Cohort

OCs

*Millikan
et al.
(2000)

Case-Control,
Rural
populationbased, farm
workers, AAW
& WW
(North
Carolina)

DDE &
PCBs

Nested, Nurses’
Health Study
(NHS), Boston,
Massachusetts

DDE,
PCB
congen
ers
118,
138,
153,
180 &
∑PCBs

370
Median (µg/g)

DDE &
31
other
organochlorin
es

409
Mean Range
(∑OCs:
3.3 - 639.0 µg/Kg
lipids)

Laden et al.
(2001)

RaaschouNielson et
al. (2005)

Nested, Danish
Diet, Cancer &
Health Cohort
(Postmenopausal
women only)

# of Cases
(Mean exposure)

# of Controls
(Mean exposure)

AAW
292
(DDE:
9.90 ppb ng/ml
PCBs:
2.79 ppb ng/ml)

AAW
270
(DDE:
8.82 ppb ng/ml
PCBs:
2.56 ppb ng/ml)

WW
456
(DDE:
3.52 ppb ng/ml
PCBs:
1.89 ppb ng/ml)

WW
389
(DDE:
3.94 ppb ng/ml
PCBs:
1.89 ppb ng/ml)

370
Median
(µg/g)

DDE = 0.77

OR
(95% CI)

RR
(95%
CI)

AAW
DDE
1.47
(0.87-2.2)
PCBs
1.74 (1.0 –
3.0)
WW
DDE
0.98
(0.67-1.4)
PCBs
1.03 (0.681.6)
DDE
0.82
(0.491.37)

Exposure
Assessed

P - Value

3rd vs. 1st
tertile

Ptrend ≥ .05
DDE &
PCBs in
AAW* or
WW

5th vs. 1st
quintile for
all

Ptrend
DDE =
0.15

DDE = 0.82
∑PCBs = 0.54
∑PCBs = 0.54
Congener
118 = 0.9
138 = 0.9
153 = 0.11
180 = 0.07

Congener
118 = 0.07
138 = 0.09
153 = 0.11
180 = 0.08

409
Mean Range
(∑OCs:
3.3 - 686.3
µg/Kg lipids)

∑PCBs =
0.56
PCB118 =
0.67
PCB138 =
0.21
PCB153 =
0.26
PCB180 =
0.67

∑PCBs
0.84
(0.471.52)
PCB118
0.69
(0.391.22)
PCB138
0.87
(0.5-1.5)
PCB153
0.83
(0.471.48)
PCB180
0.98
(0.551.75)

∑OCs
1.1
(0.7 1.7)

4th vs. 1st
quartile for
∑OCs &
DDE

DDE
0.7
(0.5 1.2)

(table continues)

Ptrend
∑OCs =
0.44
Ptrend
∑DDE =
0.29
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Reference
& Year

Type of Study
& Cohort

OCs

Rubin et al.
(2006)

Case-Control,
Native
American
Communitybased
(Alaska)

Gatto et al.
(2007)

Iwasaki et
al. (2008)

# of Cases
(Mean exposure)

# of Controls
(Mean exposure)

OR
(95% CI)

DDE &
28
congen
ers
(∑PCB
s)

63
(DDE:
8.6 ppb)

63
(DDE:
7.36 ppb)

DDE
0.42
(0.07-2.38)

(∑PCBs:
4.55 ppb)

(∑PCBs:
6.1 ppb)

∑PCBs
1.43
(0.46-4.47)

Nested, multicenter,
Women’s
Contraceptive
& Reproductive
Experiences
(CARE) Study

DDE &
PCB
congen
ers
(PCBs)

355
(PCBs:
2.2 g/L (serum)
0.31g/g
(lipid)

327
(PCBs:
2.0 g/L (serum)
0.31g/g
(lipid)

DDE
1.02
(0.61-1.72)

(DDE:
9.9g/L
(serum)
1.4g/g
(lipid)

(DDE:
8.1g/L
(serum)
1.3g/g
(lipid)

Nested CaseControl study,
Japanese Public
Health Center

p,p’DD
T,
p,p’DD
E,
HCB,
&
β-HCB

139

278

RR
(95%
CI)

Exposure
Assessed

P - Value

4th vs. 1st
quartile for
DDE &
∑PCBs

Ptrend
≥0.05 for
DDE &
∑PCBs

5th vs. 1st
quintile

Ptrend
DDE =
0.74
PCBs =
0.56

4th vs. 1st
quartile

Ptrend
DDE =
0.25

PCBs
1.01
(0.63-1.63)

p,p’DDE
1.48
(0.70-3.13)
p,p’DDT,
HCB, &
β-HCB
<1.0

Note. OCs=Organochlorines, OCPs=Organochlorine pesticides, AAW=African American
Women, WW=White Women, ^=Controls with Breast Disease [Benign Breast Disease
(BBD) or mammomegaly], ^^ =Mean differences in the amount of DDE found between
the cases and the controls was statistically significant (p=.005 and .006 for serum and
lipid, respectively), *=Study used race-specific Body Mass Index (BMI). In this study,
stratification for BMI showed a positive association in the highest levels of BMI for
AAW for total PCBs (OR=4.92, 95% CI=1.63-14.83) & DDE (OR=1.90, 95% CI=0.715.09). (Table was made by self using Microsoft Word, 2007).
A major shortcoming in several of the larger case-control studies that have
yielded a negative association between organochlorine exposures and breast cancer risk
(Zheng et al., 1999; Bagga et al., 1999; Zheng et al., 2000; and Stellman et al., 2000) is
the usage of controls that suffer with breast disease; either benign breast disease (BBD)
or mammomegaly (MM). A study by Dupont et al. (1994) reported that women that have
had a history of BBD have a greater probability of developing breast cancer, and
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enrolling a control population with a previous breast condition may have skewed the
results towards the null by acting as possible confounders in these studies. Furthermore,
in the study conducted by Bagga et al. (1999) the mean values of lipid and serum DDE
between the controls and the cases were found to be significantly different (serum: 642
vs. 693.6 ng/g, P=.005; lipid: 709.1 vs. 800 ng/g, P=.006 respectively), however, the odds
ratios were found to be non-significant. The use of unmatched controls for the study may
have caused this discrepancy in the study result.
Interestingly, the study conducted by Millikan et al. (2000) overall did not show a
positive association, but when the AAW were stratified using race-specific BMI, then the
women with the highest BMI values were found to be at risk for breast cancer with
exposures to PCBs and DDE. These facts may add up since xenoestrogens
(organochlorines) are stored in the adipose (fat) cells in the body, so a person with higher
BMI values may have a greater risk of developing breast cancer upon exposure to
xenoestrogens.
Some case-control studies conducted on organochlorine (DDE) exposure for their
associated risk for breast cancer in the 1990s (Djorveck et al., 1994; Falck, Ricci, Wolff,
Godbold, & Deckers, 1992) had shown a positive association between the variables, but
the sample size was too small (<20 subjects in each group). Falck et al. (1992) had
enrolled 20 cases and controls, and the study conducted by Djorveck et al. (1994) the
sample size consisted of only 5 cases and control subjects. In another study conducted in
Canada by Dewailly et al. (1994), the researchers found a positive association of DDE
exposures and breast cancer risk, but only in women with breast cancer that had a
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positive ER status, but this study only had 18 cases and controls, of which 9 case subjects
were ER-positive. Due to the extremely small sample sizes in these aforementioned
studies the positive results will need to be viewed with extreme caution.
Pharmaceutical Estrogens
Gammon et al. (1999) utilized a case-control design to evaluate the relationship
between the use of oral contraceptives (OCs) and Her2 protein over-expression. Her2
expression was assessed by IHC on paraffin-embedded tissue on a cohort of women
between 20 to 44 years, with newly diagnosed invasive breast cancer. Information was
obtained by in-person interviews from 509 cases and 462 controls. Confounders assessed
were contraceptive use, body mass index (BMI), reproductive and family history. IHC
experiments were successfully conducted only in 371 of the 509 cases. Among those that
were tested, 159 (43%), cases showed an over-expression of Her2 receptor, and these
women had a more aggressive disease. Furthermore, when compared to controls, these
women were mostly ER negative. The study had also demonstrated that the risk of having
a Her2 positive cancer is heightened by more than two-fold when contraceptive usage
begins early (<18 years) (OR = 2.39, 95% CI = 1.08 to 5.30, p = <.05). A Her2 positive
status indicated that the Her2 proto-oncogene found in two copies in each human cell
(i.e., Her2 negative state) had mutated into its oncogenic state, and resulted in the copy
number increase/amplification of the Her2 gene. In its mutated or oncogenic form in the
breast tissue, this gene causes breast cancer with a more aggressive disease and high
mortality rates (Hynes et al., 1994; Meng et al., 2004; Slamon et al., 1989). This study
found that a significant amount of risk is associated with the use of oral contraceptives
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when their usage had started at an early age (<18 years old), and the risk of having a
Her2 over-expressed tumor increased when the usage of contraceptives had begun during
adolescence.
Von Hoften et al. (2000) conducted a case-control study in the Netherlands, where
309 histology confirmed cases of breast cancer were compared to 610 disease-free
controls with respect to oral contraceptive use. Questionnaires were administered to study
participants capturing information to oral contraceptive usage, medical and reproductive
history, and demographic and behavioral data (e.g., weight, height, diet). The study found
that women who used an OC for more than a decade had twice the risk of breast cancer
(OR = 2.1, 95% CI = 1.1 to 4.0), nevertheless, it was non-significant. The authors noted,
however, that 13.6% of cases and 9% of control participants were also using oral
contraceptives. This may have skewed the OR values. Additionally, the type of oral
contraceptive was not determined, which made it impossible to assess whether one oral
contraceptive increased the risk of breast cancer more than the other.
To answer this question and reduce recall bias, Kumle et al. (2000) specifically
designed a population-based prospective study. Women that were between the ages of 30
to 49 years from Norway and Sweden were randomly enrolled to study the associated risk
of breast cancer in relation to the type of oral contraceptive preparation and the duration
of its use in pre-menopausal women. The sample consisted of 103,027 women, 1008 of
which had developed breast cancer. Exposure information was based on a questionnaire
filled during enrollment. Contraceptive use was defined as the various time-periods an
oral contraceptive was used and the type of contraceptive pill that was used. Summing all
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of the time-periods yielded the duration of oral contraceptive usage. A significant
interaction (p = .031) was noted between current use of oral contraceptive and age at
follow-up, so the sample was further stratified into two age-groups: 30 to 39, and 40 to 49
years with respect to their possible menopausal status at the end of follow-up. Regardless
of the type of oral contraceptive used, the current users were at an increased risk (RR =
1.6, 95%CI = 1.2-2.1). Similar risk estimates were noted for women using a combination
of estrogen and progestin pills, as well as for those who used progestin pills alone (RR =
1.5, 95% CI = 1.0-2.0). Trend data compared women who had used oral contraceptives
for more than five years to those that were never users showed that women that had used
oral contraceptives for an extended period of time (≥5 years) were at an increased risk of
developing breast cancer compared to those that had never used any oral contraceptives
in their lives (p = .005).
Weiss et al. (2002) investigated the risk associated with hormone replacement
therapy (HRT) regimens, recent use, and duration in relation to breast cancer in postmenopausal women between the ages of 35 and 64 years. Cases (n = 1,870) of breast
cancer were histologically graded, and age and residence matched to the controls (n =
1,953). Exposures were stratified by estrogen replacement therapy (ERT), combined
HRT, and ERT plus combined HRT. An increased risk of breast cancer was associated
only with an HRT regimen that consisted of a progestin component, and had been used
for five or more years. The risk of developing breast cancer was almost one and a half
times more when combined HRT was used for five or more years (OR = 1.45, 95% CI =
1.09 to 1.91), and statistically significant (p = .01). Trend analysis also showed an
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elevated risk with increased usage duration of the combined (Ptrend = .003), and
continuous combined HRT (Ptrend = .01) regimens. Similarly, trend analysis between past
and recent users demonstrated that combined as well as continuous combined HRT
represents a significant risk (p = .04 and .03 respectively). No risk was noted with ERT.
In this particular instance, the evidence suggested that progestin and the duration of
therapy increased the risk of developing breast cancer. Importantly, this study suggested
that all oral contraceptives (xenoestrogens) may not incur a similar level of risk of breast
cancer and that they had different carcinogenic potential.
Althuis et al. (2003) examined the relationship between breast cancer risk and
various strengths and types of oral contraceptives pills in women between the ages of 25
and 54 years. A sample of newly diagnosed breast cancer patients (n = 1,640) were
compared to randomly selected controls (n = 1,492). Results showed that women who
were younger than 35 years who had used birth control pills within five years of their
diagnoses had the greatest risk of developing breast cancer (RR = 2.22, 95% CI = 1.4 to
3.5) compared to older women (35 to 44 years) (RR = 1.44, 95% CI = 1.30 to 1.80).
More than 35 micrograms of EE was associated with a significant risk of breast cancer
for women under 35 years of age (RR =3.62, 95% CI = 1.7 to 7.9) compared to women
between the ages of 35 and 44 years (RR=1.52, 95% CI=.8 to 2.8, Ptrend = <.01). When
the type of hormone was examined, an increased risk was observed in women under the
age of 35 years using high strength progestin (RR = 8.11, 95% CI = 2.1 to 31.6) and
estrogen (RR = 2.56, 95% CI = 0.7- to .9) pills.
To take stock of the various studies conducted in this area of research,
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Kahlenborn, Modugno, Potter, & Severs (2006) conducted a meta-analysis by pooled
data from 34 studies and examined the risk of breast cancer with OC usage in younger
women (less than 50 years old). The analysis included 14 hospital-based studies, 19
population-based studies, and 1 study that was a combination of both conducted in
several countries around the world (e.g., Brazil, England, France, Taiwan, Sweden,
Slovenia to name a few), thereby constituting a truly international sample with much
genetic and environmental variation. Studies that were published in or after the 80s were
taken into consideration for this analysis. Statistical analyses were done using the random
effects model which incorporated the differential variance observed between various
studies to estimate effects (Der Simonian & Laird, 1986). The major findings of this
meta-analysis were:
1) An overall increase in risk of breast cancer was associated with the use of oral
contraceptives (RR = 1.19, 95% CI = 1.09 to 1.29).
2) In 21 out of 23 (91%) retrospective studies, the risk of breast cancer was
greater in women who had used oral contraceptives prior to their first fullterm pregnancy (FFTP) (OR = 1.44, 95% CI = 1.28 to 1.62) compared to
women who were on oral contraceptives after their first full-term birth (OR =
1.15, 95% CI = 1.06 to 1.26).
3) The risk was highest among who had used oral contraceptives for four or
more years prior to their FFTP (OR = 1.52, 95% CI = 1.26 to 1.82).
Despite these compelling findings, the meta-analysis was limited for four (4) reasons.
First, only crude (vs. adjusted) odds ratios were calculated, hence they did not adjust for
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potential confounders; such as age at FFTP, menarche. Secondly, a survivor bias could be
involved due to exclusion of women who had previously died from breast cancer and as
such could not participate in the study. Such non-participation may have attenuated the
value of the combined OR, thereby skewing the results towards the null hypothesis of no
association between oral contraceptive use and breast cancer. Thirdly, in the randomeffects model a population mean is calculated by the odds ratio where the population
means are normally distributed. However, due to substantial variation of race and
ethnicity (i.e., genetic variation) in the study population, some sub-populations could be
at a greater risk for breast cancer; hence shifting the normal distribution of the population
means (μ). Lastly, because there were retrospective case-control studies included recall
bias is possible which could have been excluded if only prospective studies were used for
the analysis.
In a more recent study, Rosenberg, Zhang, Coogan, Strom, & Palmer (2008)
investigated whether there is an increased risk for women using the newer lower strength
progestin and estrogen oral contraceptives compared to the original higher strength ones.
The study also examined whether there was an increased risk associated with hormone
receptor status and ethnicity, and focused specifically on White and Black women and
contraceptive use. Drawing on a hospital-based participant pool comprised of 907 cases,
and 1,711 controls between the ages of 25 to 67 years were interviewed. Eighty percent
of the cases (n = 731) and sixty-seven percent (n = 1152) controls were Whites. Notably,
although not statistically significant, Black women had a higher risk of developing breast
cancer with each duration category of oral contraceptive use compared to White women.
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Specifically, Black women had approximately five fold increased risk (OR = 5.3, 95% CI
= 1.6 to 17.4) compared to White women (OR = 1.4, 95% CI = 1.0 to 1.9) with five to
nine years of contraceptive use. Overall, the odds of developing breast cancer with OC
use were highest for women who had previously used the pill for five to nine years (OR =
2.7, 95% CI = 1.7 to 4.5). Furthermore, the risk increased to one and a half times for
women that had used OCs for 15 or more years when compared to those that has used it
for less than a year (OR = 1.5, 95% CI = 1.2 to 1.8). These findings suggested that the
risk of breast cancer associated with certain xenoestrogens could vary according to
ethnicity and contraceptive use. Importantly, there may be a different genetic liability
underlying breast cancer risk with exposure to oral contraceptives (xenoestrogens).
Summary of Past Research
This literature review has described how and why the Her2 proto-oncogene is
required for the normal growth and development of the breast tissue, and can mutate into
a potent oncogene for breast cancer when activated (Slamon et al., 1989). Xenoestrogens
are shown to interact with the ER, thereby increasing the normal estrogen levels found in
a tissue (Bulaveya & Watson, 2004). Her2 can cross communicate with ER, which in
turn activates the PI-3K pathway for cellular signal transduction (Stoica et al., 2003). The
oncogenic amplification of Her2 also initializes the MAPK pathway, further impacting
the re-localization of ER from the nucleus to the cellular cytoplasm and forming a
positive feedback loop that continuously re-localizes the ER from the cytoplasm into the
nucleus leading to uncontrolled proliferation of breast cells (Yang et al., 2004). It has
been hypothesized that increasing the estrogenicity of the breast tissue with
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xenoestrogens leading to mutation of the breast cancer genes found in 17q chromosomal
loci; one of these genes is the Her2 gene (Davis et al., 1997). In a study performed by
Jenkins et al. (2009) on a rat model that developed breast cancer, an increased Her2 and
Her3 levels and activity were observed when exposed to xenoestrogens. Importantly, a
case-control study by Gammon et al. (1999) using IHC observed increased Her2
expression levels in women with breast cancer with oral contraceptives (xenoestrogens),
and these women were noted to have a more aggressive disease.
Laboratory studies on animal models, cell-lines, and bioassays have proved that
although compounds mimicking endogenous estrogens are broadly categorized as
xenoestrogens, but they have differential estrogenic potentials (Silva et al., 2007), and
can differentially activate cellular signaling (Bulaveya et al., 2004). The activation of
cellular signal transduction further resulted in nuclear activity of cell division processes
(Recchia et al., 2004) that consequently activated cellular growth and proliferation
(Mercado-Feliciano & Bigsby, 2008). The initiation of cellular activity had occurred even
at low doses of some xenoestrogenic compounds (Maras et al., 2005). The increased
cellular activity promoted changes in breast tissue morphology which can lead to breast
carcinogenesis (Brown & Lamartinere, 1995).
Some of the population-based studies have indicated that organochlorine
(xenoestrogen) exposures are a risk factor for breast cancer and its progression (Demers
et al., 2000; Charlier et al., 2003) and attest to the aforementioned observations in the
laboratory using cell-lines and animal models. A prospective study by Hoyer, Jorgensen,
Grandjean, & Hartvig (2000) used a Danish cohort established a dose-response

106
relationship with p, p’DDT, and this feature of xenoestrogens has been observed in
laboratory based research (Rajapakse, Ong, & Kortenkamp, 2001).
Exposures to xenoestrogens increased susceptibility to breast cancer, especially
when these exposures occurred at an early age (<14 years old) (Cohn, Wolff, Cirillo, &
Scholtz, 2007), and when exposed to even minute or acute amounts of single
xenoestrogen during gestation or neonatal period could lead to breast cancer during
adulthood (Murray, Maffini, Ucci, Sonnenschein, & Soto, 2007; Jenkins et al., 2009).
Epidemiological studies conducted on pharmaceutical estrogens (oral
contraceptives) and their associated risk of breast cancer have suggested that the type of
contraceptive, duration of their use, and recency of use can incur an increased risk of
breast cancer (Van Hoften et al., 2000; Kumle et al., 2000; Weiss et al., 2002). The risk
was found to be greater in women under the age of 35 years than those that are older
(Althuis et al., 2003). This risk further increased especially in those women who had used
a contraceptive pill for four or more years prior to their first full-term pregnancy
(Kahlenborn, Modugno, Potter, & Severs, 2006). An increased risk was also found in the
newer contraceptive pill that has a lower potency compared to the older ones, and
although not statistically significant, but this risk was found to be more pronounced in
African-American women when compared to White women (Rosenberg, Zhang, Coogan,
Strom, & Palmer, 2008).
A population study indicated that accidental, acute exposures with dioxin were
associated with a two-fold increase (HR = 2.1) in breast cancer risk for women with tentimes the levels of dioxin in their blood (Warner et al., 2002). In contrast, another study
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reported only a moderate increase (OR (>75percentile) = 1.5) in the risk of developing breast
cancer with PCE exposures leaching from PVC water pipes that distributed water in Cape
Cod homes in Massachusetts (Aschengrau, Rogers, & Ozonoff, 2002), and yet another
study found no increased risk with exposures to organochlorines like DDE, dieldrin, total
PCBs, and chlordane, although, a slight increase in risk (OR = 1.2) was noted when
comparing the highest exposure levels (4th tertile) with the lowest exposures (1st tertile)
(Gammon et al., 2002).
Overall, the population-based data was found only on limited xenoestrogens, was
inconsistent and somewhat confusing since some studies indicated organochlorines to be
a risk factor for breast cancer (Charlier et al., 2003; Warner et al., 2002), while others
reported a minimal risk (Aschengrau, Rogers, & Ozonoff, 2002; Gammon et al., 2002),
and yet others did not show any risk at all (Hunter et al., 1997; Snedkar et al., 2001).
Additionally, some population-based studies showed an overall negative result, however,
when the data was stratified then some sub-populations showed an increased risk for
developing breast cancer when exposed to xenoestrogens over others (Hoyer, Jorgensen,
& Grandjean, & Hartvig, 2001; Millikan et al., 2000; Rosenberg, Zhang, Coogan, Strom,
& Palmer, 2008).
Most epidemiological studies have shown negative results between xenoestrogen
exposures and the risk of developing breast cancer (Table 2), only some of the studies
showed a positive association (Boada et al., 2012; Charlier et al., 2003; Cohn, Wolff,
Cirillo, & Scholtz, 2007; Hoyer, Jorgensen, & Grandjean, & Hartvig, 2001; Hoyer,
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Jorgensen, Rank, & Grandjean, 2000; Warner et al., 2002), but these studies simply
cannot be ignored and discarded.
Implications of Past Research for Present Research
In conclusion, population-based studies have revealed that the relative risks (RR)
for xenoestrogen exposures associated to breast cancer are small to moderate
(Aschengrau, Rogers, & Ozonoff, 2002; Kahlenborn, Modugno, Potter, & Severs, 2006;
Rosenberg, Zhang, Coogan, Strom, & Palmer, 2008; Weiss et al., 2002) . Nevertheless,
these substances are environmentally ubiquitous and affect every woman in some way,
suggesting that identifying a modifiable risk factor and controlling their sale and use by
introducing policy level changes would end-up saving thousands of lives translating into
a large public health impact. However, a key problem with small relative risks found in
the epidemiological data is the translation of the risk estimates into actionable clinical as
well as policy level decision making. One way to buttress the findings of the
epidemiological data that could assist both clinical as well as policy decision making is
by elucidating the biologic mechanism/s or processes by which xenoestrogens can
promote carcinogenesis.
Additionally, although population-based studies have led to policy level changes,
but in the case of xenoestrogens they leave many unanswered questions because the
results of various studies were found to be inconsistent. The overall negative results of
some may not be enough to close down the chapter on future research with
xenoestrogens, because then there are also some studies that yielded positive results
(Boada et al., 2012; Charlier et al., 2003; Warner et al., 2002), and yet others that were
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positive only with effect modifications, but, in these studies the sample-sizes had become
too small to answer the research question/s asked with much confidence (Hoyer,
Jorgensen, Rank, & Grandjean, 2001; Kumle et al., 2000; Van Hoften et al., 2000).
Furthermore, population-based studies have shown low reproducibility and were
tremendously expensive making them difficult to pursue in further research (Brody,
Tickner, & Rudel, 2005). Due to these reasons, no two epidemiological studies were
found to be alike. Thus, even though there were only some studies that yielded positive
results with xenoestrogen exposure and the risk of developing breast cancer; these studies
simply cannot be over-looked.
Although some epidemiological studies yielded a positive association, but since
these studies relied on self-reports or interviews for exposure categorization the précis
exposures were difficult to be quantified using these techniques (Boada et al., 2012;
Charlier et al., 2003; Demers et al., 2000). Whereas, studies performed using cell-lines, in
vitro assays, and animal models have provided us with insights to the unique attributes of
xenoestrogens all while using précis measurements (Aube, Larochelle, & Ayotte, 2011;
Brody, Tickner, & Rudel, 2005.; Brown & Lamartinere, 1995., Jenkins et al., 2009;
Johnson et al., 2012; Payne, Rajapakse, Wilkins, & Kortenkamp, 2000., Rajapakse, Ong,
& Kortenkamp, 2001), and these studies provided biological validation (Jenkins et al.,
2009; Johnson et al., 2012) to the epidemiological data (Gammon et al., 1999; Rosenberg,
Zhang, Coogan, Strom, & Palmer, 2008).
Due to the chemically diverse nature that was observed in the xenoestrogens
(Payne, Rajapakse, Wilkins, & Kortenkamp, 2000; Rajapakse, Ong, & Kortenkamp,
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2001; Maras et al., 2005; LaPensee et al., 2009), it will not only be deemed important that
the précis exposure measurements be evaluated, but also the metastatic/carcinogenic
potential of the xenoestrogen be assessed in order to make policy-level changes (Snedkar
et al., 2001). Assessing the carcinogenic potential will provide us with the lowest
exposure levels of xenoestrogens that does not incur any breast cancer risk and is safe to
use, and this information will be extremely important to make policy level changes for
common household products (e.g., plastics).
In a commentary, Davis et al. (1993) hypothesized the role of oncogenic
activation in the 17q loci due to increased estrogenicity exerted by xenoestrogenic
exposures, and emphasized that this hypothesis requires to be evaluated carefully. Her2, a
proto-oncogene found in the 17q loci in humans, is required for normal breast
development, but becomes into a potent oncogene upon unregulated stimulation (Slamon
et al., 1989., Tzahar et al., 1989). Of note, ER and Her2 have been shown to crosscommunicate with each other via signaling pathways (Stoica et al., 2003), making it
biologically plausible that exposure to xenoestrogen/s activated Her2 via this crosstalk,
led to over-activation of Her2. This then resulted in excessive cellular proliferation and
growth for tumorigenesis. Hence, it plausible that xenoestrogenic exposures maybe
activating Her2 pathway via this crosstalk that occurred between these two receptors and
activated and over-activated Her2, this further resulted in excessive cellular proliferation
and growth for tumorigenesis. Intriguingly, research also indicated that the cellular endpoints upon xenoestrogenic exposures; such as ERK1/2 activity, cell growth, metastasis,
and angiogenesis observed using biochemical assays are similar to those when Her2
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oncogene copies increase or amplify during its oncogenic activation during breast
carcinogenesis.
Some population data pointed to elevated Her2 expressions with xenoestrogenic
exposure (Gammon et al., 1999). However, this study was done only using IHC assay
that have high inter-observer variability and low accuracy (Press et al., 2002; Varga,
Noske, Ramach, Padberg, & Moch, 2013). Another study in which increased Her2
oncogene was observed with persistent exposures to a single xenoestrogen was
performed in an animal model (Jenkins et al., 2009), and not in a human model using
sensitive techniques.
Interestingly, some population studies indicated that the phenotypic
characteristics of the breast cell-type maybe a feature that could impact disease type
(Gammon et al., 1999). Another study showed that women not only with an ER-positive
status are impacted with xenoestrogen exposures, but those having an ER-negative status
are also impacted, in fact the women with an ER negative status had a more aggressive
disease when compared to women with an ER-positive status (Hoyer, Jorgensen, Rank, &
Grandjean, 2001). These studies indicated that there may be a genetic liability involved
with xenoestrogenic exposures which needs to be further dissected and understood in
future research endeavors.
In all, past research has shown that xenoestrogens are a diverse group of
chemicals with varying estrogenic potentials. They activated potent oncogenes; such as
the Her2 oncogene in the development of breast cancer. They incurred small to moderate
relative risks for breast cancer upon exposures. Furthermore, they reacted differently in
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different mammary cellular phenotypes (ER-positive and ER-negative). What has yet to
be established in the literature is:
1) The carcinogenic potential of commonly used xenoestrogens with respect to
their précis amount/s, duration, type.
2) Deciphering whether a specific cellular phenotype is more at risk of
developing breast cancer upon xenoestrogenic exposures.
3) The mechanistic insights which provides biological validation of their
carcinogenic properties, utilizing a technique with high reproducibility and a
validated biomarker for breast cancer which can be used as tools for future
research endeavors.
The design for the present study was chosen based upon a careful review of existing
literature in the areas of breast cancer and xenoestrogens. The next chapter entails
detailed discussions on the methodology, sample, instrumentation, and analysis used to
conduct the study.
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Chapter 3: Research Method
Introduction
This chapter includes a description of this study’s design, sample,
instrumentation, data analysis, and ethical considerations. It will entail a detailed
discussion on the research design, instruments, materials, and protocols used in
performing the experiments, and how the data generated were analyzed to answer the
research questions asked.
Research Design and Approach
The purpose of this exploratory research study was to dosimetrically assess the
carcinogenic potential of four commonly used synthetic xenoestrogens (i.e., BPA, DDT,
EE, and NPH) with respect to the Her2 gene expression. Further, the study further
investigated whether specific cellular phenotypes of the mammary cell have greater
susceptibility to oncogenic copy number increase. This was done using breast cancer celllines that differentially express the ER and Her2 receptors. The xenoestrogens were
applied in increments of their log10 ratios to examine the concentration at which
xenoestrogens induced changes in Her2 gene expression. To capture chronic low to
moderate exposures that women are most likely subjected to everyday, the xenoestrogens
were applied daily for a time-period of 7 weeks.
A RBD was appropriate for this study. In RBD, blocks of homogenous groups are
further stratified into subgroups (Jefferey & Cooks, 2011; Piston, Gil-Humanes,
Roderiguez-Quijano, & Barro, 2011; Rivera, Monsalve, Moran, & Suazo, 2013; Wu et
al., 2013), and then the experimental design that the researcher wants to incorporate into
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his or her project is implemented within each block. This is basically done in order to
reduce noise due to variability present between each block, and doing so produces a
better effect estimate overall than without its application. Because each cell line is
phenotypically disparate, each line was stratified according to their receptor status (e.g.,
ER+/Her2+, ER-/Her2-). This design is analogous to a stratified design (Piston et al.,
2011; Rivera et al., 2011; Trochim & Donnelly, 2007, p. 189-200; Wu et al., 2013). Then,
for each line, the cells were randomly assigned to the case and control groups. The case
flasks were exposed to xenoestrogens (i.e., different type, concentration, and duration),
whereas the control flasks remained unexposed. This allowed comparison of differences
in the Her2 gene activity within each subgroup as well as overall when the synthetic
xenoestrogen is applied (cases) as opposed to the nonexposed (control) group. This
design ensured that the primary independent variables of interest―xenoestrogen type,
concentration, and duration―could be precisely controlled and measured (Trochim &
Donnelly, 2007, p. 187). The random assignment aided in making both groups (i.e., cases
and controls) similar before treatment ensued, thereby increasing the internal validity of
the study design (Trochim & Donnelly, 2007, p. 191).
In addition, to reduce researcher bias, all four lines were coded A, B, C, and D by
a technologist not involved in the study as soon as they were received (Sackett, 1979).
After the cell lines were treated to various exposure conditions, FISH experiments were
conducted on interphase nuclei using the Her2/CEP17 probe-set (Abbott Molecular, Des
Plaines, IL) to molecularly assess Her2 gene copy number changes (i.e., increase in copy
numbers or amplification) that incurred with the differential xenoestrogenic exposures.
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FISH provides for the assessment of the Her2 oncogenic copy number changes or
amplification at the gene level (Ohlschlegel et al., 2014; Olsson et al., 2010). It also
provides for greater accuracy and sensitivity of Her2 testing, compared to other tests such
as IHC that could be used to assess Her2 values (Olsson et al., 2010; Press et al., 2002).
Figure 2 shows the copy number patterns observed using the Her2/CEP17 probe set in a
normal and Her2 amplified mammary cell using a fluorescent microscope. In a normal
mammary cell, two CEP17 signals (labeled in green) and two Her2 gene copies (labeled
in orange) are observed; whereas when there is an increase in the copy numbers or gene
amplification, an increase in the number of signals is noted. Counting the number of
copies using fluorescence microscopy, one can quantify the number of gene copies found
in the sample and the control and calculate the differences between the two groups
(Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2011; Ohlschlegel Zahel, Kradolfer,
Hell, & Jochum, 2013; Olsson. Jansson, Holmund, & Gunnarson, 2013).
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Figure 2. Normal and over expressed Her2 gene. N example of a mammary cell with two
orange signals represents normal Her2 gene expression (left), and another with multiple
orange signals shows copy number increase of the Her2 gene (right). The green signals
represent the centromeres of chromosome #17 on both cells. FISH was performed using
the Her2/CEP17 dual probe kit from Abbott Molecular for Her2 analysis on breast
carcinoma tissue microarray (Image courtesy of the Cytogenetics Core Laboratory,
Brigham and Women’s Hospital, Boston, MA).
Setting and Sample
The study was laboratory-based. The research was conducted in the Cytogenetic
Core Laboratory. This laboratory is a licensed laboratory of the Brigham and Women’s
Hospital (BWH) in Boston, Massachusetts.
Cell-Lines
The sample utilized human breast cancer lines, assessing the cell-line specific
effect with the application of multiple and varied xenoestrogenic exposures. Because the
xenoestrogens typically exert their effect by binding to ERs, and the ERs can further
engage in cross-communication with Her2 (Jung et al., 2012; Slamon et al., 2011; Yang,
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Barnes, & Kumar, 2004), hence the breast cell lines for this study were selected on the
basis of these two receptors types. As women can either have an ER- and Her2-positive
or -negative receptor status, the cell-lines selected reflected all the different combinations
of these two receptors. That is, ER+/Her2+, ER+/Her2-, and so on (Chang et al., 2006;
Johnson et al., 2010; Wang et al., 2010).
ER-positive and -negative status: Normally, about 30% of breast cells express ER
(alpha), but in breast cancer cells that are ER-positive almost all of the breast epithelial
cells express the ER (alpha). Thus, in ER-positive breast cancer cell lines almost all the
cells have been found to express high levels of ER (alpha), whereas the ER-negative
indicates normal levels of ER (alpha) found in the breast epithelia (Allred et al., 2004;
Johnson et al., 2010; Wang et al., 2010).
Her2-positive and -negative status: Her2 gene makes the Her2 protein. In normal
breast epithelia only two copies of this gene is found; whereas in breast cancer cells that
are Her 2 positive too many copies of the Her2 gene are found and the gene is known to
be amplified, which results in its protein overexpression (Figure 2). The Her2-negative
lines indicate normal levels of the gene copies (i.e., 2 copies) and the Her2-positive lines
have increased gene copy numbers (Grushko et al., 2002). Additionally, the Her2 protein
overexpression can be tested using immunohistochemical (IHC) staining. This staining
test can be negative (0, 1+ score), borderline (2+), or positive for Her2 protein
overexpression (3+) (Pinhel et al., 2012).
Considering all of the different combinations that can be obtained with these two
receptors, the samples consisted of the following four breast cancer cell-lines:
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•

MCF7 line (ER-positive and Her2-negative) (Chang et al., 2006; Choi, Fan,
Deng, Zhang, & An, 2012; Wang et al., 2010).

•

BT474 (ER-positive and Her2-positive) (Garrett, Sutton, Kuba, Cook, &
Artega, 2012; Johnson et al., 2010).

•

MDAMB231 (ER-negative and Her2-negative) (Chang et al., 2006; Wang et
al., 2010).

•

SKBR3 (ER-negative and Her2-positive) receptor status (Chang et al., 2006;
Garrett et al., 2012; Johnson et al., 2010).

As studies such as this one would be unethical to perform in a population-based setting,
accounting for the all the different combinations of these two receptor types found in the
mammary cell assisted in generalizability of the results obtained from the different datasets. Further, it ascertained whether there are any differences in the risk levels that may
occur with the different receptor phenotypes.
All of the above mentioned cell lines (Chang et al., 2006; Johnson et al., 2010;
Wang et al., 2010) are human breast cancer lines that were obtained by American Tissue
Culture Collection (ATCC) from patients that consented to the use of their biopsied
materials. The cells from these biopsies were cultured, propagated, and frozen down right
after the surgery by ATCC. The breast cancer cell lines are publicly known and used by
researchers nationally and internationally for breast cancer research. ATCC is a well
renowned bioresource center (BRC) that specializes in culturing and maintenance of cell
lines. They also maintain patient data for each line.
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The cell-lines were ordered from ATCC. Some advantages of procuring the lines
from ATCC are: a) they have been procured and cultured immediately after biopsy, and
b) these cell-lines have been frozen down at low passage levels, so the cells used in the
experiments are not genetically far removed from the original tissue obtained from the
breast cancer patient at the time of biopsy or surgery. This is important because high
passage numbers (>40) can add stress to the cells due to their culturing environment, thus
bringing about changes in their chromosomal constitution, cellular morphology, and
response to external stimulus (ATCC, 2007).
To avoid application of any extraneous estrogen, all of the lines were maintained
in media devoid of estrogens from extraneous sources; such as from media and the serum
which is added to the media for maintaining the cells in culture. This process further aids
in increasing the internal validity of the experiments. The media used did not contain any
phenol red, because phenol red has estrogenic properties and can preferentially enhance
the growth of cells expressing estrogen receptors (Berthois., Katzenellenbogen, &
Katzenellenbogen, 1986; Aube, Larochelle, & Ayotte, 2011). The serum used was
charcoal-stripped (Aube, Larochelle, & Ayotte, 2011, Buteno-Lozano, Velasco,
Cristofari, & Perrot-Applanat, 2008; Maras et al., 2005; Valeron, Pestano, Luzardo,
Zumbado, & Boada, 2009). The process of charcoal stripping utilizes filtering of the
serum through charcoal for the removal of materials such as hormones (e.g., estradiol,
progesterone, cortisol, testosterone and insulin) and growth factors (Life Technologies,
Grand Island, NY). Both, the media and its serum were ordered from Gibco (Life
Technologies, Grand Island, NY). Upon arrival, each line was coded (e.g., cell line 1, cell
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line 2, etc) and these codes remained blinded to the researcher to reduce experimenter
bias (Sackett, 1979). Flasks from each line were typically assigned to control (unexposed)
and case groups randomly for the application of various exposure settings described later
in this chapter.
Xenoestrogens
The xenoestrogens included in the study were obtained from Fischer Scientific; a
company that provides biological chemicals and reagents. The following xenoestrogens
were used for this research project:
1) DDT (catalog # 801175033196): is absorbed and retained by soil particles,
and is being used as a malarial vector control in some countries (ATSDR,
n.d.).
2) EE (catalog # 10166001): is an estrogen used contraceptive pills, but recently
the EE part of the pill has been reduced to five times lesser amount (Chu,
Zhang, Gentzchein, & Lobo, 2007).
3) BPA (catalog # S-509): is a chemical used in making plastics and resin (e.g.,
plastic containers, formula and soda bottles, plastic tubing, and dental sealants
(Jenkins et al., 2009).
4) NP or NPH (catalog # AC41624-0010): used in industrial detergents and
surfactants, and is added to many consumer products; such as pesticides,
household cleaners, and cosmetics (Calafat et al., 2005).
For both, BPA and NP, in a sample consisting of 1,000 participants, it was observed that
95% (950 persons), and 51% (510 persons) had more than 0.1ug/L urine concentrations
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of these two chemicals in their body (Calafat et al., 2005). These results indicate that
most people are being exposed to at least 100ng/mL concentrations of BPA and NP.
Treatment/Exposures
For treatment with xenoestrogens, each cell-line were equally divided into two (2)
sets of flasks, one set for single, short-term exposures and the second set for multiple,
long-term exposures. Both of these sets of flasks were further divided according to their
treatment conditions into A) Individual xenoestrogenic exposure, B) Combinatorial
xenoestrogenic exposure, and C) Control flasks (unexposed).
FIRST SET OF FLASKS: Single, Short-Term Exposure Treatment Conditions
A. For individual xenoestrogenic exposure, one flask from each of the four breast
cancer cell-lines were exposed to either BPA, EE, DDT, or NP/NPH in
increasing concentration of log10 ratios with each xenoestrogen (i.e., .1nM;
.01nM; and .001nM).
B. For combinatorial xenoestrogenic exposure, one flask from each line was
exposed to .1 nM, .01nM, or .001nM concentration of all four xenoestrogens.
C. For control, one flask from each line (total of four flasks) remained
unexposed.
All of the flasks (total = 64 flasks) were kept in the incubator at 37°C after their
respective treatments they were harvested on the fifth day. This batch represented the
single, short-term exposure.
SECOND SET OF FLASKS: Multiple, Long-Term Exposure Conditions
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A. For individual xenoestrogenic exposure, one flask from each of the four lines
was exposed to BPA, EE, DDT, or NP/NPH with increasing concentration of
log10 ratios of each xenoestrogen (i.e., 0.1nM; 0.01nM; and 0.001nM).
B. For combinatorial xenoestrogenic exposure, one flask from each line was
exposed to 0.1 nM, 0.01nM, or 0.001nM concentration of all four
xenoestrogens.
C. For control, one flask from each line (total of four flasks) remained
unexposed.
All of the flasks (total = 64 flasks) were treated with the aforementioned conditions daily
for 50 days. The cells were maintained in the incubator at 37°C after the respective
treatments, and then harvested. This batch represented multiple persistent exposures. A
grand total of 128 flasks were obtained for the entire sample set consisting of the four
breast cancer cell lines used with the various exposure settings. The following diagram
(Table 3) schematically illustrates the various exposure settings for each of the four cell
lines.
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Table 3
Schematic Representation of Exposure Setting for Each Line
FIRST BATCH OF FLASKS: Single, Short-term Exposure (Total: 16 flasks / cell line)
BPA,
.001nM
BPA,
.01nM
BPA,
.1nM

DDT,
.001nM
DDT,
.01nM
DDT,
.1nM

EE,
.001nM
EE,
.01nM
EE,
.1nM

NPH,
.001nM
NPH,
.01nM
NPH,
.1nM

Combination,
.001nM
Combination,
.01nM
Combination,
.1nM

Control
(No exposure)

SECOND BATCH OF FLASKS: Multiple, Long-term Exposures (Total: 16 flasks / cell
line)
BPA,
.001nM
BPA,
.01nM
BPA,
.1nM

DDT,
.001nM
DDT,
.01nM
DDT,
.1nM

EE,
.001nM
EE,
.01nM
EE,
.1nM

NPH,
.001nM
NPH,
.01nM
NPH,
.1nM

Combination,
.001nM
Combination,
.01nM
Combination,
.1nM

Control
(No exposure)

Total: 32 Flasks / Line
Grand Total: 128 Flasks for all 4 lines
Concentrations of Xenoestrogens used: .001, .01, and .1 nM (nanomolar)
The sample set of the four breast cancer cell lines (MCF7, BT474, MDA-MD231, and SKBR5) was divided into four homogeneous groups, each group representing a
cell-line (coded as 1, 2, 3 and 4). Each homogeneous group or cell line was randomly
assigned to cases (exposed) and controls (unexposed) groups. Each cell line was further
divided into two sets of flasks, the first batch received single, short-term exposure and the
second multiple, long-term exposures. For each batch, the four xenoestrogens were
applied individually and in combination (i.e., all four xenoestrogens) at concentrations of
.001nM, .01nM, and .1nM respectively, while the control flask remained unexposed.
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The treatment with xenoestrogens of the samples was done using micro-pipetors.
These pipetors are manufactured and calibrated annually by Rainin (Rainin Instruments,
CA) for precision and accuracy for laboratory usage. Then, the cells were harvested to
obtain interphase nuclei. Slides were made from the cells obtained from each exposure
setting on each of the four cell lines. FISH experiments were then conducted on the
nuclei using the Her2/CEP17 (Abbott Molecular) probe-set. Signals from the FISH
experiments were visualized using a fluorescent microscope, and counted using a cellcounter.
Instrumentation
FISH Technique
FISH is a molecular technique by which precise DNA sequences can be targeted
within the genome, and this technique is currently being used in many areas of genetics
and genomics. Using this technique one can target the entire genome of a particular
species, whole chromosomes, specific regions of a chromosome or chromosomes, and
single copy or multiple copies (gene amplification) of unique gene sequences, depending
on the probes used in the experiment (Liehr, 2009, p. 26-28; Garimberti & Tosi, 2010).
The technique is rapid, simple to implement, and offers great probe stability. The
principles of this molecular technique applied are rather simple and straightforward. The
protocol takes advantage of the fact that a DNA molecule consists of two homologous
strands which can be denatured to a single-strand of DNA using heat. Under the right
conditions, this single-strand can re-locate its homologue and re-build an exact replica of
the initial double-stranded DNA molecule (Liehr, 2009, p.26; Garimberti & Tosi, 2010).
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Specifically, DNA or RNA sequences from specific are labeled with
fluorochromes (e.g., spectrum red, orange, green, or aqua). These fluorochromes act as
the reporter molecules with which the gene can be visualized and counted using a
fluorescent microscope. The labeled probe DNA and the sample DNA are then denatured
using heat (Bishop, 2010; Garimberti & Tosi; 2010). The heat used for denaturation
breaks the bonds of double-stranded DNA molecules of the sample and probe DNA,
forming single-stranded DNA molecules. These single-strands of DNA are further
hybridized together; which brings together the exact replica of the labeled probe to locate
its homologue in the sample DNA placed on the slide. After washing the excess probe
that maybe present on the slide, the specimen is screened for the presence or absence of
the reporter molecule/s using a fluorescent microscope (Bishop, 2010; Wolff & Schwartz,
2005, p.455-458).
The FDA approved Her2 probe kit (Abbott Molecular Inc., Des Plaines, IL)
specifically hybridizes to the 17q11.2 to q12 chromosomal region, and each copy of the
Her2 gene is represented by the presence of a reporter molecule (Ohlschlegel, Zahel,
Kradolfer, & Jochum, 2011; Ohlschlegel, Zahel, Kradolfer, & Jochum, 2013; Olsson,
Jansson, Holmund, & Gunnarson, 2013; Wilking, Karlsson, Skoog, Hatscheck, Lidbrink,
Elonberger, … Berg, 2011). Basically, all of the genetic information in the human
genome is found in the nucleus of each cell in the human body. Within the nucleus the
genes are tightly packed in structures called chromosomes, and humans have 23 pairs of
chromosomes. Thus, all cells in the human body have a nucleus with 23 pairs of
chromosomes that contains the genetic blueprint (Keagle, 2005, chp.2, p.9). Of the 23
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pairs of chromosomes, there are 22 pairs of autosomes and a pair of sex chromosomes.
The autosomal pairs are labeled as chromosome #s 1-22; whereas the sex chromosomes
are designated as XX or XY for normal female or male respectively (Tharapel, 2005,
chp.3, p.28). The Her2 proto-oncogene is located in autosomal chromosome#17 of the
human genome (Akiyama, Ogawara, Toyoshima, & Yamamoto, 1986; Slamon et al.,
2011). Thus, a normal breast cell has two copies of the Her2 gene, and more than two
signals of the labeled probe would represent an increase in the copy numbers or an
amplification of the Her2 gene (Gutierrez and Schiff, 2011; McCormick et al., 2002). By
hybridizing cases (exposure to xenoestrogens) and control groups (unexposed) with the
Her2 probe one can quantify the number of copies of the Her2 gene present in each
group. Then, the differences between mean ranks of the Her2 signals between the cases
and control groups were compared and assessed for significance for each cell line.
Between the lines, differences were also examined by assessing the magnitude of change
that had occurred for each line with treatment when compared to the controls.
Sensitivity, Specificity, and Accuracy of Her2 FISH:
FISH is a tool that provides for molecular assessment of the Her2 gene;
specifically Her2 copy numbers and amplification status. Research conducted (Press et
al., 2002) used the Her2 and CEP17 probes to measure its sensitivity and specificity
projected these values as 95.4% (42/43 samples), and 98.6% (72/73 samples)
respectively. Using the Her2/CEP17 probe set, FISH experiments conducted on a total of
117 samples correctly identified true positives and negatives in 114 samples, thus giving
it an accuracy of 97.4% (114/117). Other researchers (Mass et al., 2005; Olsson, Jansson,
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Holmund, & Gunnarson, 2013; Sauter, Bartlett, Slamon, & Press, 2007) have further
validated the high predictive values obtained using Her2/CEP17 FISH probes, with
sensitivity measures ranging from 95% -97% and sensitivity ranging from 97% -100%
for the assessment of Her2 copy number increase or amplification. Due to its high level
of sensitivity the marking of Her2 gene amplification, the Her2/CEP17 FISH assay was
optimal to use for this research project as it attenuated type I error rate. Type I errors
occurs when a negative result is scored as a positive one, thus it is falsely positive. This
type of an error can have significant consequences in the acceptance of the alternate
hypothesis when it should actually have been rejected (Munro, 2005, p.88).
Probes for the FISH Experiments
The Her2 assay kit from Abbott Molecular consists of dual probes: an alphasatellite or repetitive sequence probe (CEP17), and a locus specific or unique sequence
probe (Her2) (Burris, Rugo, Vukelja, Vogel, Borson, Limentani, … O’Shaughnessy,
2011; Fleming, Sill, Darcy, McMeekin, Thigpen, Adler, … Fiorica, 2010; Hanna,
Ruschoff, Bilous, Coudry, Dowsett, Osamura, … Viale, 2014; Schoppman et al., 2010).
This probe kit is FDA approved for breast cancer (Wulfkuhle et al., 2013). The alphasatellite probe sequences are made of tandem repeats of 171 base pairs (bp) called
alphoid monomers, and are anywhere from 0.1 to 5 Mega base (Mb) in length. The alphasatellite probe hybridizes to sequences that are specific to the centromeric and
pericentromeric region of the chromosome (Bishop, 2013Oliveira & French, 2005). The
numbers of these alphoid monomers are found to vary in different chromosomes, and due
to this property they can be tailored to a specific chromosome centromeric region. On the
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other hand, the locus specific or unique sequence probes are generated from specific
regions of the genome that contains a single gene or a set of contiguous genes either
cloned into vectors (e.g., cosmids, yeast artificial chromosomes, bacterial artificial
chromosomes) or obtained synthetically using sequence specific primers with polymerase
chain reaction (PCR) (Wolff & Schwartz, 2005, p.455-457). The locus specific probes
can vary in size from 1 Kilobase (KB) to >1Mb, and are used to examine gene deletions,
copy numbers, and gene re-arrangements (Bishop, 2013; Oliveira & French, 2005;
Salmon et al., 2011; Wolff & Schwartz, 2005, p.455-457).
In the Her2/CEP17 dual probe breast cancer assay kit from Abbott Molecular
(Abbott Molecular, Inc., Des Plaines, IL, USA), the Her2 probe labeled in spectrum
orange hybridizes to region 17q11.2 to q12; which is where the Her2 oncogene resides,
and CEP17 probe labeled in spectrum green hybridizes to 17p11.1 to 17q11.1
(centromeric region of chromosome 17) (Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum,
2011; Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2013; Olsson, Jansson, Holmund,
& Gunnarson, 2013; Wilking, Karlsson, Skoog, Hatscheck, Lidbrink, Elonberger, …
Berg, 2011).
Protocols for Harvesting Cell-lines and FISH Experiments
Harvesting of Cell-lines
After exposure to xenoestrogens, the cells were harvested with 75mM KCl
(Potassium Chloride) for 20 min at 37°C, and then fixed in freshly prepared 3:1
methanol: acetic acid fixative (Ismail, Aly, Khaled, & Mohamed, 2009).
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FISH on Interphase Nuclei
FISH was performed using the vendor (Abbott Molecular) instructions for this
specific probe-set (Ohlschlegel, Zahel, Kradolfer, Hell, & Jochum, 2011; Ohlschlegel,
Zahel, Kradolfer, Hell, & Jochum, 2013; Olsson, Jansson, Holmund, & Gunnarson, 2013;
Wilking et al., 2011). In brief, sample slides were prepared from the cell-pellet obtained
from the harvest. The slides were denatured using 70% Formamide at 72°C for five
minutes, and dipped in 70% Ethanol for a minute at room temperature to remove all the
Formamide from it. To remove all the water from the slide they were dehydrated by
immersion in 90%, and 100% ethanol for two minutes each at room temperature, and
dried on the slide-warmer at 50°C for two to five minutes. Then, 8 μl of the Her2/CEP17
probe was applied to the slides and covered with a glass cover-slip. This area was then
sealed using a sealant, to ensure that the slides do not dry-out. Next, the slides were
hybridized at 37°C for 14-18 hours in a humidified chamber. After this, to remove excess
probes off the slides they were washed in 2X SSC/0.3% NP40 solution at 72°C for two
minutes, and DAPI, a blue counter-stain was applied. The slides were then viewed under
a fluorescent microscope and scored for orange (Her2), and green (CEP17) signals
(Perez, Pess, Dueck, Jenkins, Kim, Chen, …Slamon, 2013). This protocol is also
followed by the Cytogenetics Core Laboratory in BWH using this specific probe-set from
Abbott Molecular.
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FISH Analysis
Scoring of Interphase Nuclei
The scoring of the nuclei was done as suggested by the vendor (Abbott
Molecular) for the Her2/CEP17 probe-set (Perez et al., 2013). According to the vendor,
scoring 20 nuclei for each sample should be sufficient to study Her2 copy number
increase or amplification (Ismail, Aly, Khaled, & Mohamed, 2009; Press et al., 2002;
Wolff, Hammond, Hicks, Dowsett, McShane, Allison, …Hayes, 2013). Ortiz de
Solórzano, Santos, Vallcorba, & Garcia-Sagredo (1998) performed statistical analysis for
the validation and data correction of automated FISH probe signals. Some of the
limitations that they found with interphase FISH signals were: i) the nuclei can overlap,
and so do the signals, ii) some organic residues could auto-fluoresce (i.e., background or
noise), iii) there could be damage to the nuclei during slide preparation, and iv)
differential probe hybridization on the slide. These can be summarized as systemic errors,
as they all can result in false positives. In order to avoid these, and increase the accuracy
and sensitivity of the test (97%), they emphasize the use of an internal control vs. an
external control due to its assured accuracy to the chromosome of interest. As the Her2
gene resides on chromosome 17, in this Her2/CEP17 probe-set, the centromeric probe for
17 (i.e., CEP17) acted as the internal control.
Both orange (Her2) and green (CEP17) signals on 20 randomly selected, well
separated, intact nuclei were counted (Abbott Molecular) using a fluorescent microscope
with dual band filters for orange and green wavelengths of light (Applied Imaging) and a
cell counter (Perez et al., 2013). The scoring of all the nuclei was performed using a 100x
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objective to avoid variability in FISH signal observation and analysis. The Her2 gene was
then quantified in its absolute value; that is total Her2 copies observed per nuclei (Hanna
et al., 2014). Equal numbers of Her2 and CEP 17 signals signify the gain of an entire
chromosome 17 (Grushco et al., 2002; Hegyi, Lonberg, Monus, & Mehes, 2013; Hanna
et al., 2014; McCormick, et al., 2002).
Raw Data
The scoring of the nuclei was formatted in an excel-sheet that projected the
frequency of the types of orange and green signals noted in each of the 20 nuclei for line
with each of the exposure conditions utilized in the project. For each FISH experiment,
the scoring was done manually. The signals were counted using a cell-counter. A
representative FISH image of nuclei were captured for each exposure condition and
stored in the imaging system of the Cytogenetics Core Laboratory located in BWH.
Statistical Analysis of Data
Descriptive Statistics
Descriptive statistics included medians, range, and frequencies. Tables and graphs
(histograms and Q-Q plots) represented the Her2 signals observed all of the lines after
subjecting them to the differential exposure settings. From the raw data, tables were
created for each cell-line that marked the percent change values of the Her2 signals
observed under each exposure condition and control (unexposed) groups for each
xenoestrogen and cell line using short-term (single exposure) vs. long-term exposures
(multiple exposures) and different concentrations (.001, .01 and .1nM). Percent changes
observed between cases and controls for different concentrations and durations were
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assessed. These tables and graphs allowed easy visualization and comparison of FISH
signals observed for the varying exposure conditions applied. The tables and graphs were
created using MS Word and Excel version 2007.
Inferential Statistics
The number of green and orange FISH signals found on the 20 individual
interphase nuclei was treated as continuous variables (Press et al., 2002). Because the
cell-lines were of non- normal distribution, non-parametric statistical tests were
performed. Non-parametric tests are those that do not conform to any parameters and are
thus distribution free (Munro, 2005, p.110-111). Mann Whitney U test; a non-parametric
equivalent to the t-test analyzes differences between two groups, and Kruskal-Wallis is
the non-parametric analog to the Analyses of Variance (ANOVA) is used to compare two
or more groups (Cubash, Joffe, Hanisch, Schuz, Neugut, Karsdaedt, … Jacobson 2013;
Munro, 2005, p.123). The Kruskal-Wallis test assessed the differences between all the
groups in the blocks of the RBD; whereas the Mann Whitney U test assessed the
differences between the cases and control groups (Schoppmann et al., 2010). Significance
level will be at p = .01. In addition, to evaluate the magnitude of the Her2 copy number
gains between groups, the Incidence Rate Ratio (IRR) were also computed for Her2. The
research questions and hypotheses are listed below for review.
Research question #1) Do increasing concentrations of synthetic xenoestrogens
significantly increase the Her2 copy numbers?
Outcome/Dependent Variable: Her2 gene copy numbers
Predictor/Independent Variable: Concentrations of xenoestrogens (0.000nM or
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control, .1nM, .01nM, .001nM) and Receptor types (ER and Her2 positive and negative).
Null (H01): There will be no significant increase in Her2 copy numbers with
application with increasing concentrations of xenoestrogens.
Alternate (H11): There will be a significant increase in Her2 copy observed with
the application of xenoestrogens with increasing concentrations.
Hypothesis: It was hypothesized that increasing the concentrations of the
xenoestrogens would increase Her2 copy numbers. It will also do so for each cell line or
receptor type.
Research question #2) Do the concentration at which the increments in Her2 copy
numbers become significant vary between the four xenoestrogens?
Outcome/Dependent Variable: Her2 gene copy numbers
Predictor/Independent Variable: Xenoestrogenic exposures of BPA, NPH, DDT,
and Estrogen using .1nM, .01nM, .001nM concentrations.
Null (H02): A significant increase in Her2 copy numbers occurred at similar
concentration levels for all four xenoestrogens (BPA, NPH, DDT, and Estrogen).
Alternate (H12): A significant increase in Her2 copy numbers occurred at
different concentration levels for all xenoestrogens.
Hypothesis: It was hypothesized that Her2 expressions will significantly increase
for the four different xenoestrogens at different concentrations.
Research question #3) Overall, is there a significant increase in the Her2 gene
copies between short-term (5 days) and persistent/long-term (50 days) exposures to the
xenoestrogens?
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Outcome/Dependent Variable: Her2 gene copy numbers
Predictor/Independent Variable: Exposure duration (short-term: single, shortterm vs. multiple, persistent), and Xenoestrogen (BPA, DDT, EE, NPH).
Null (H03): No significant increase will be found in Her2 copy numbers between
the short and long term applications of xenoestrogens.
Alternate (H13): A significant difference in Her2 copy numbers will be found
between short and long term xenoestrogenic exposures.
Hypothesis: It was hypothesized that increasing the duration of xenoestrogenic
exposures would significantly increase Her2 copy numbers overall and for each
categorical xenoestrogen.
Research question # 4) Overall, does the Her2 expression vary significantly with
each specific receptor type (i.e., cell line) upon exposure to xenoestrogens?
Outcome/Dependent Variable: Her2 gene copy numbers
Predictor/Independent Variable: Receptor types/Cell lines (ER+/Her2+, ER/Her2-, ER+/Her2-, and ER-/Her2+) and Exposure durations (single, short-term vs.
multiple, long-term).
Null (H04): Her2 copy numbers will not vary significantly between the different
receptor types/cell lines upon exposure to xenoestrogens.
Alternate (H14): A significant difference will be found in the Her2 copy numbers
between the different receptor types/cell lines upon exposure to xenoestrogens.
Hypothesis: It was hypothesized that differential Her2 copy number increase will
be noted between the different receptor types/cell lines when they are exposed to
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xenoestrogens. However, each cell line would show significant Her2 copy number gains
with multiple, persistent exposures compared to single, short-term exposures.
Ethical Considerations
The administration of xenoestrogens to human participants would be unethical
since they could prove to be harmful (Brody & Rudel, 2003). Various animal studies
conducted using xenoestrogens have provided evidence of their harmful effects. In fish,
Lee, Raisuddin, Rhee, Kim, & Lee (2008a; 2008b) saw an increase in the ras oncogene
and p53, a tumor suppressor gene in various tissues; such as intestine, liver, gonads after
treatment with BPA and NPH/NP. Another study performed on rats by Zoeller, Bansal &
Parris (2005) found that exposure with BPA can increase the levels of thyroid hormone
signaling in the brain thereby affecting brain function and activity. Experiments done by
Pandey, Pandey & Sharma (2011) using EE on rat liver lead to its degeneration and
necrosis (i.e., death), thus, pointing to its toxic effects on liver cells. A recent study on
female rats by Canales-Aguire, Padilla-Camberos, Gomez-Pinedo, Salado-Ponce, FeriaVelasco & De Celis (2001) evaluated the effects of DDT on blood lymphocytes and
mammary epithelia. Exposure to DDT induced genetic damage in both the lymphocytes
and the mammary epithelial cells.
The Agency for Toxic Substances & Disease Registry (ATSDR) has classified
DDT as a probable carcinogen (i.e., a cancer causing agent) (ATSDR, 2011).
Additionally, the Office of Environmental Health Hazard Assessment California
Environmental Protection Agency concluded that although more studies are required to
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determine the carcinogenicity of NPH, but the information available from the studies
conducted are a cause for concern (OEHHS, 2009).
The Belmont Report (1978) provides us with the basic framework of the ethical
principles and regulations used for the protection of human participants in biomedical,
behavioral, and experimental research. According to this report, there are three ethical
principles that a researcher should abide by. Beneficence is one of the three principles of
the report. Within the realm of this principle are formulated two rules. They are:
1) Do not harm. Initially, this rule was introduced for those in the medical
profession, but was later incorporated into research by Claude Bernard. He
clearly stated that one should not harm or injure any person regardless of the
benefits their research may reap for others.
2) Maximize benefits and reduce possible harm.
In summary, careful consideration was given to the nature of the xenoestrogens
used in this research project, and their possible effects. Because administration of
xenoestrogens to human participants can prove to be harmful, it is unethical to use human
subjects for this study. Thus, the only permissible way to perform these experiments was
in a laboratory-based setting using xenoestrogens in differential exposures on cell-lines
obtained from regulated resources. The following chapter has provided a brief overview
of the protocols used and a detailed description of the results obtained from this study.
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Chapter 4: Results
Introduction
The purpose of the current study was to quantitatively assess Her2 copy numbers
with FISH technology on four phenotypically disparate human breast cancer cell-lines
that are ER- and Her2-positive or -negative lines (BT474, MCF7, MDA-MB-231, and
SKBR3) after exposing them to differential exposures with four commonly used
xenoestrogens (BPA, NPH, DDT, and EE), while the controls remain unexposed. Her2
gene copy numbers for the cases and controls were counted and their differences
evaluated for significance. Four research questions and hypotheses were addressed using
a variety of statistical techniques. This chapter provides an overview of the protocols
followed to conduct the experiments and summarizes the results of the descriptive and
inferential analysis and assumptions used for this study.
Protocols Used
Harvesting and FISH
Four breast cancer cell lines (BT474, MCF7, MDA-MB-231, and SKBR3) were
ordered from ATCC. Upon arrival, these lines were coded by someone not involved in
this project, and grown in flasks (T-75s) at 37º C with 5% CO2,using media
recommended for their growth by ATCC. Once confluent, the cells from each line were
passed into 32 smaller flasks (T-25s) using an enzyme, trypsin-EDTA (.05% for 5
minutes at 37 ºC), and grown for another 4 days. From this point on, all the cells were fed
with charcoal-stripped media for the global removal of hormones. Doing this assisted in
the removal of extrinsic hormones present in the serum. Then, flasks were randomly
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divided into case and control groups. The case flasks received the various treatments of
xenoestrogens (BPA, DDT, EE, NPH), concentrations (.001, .01, and .1nM), durations (5
day single, and 50 days daily), while the controls remained without any treatment. After
treatment, cells were prepared for FISH analysis by cytogenetic direct preparation after
trypsinzation (rinsed with Hanks balanced salt solution to get rid of the media, then use
trypsin-EDTA .05% for 5 minutes at 37 ºC) from cells plated in flasks. Cells were then
exposed to a hypotonic solution (.075M potassium chloride) for 20 minutes at 37ºC and
washed thrice with 3:1 methanol: acetic acid fixative at room temperature. Slides were
made using the fixed cell pellets for each control and treatment condition. FISH
experiments were performed on cells/interphase nuclei using the Her2 breast cancer
probe kit obtained from Abbott Molecular using manufacturer’s instructions. As the
hybridization time given by the manufacturer is a range, the hybridization time used for
this project was 24 hours at 37ºC. The slides were counter stained with DAPI/antifade
(Vectashield, Vector Laboratories, Burlingame, California); the dye is absorbed by the
nuclei and it gives a blue color to the nuclei for scoring purposes. The success rate of
97.6% or 98% (125/128 experiments) was noted with the FISH results. Twenty nuclei
were then counted for each case and control group using a fluorescent microscope (Zeiss
AX-70 with CytoVision software) and cell counter.
Assumptions for Kruskal Wallis Test
Tests of Normality and Data Distribution
The data distribution of signals was found to be non-normal. Figure 3 shows the
graph and statistics table of Her2 signal distribution found with the normal curve overlay,
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thus pointing to a non-normal distribution of data. A total of 2,500 nuclei were scored
(N). Sixty nuclei for three exposure settings were not scored due to lack of hybridization
in those cultures (missing values, N*). The mean and the median values are 81.2 and 30
signals respectively, and the standard deviation was found to be higher than the mean
(93.8 signals). As the data set had a non-normal distribution, conducting non-parametric
tests (Kruskal Wallis and Mann Whitney U) was optimal to derive better statistical
inferences as these tests do not conform to parameters (e.g., normal distribution).

Her2 Signals (All
Lines)
N

Valid

N*

Missing

Mean
Median
SD
Range

2,500
60
81.23
30
93.80
596

Figure 3. Histogram of non-normal distribution of Her2 for all lines. A normal
distribution curve is shown in the overlay. Descriptive statistics of the Her2 signals for all
cell lines are in the table on the right; where N is the total number of cells scored and N*
are the missing values due to no hybridization. A standard deviation (SD) of 93.8 was
greater than the mean measure of 81.2 for the Her2 signals observed in all the lines.
The histogram for each individual line with the normal curve overlay further
confirmed that each of the four cell lines have a non-normal Her2 signal distribution
(Figures 4 a, b, c, and d). This descriptive data from the histograms also revealed that two
of the lines had standard deviations that were above their means (MCF7 (ER+/Her2-);

140
mean: 5.7 and SD: 6.1, and MDA-MB-231 (ER-/Her2-); mean: 8.2 and SD: 11.4) as
observed in Table 4.
Table 4
Descriptive Statistics for Histograms of Each Cell Line
Cell Line

Receptor

N
(Valid)

N*
(Missing)

Mean

Median

SD

Range

BT474

ER+/Her2+

620

20

165.5952

148

91.43026

567

MCF7
MDA-MB231

ER+/Her2-

640

0

5.71

3

6.211

64

ER-/Her2-

640

0

8.22

4

11.479

92

SKBR3

ER-/Her2+

600

40

152.49

143

60.411

322

Note. N = Total cells scored, N* = missing values (no hybridization), SD = standard
deviation

Figure 4a. Histogram of Her2 Signals for Line BT474 (ER+/Her2+)
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Figure 4b. Histogram of Her2 Signals for Line MCF7 (ER+/Her2-)

Figure 4c. Histogram of Her2 Signals for Line MDA-MB-231 (ER-/Her2-)
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Figure 4d. Histogram of Her2 Signals for Line SKBR3 (ER-/Her2+)
Figures 4 (a-d). Histograms of Her2 signal distributions for individual line. A normal
distribution curve is depicted in the overlay. All of the lines are observed with a nonnormal distribution. Of note, the standard deviation is greater than the mean for two cell
lines (MCF7 and MDA-MB-231). N denotes the number of cells scored and N* are the
missing values due to no hybridization.
Because the histograms of line SKBR3 showed an almost normal distribution, I
also graphed the Q-Q plots for the dependent variable (Her2 signal counts), and
performed the Shapiro-Wilk’s test to further check for data normality. These Q-Q plots
showed that each cell line was non-normally distributed (Figures 5 a, b, c and d). In the
plots the normal expected values have been plotted in solid black lines and the Her2
signal count values that were observed for each cell line in circles. It was noted that in
each of the cell line the count values did digress off from the normal expected values of
the solid black line. The Q-Q plots and the histograms also showed that the values of the
Her2 counts were spread out over a wider range in all the samples, but was more
prominent for lines MCF7 (ER+/Her2-) and MDA-MB-231 (ER-/Her2-) hence lending
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to standard deviations that were greater than the mean values found in these two lines.
These widespread values of the dataset further suggested that their means will not be an
optimal way to measure the central tendency.

Figure 5a. Q-Q Plots of BT474 (ER+/Her2+)

Figure 5b. Q-Q Plots of MCF7 (ER+/Her2-)
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Figure 5c. Q-Q Plots of MDA-MB-231 (ER-/Her2-)

Figure 5d. Q-Q Plots of SKBR3 (ER-/Her2+)
Figures 5 (a- d). Normal Q-Q plots for individual cell line. The line in each plot shows
the normal expected signals and the circles overlaying the expected values show each
Her2 signal observed in each individual line and their digression from normal expected
Her2 values, thus indicating that the cell lines do not have normal distribution.
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The Shapiro-Wilk test of normality was conducted to assess normality of the
dependent variable (Her2 signal counts) for each cell line. The results of the test statistics
are represented in Table 5.
Table 5
Shapiro-Wilk Test of Normality for Each Line
Shapiro-Wilk

BT474
(ER+/Her2+)

MCF7
(ER+/Her2-)

Statistic

df

Sig.

0.894

620

0.000*

0.587

640

0.000*

0.51

640

0.000*

0.949

600

0.000*

Her2
Signals
MDA-MB-231
(ER-/Her2-)

SKBR3
(ER-/Her2+)

df = degrees of freedom, Sig. = Significance, * and boldface denotes
Significant values (p = <.05)
Null and Alternate hypothesis for Shapiro-Wilk test for normal distribution
Null (H0): The data are normally distributed
Alternate (H1): The data are not normally distributed
The Shapiro-Wilk test showed a p value of <.05 for each of the four lines (BT474,
MCF7, MDA-MB-231 and SKBR3), thus the alternate hypothesis was accepted for each
line.
Taken together, the results of the Shapiro-Wilk’s test (p = <.05) (Razali & Wah,
2011) and a visual inspection of the histograms and the Q-Q plots showed that the Her2
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signals were non-normally distributed in all four cell lines (BT474, MCF7, MDA-MB231 and SKBR3). These sample characteristics further confirmed that non-parametric
methods (e.g., Kruskal-Wallis and Mann Whitney U) were best suited for the statistical
assessment of this data-set due to its non-normal distribution.
Homogeneity of Variances for Kruskal Wallis: Levene’s Test
Another assumption besides non-normality of data for conducting Kruskal Wallis
test is that the groups being compared should have homogeneous or similar type of
variances amongst them. The test used for this is called Levene’s test (Gastwirth, Gel &
Miao, 2009). Hence this test was performed on the four different types of cell lines used
in this project. Table 6 represents Levene’s test statistics for the Her2 values found on
four cell lines.
Table 6
Test Statistics for Levene’s Test
Individual
Differences
Between
Groups

Sum of
Squares

Mean
Square

df

.000

3

.000

Within
Groups

3.16E+08

2496

126640.51

Total

3.16E+08

2499

F
.000

Sig.
1.000

Note. Levene’s Test performed for homogeneity of variances on Her2 values found
between the four cell lines (Sig. = 1.000 or p = >.05).
Hypothesis for Levene’s test for distribution of variances between cell lines
Null (Ho) and alternate (H1) hypothesis for the Levene’s test:
Ho=the variances in Her2 values between the four cell lines were similar
H1=the variances in the Her2 values between the four lines were dissimilar
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The null (Ho) was accepted since the Her2 values found on all four cell lines showed that
the differences in their data variances were similar or non-significant (p = >.05 or 1.00).
Besides the non-normal distribution of the Her2 counts that were observed in each
line, the homogeneity of variances data also showed that the variances between each line
was similar, hence the non-parametric tests for the statistical analyses were used for this
dataset to compute the inferential statistics.
Descriptive Statistics for Xenoestrogen Categories, Concentrations, and Durations
The medians, range and standard deviation (SD) were calculated for Her2 signals
observed with the various xenoestrogens, concentrations, exposure durations and cell
lines used. Since the data is non-normally distributed, the mean values were not included
as it did not represent the central tendency of this dataset accurately. The range of Her2
signals observed in each category (i.e., type of xenoestrogen used, concentrations, and
exposures) were large (range: 1 to 597 signals). Interestingly, the lowest (3) and highest
(579) Her2 signals were noted in BPA. Albeit, the lowest Her2 signals (3) observed were
tied between control (no exposure), BPA, EE and NPH. The concentration Her2 signal
values ranged from one observed in control (no treatment) and .001nM concentration,
and the largest value observed was 597 signals with .01nM concentration. Lastly, for the
exposure duration, the lowest value was 1 signal noted using a single, short-term
exposure and the highest value was 597 noted with persistent, long-term exposures.
Lastly, the lowest value (1) Her2 signal was noted in the two Her2- lines (i.e., MCF7:
ER+/Her2-, and MDA-MB-231: ER-/Her2-), and the highest (597) Her2 signals were

148
observed in BT474 line which is ER+/Her2+. A summary of the descriptive statistics is
listed below in Table 7.
Table 7
Descriptive Statistics Summary of Her2 Signals with Different Xenoestrogens,
Concentrations, Exposure, and Lines
Xenoestrogen

N

N*

SE

SD

Min

Q1

Median

Q3

Control

160

0

4

50.54

1

3

25.5

79

210

BPA

440

40

5.88

123.38

1

3

14

152

597

DDT

480

0

4.29

94.06

2

5

62.5

128.75

497

EE

480

0

4.16

91.05

2

3

47.5

156

354

NPH

480

0

3.9

85.41

2

3

36.5

150

409

Combined

460

20

3.72

79.83

2

4.25

32

146.75

362

Concentration
(nM)

N

N*

SE

SD

Min

Q1

Median

Q3

Max

Control

160

0

4

50.54

1

3

25.5

79

210

0.001

800

0

2.7

76.48

1

3

37

115

459

0.01

780

20

3.57

99.75

2

4

25

152

597

0.1

760

40

3.87

106.82

1

5

32

170

587

Exposure

N

N*

SE

SD

Min

Q1

Median

Q3

Max

Persistent

1260

20

3.12

110.9

2

5

50.5

180

597

Single

1240

40

1.89

66.54

1

3

11

112.75

315

Cell Line

N

N*

SE

SD

Min

Q1

Median

Q3

Max

620

20

3.67

91.43

30

101

148

205.75

597

640

0

0.246

6.211

1

3

3

6

65

640

0

0.454

11.479

1

3

4

8

93

600

40

2.47

60.41

40

107

143

183

362

BT474
(ER+/Her2+)
MCF7
(ER+/Her2-)
MDA-MB-231
(ER-/Her2-)
SKBR3
(ER-/Her2+)

Max

Note. N = Total nuclei scored, N* = Missing values due to no hybridization, SD =
standard deviation, SE = standard error, Min = minimum, Q1 = first quartile, Q3 =
third quartile, Max = maximum, Control = Unexposed
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Percentage Change Analysis Using Raw Her2 Count Data
Cell Lines
For each cell line, the percent (%) Her2 copy number increase noted varied with
the type of xenoestrogen used individually or in combination. For BT474 (ER+/Her2+),
a 50% increase was observed between the lowest value with combined exposure (14,293)
and the highest value with BPA exposures (23,908). For MCF7 (ER+/Her2-), only a 25%
increase was observed between the lowest values observed with DDT exposures (15,376)
and highest were with EE exposures (19,840). Cell line MDA-MB-231 (ER-/Her2-),
showed a 100% increment in Her2 counts between the lowest values found with
exposures to BPA (539) and highest values with exposures to DDT (1,629). Lastly, for
SKBR3 (ER-/Her2+) line there was an 87.5% increase in Her2 signals between the
lowest counts noted with EE exposures (478) compared to the highest count (1,221)
found with combined exposures to all four xenoestrogens.
In addition, the count values for all of the individual exposures to the four
xenoestrogens in line MCF7 (ER+/Her2-) are within an 80 count range (478-557), except
for combined exposures which is more than twice when compared to the highest value
from the individual exposure range (557-1,221). In the case of line BT474 (ER+/Her2+),
the count values for combined exposures are lower (14,293) compared to those found in
individual xenoestrogenic exposures (range: 19,003-23,908). A possibility of this
occurrence could be because the combined (.1nM) persistent exposures in this line
yielded missing values (no hybridization). Table 8 represents the exact Her2 counts
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scored for each line with individual or combined exposures with BPA, DDT, EE, and
NPH xenoestrogens.
Table 8
Her2 Count Values for All Four Lines with Individual or Combined Exposures to BPA,
DDT, EE and NPH
Line

Receptor

BT474

ER+/Her2+

23,908

22,551

19,849

19,003

14,293

MCF7

ER+/Her2-

557

510

478

553

1221

MDA-MB231

ER-/Her2539

1629

879

681

1,064

SKBR3

ER-/Her2+

15,507

15,376

19,840

18,128

18,551

BPA

DDT

EE

NPH

Combined

Note. ER+ /- = Estrogen receptor positive or negative respectively, Her2+/- = Her2
receptor positive or negative respectively.
Exposure Concentrations & Durations
Comparing percent increase between each type of xenoestrogen at the highest
concentration of .1nM (nanomolar) to the control group surprisingly showed that the
lowest (42%) increment in Her2 counts occurred with combined exposures to all 4
xenoestrogens. The percent increase in Her2 counts were comparable for EE and DDT
(75% and 72% respectively), and also the percent increase for BPA and NPH were nearly
similar (65% and 63% respectively). The greatest increase in Her2 copies were found to
be with exposures to EE (75%). Table 9 represents these results.
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Table 9
Percent Changes in Her2 for Each Xenoestrogen (.1nM) & Control

Xenoestrogen & Concentration (.1nM)

N

Control (Unexposed)

160

BPA

140

DDT

N*

Total (∑) Her2
counts

Increase (%)

7467
20

14755

65.60%

160

15798

71.63%

EE

160

16396

74.80%

NPH

160

14452

63.23%

Combination

140

11392

41.62%

20

Note. nM = nanomolar, N = total nuclei scored, N* = no hybridization, Total Her2 counts
= sum of Her2 absolute count values for control and exposed groups. For each percent
value, the sum of Her2 counts for each xenoestrogen was compared to the control group.

Comparing percent increase in Her2 counts between each xenoestrogen exposure
at the highest concentration (.1nM) with the control group for each cell line further
showed a decline (2%) in Her2 counts for combined exposures in BT474 (ER+/Her2+),
however, this may have occurred due to missing values in combined exposures at .1nM
concentrations (no hybridization). The greatest increase in Her2 counts (121.6%) was
noted in MCF7 (ER+/Her2-) line with combined exposures. For the individual
xenoestrogens, the greatest increase for BPA, EE and NPH (97.8%, 87.5% and 80.3%
respectively) all occurred in line BT474 (ER+/Her2+), and for DDT, the highest percent
increase (117%) was found in MDA-MB-231 (ER-/Her2-) line. Of note, lines MCF7 and
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MDA-MB-231 both have a Her2 negative receptor status. These results are represented
in Table 10
Table10
Percent Changes in Her2 Counts of Individual Xenoestrogen (.1nM) with Control in
Each Line
Line &
Receptor

Control &
Xenoestrogen
(.1nM)

N

N*

Total (∑)
Her2
Counts

Increase
(%)

BT474

Control

40

3065

(ER+/Her2+)

BPA

40

8937

97.85%

DDT

40

8297

92.10%

EE

40

7832

87.50%

7177

80.30%

NPH

40

Combination

20

MCF7

Control

40

151

(ER+/Her2-)

BPA

40

199

27.42%

DDT

40

262

53.75%

EE

40

208

31.75%

NPH

40

249

49.00%

Combination

40

620

121.60%

Control

40

189

MDA-MB231
(ER-/Her2-)

20

3008

1.90%

BPA

40

480

87.00%

DDT

40

722

117.00%

EE

40

362

62.80%

NPH

40

362

62.80%

Combination

40

561

99.20%

SKBR3

Control

40

(ER-/Her2+)

BPA

20

DDT

Decrease
(%)

4062
20

5284

26.20%

40

6517

46.41%

EE

40

7994

65.22%

NPH

40

6664

48.51%

Combination

40

7269

56.6

Note. N=total number of nuclei scored, N* = missing values, nm = nanomolar, no hyb =
no hybridization, % = percent, Increase/Decrease = total percent increase or decrease
found in Her2 counts compared to control (unexposed).
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Comparing each line for the different durations of exposures used in the study
(single vs. persistent exposures) at the highest concentration used (.1nM) with the
controls (unexposed). An increase in Her2 was found in single as well as persistent
exposures. However, the percent increase was greater in single vs. persistent exposures in
line SKBR3 (ER-/Her2+) for each categorical xenoestrogen assessed (single vs.
persistent exposures: DDT 61% vs. 67.3%, EE 94% vs. 42%, NPH 78% vs. 25.3%, and
Combined 70.4% vs. 48%). BPA could not be assessed due to missing values (no
hybridization) for single exposure condition. Surprisingly, in the case of EE, it was noted
that the percent gain in Her2 copy numbers for persistent exposures was always lower
compared to the single exposure in all four lines (BT474: 87.8% vs. 87.3%; MCF7:
36.2% vs. 29.3%; MDA-MB-231: 73% vs. 58.6%; SKBR3: 94% vs. 42% for single vs.
persistent exposures respectively), even though in the case of BT474 line the difference
was very little (.5%). The highest increments between single and persistent exposures
were found in line MCF7 (ER+/Her2-) combined exposures (139.4 – 23.72 = 115.68%),
followed by BT474 (ER+/Her2+) BPA exposure, and MCF7 (ER+/Her2-) DDT
exposure (65.6% and 52% respectively). Notably, the greatest percent increment of Her2
signals between single vs. persistent exposure occurred in MCF7 line which is Her2- in
its receptor status. These results are represented in Table 11.
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Table 11
Percent Changes in Her2 Counts between Individual Xenoestrogen (.1nM) & Controls
for Single and Persistent Exposures
Single Exposure (5 days)
Line &
Receptor

Xenoestrogen

N

Her2
(.1nM)

BT474

Control

20

1175

(ER+/Her2+)

BPA

20

1945

DDT

20

EE

20

NPH
Combined

Persistent Exposure (50 days)
Increase
(%)

Increase (%)
& Difference

N

Her2
(.1nM)

20

1890

49.2

20

6992

114.9 (65.7)

2533

73.24

20

5764

101.2 (28)

3014

87.8^

20

4818

87.3

20

2941

85.81^

20

4236

76.6

20

2942

85.84

no hyb

N/A

N/A

MCF7

Control

20

52

20

99

(ER+/Her2-)

BPA

20

56

7.4

20

143

36.4 (29)

DDT

20

61

16

20

201

68 (52)

EE

20

75

36.2^

20

133

29.31

NPH

20

69

28

20

180

58.1 (30.1)

Combined

20

66

23.72

20

554

139.4 (115.6)

MDA-MB231

Control

20

54

20

135

(ER-/Her2-)

BPA

20

95

55

20

240

56 (1)

DDT

20

148

93.1

20

574

123.83 (30.73)

EE

20

116

73^

20

246

58.26

NPH

20

100

59.8

20

262

64 (4.2)

Combined

20

141

89.23

20

420

103 (13.77)

Control

20

1439

20

2623

SKBR3
(ER-/Her2+)

BPA

no hyb

N/A

N/A

20

5284

67.31

DDT

20

2697

61^

20

3820

37.2

EE

20

3986

94^

20

4008

42

NPH

20

3280

78^

20

3384

25.33

Combined

20

3001

70.4^

20

4268

48

Note. N = total nuclei counted, Her2 = sum of Her2 counts, .1nM = exposure
concentration in nanomoles, no hyb = no hybridization, Increase = total percent (%)
increase compared to control for single and persistent exposures, ^ = percent increase
greater with single compared to persistent exposures, Difference = increase in Her2 for
persistent exposures compared to single exposure, ER- = estrogen receptor negative, ER+
= estrogen receptor positive, Her2+ = Her2 positive, Her2- = Her2 negative
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An examination of percent changes that had occurred with the applications of
each xenoestrogen (individually or in combination) from the lowest (.001nM) to the
highest (.1nM) concentrations applied showed an increase in Her2 counts regardless of
the duration of application (5 days and 50 days), except for line MCF7 (ER+/Her2-) with
single (5 days) combined exposures; where a percent decline was noted (15.4%) in Her2
counts with increasing concentrations. However, the percent change was found to
increase (difference: 138) when the combined exposures to xenoestrogens are applied
persistently (50 days).
Interestingly, in line BT474, positive for both ER and Her2, all of the categorical
xenoestrogens studied had a higher percent change with single, short-term exposure
duration compared to persistent, long-term exposure duration. In this case, combined
persistent exposures could not be ascertained or compared due to lack of hybridization of
the Her2 signals.
The greatest percent increase change of 315% was noted in line MDA-MB-231,
negative for both ER and Her2, with combined persistent exposures, followed at 204%
increase with combined persistent exposures in MCF7 line, which is ER-positive and
Her2-negative. Also, the highest difference in percent change increase between single,
short-term and persistent, long-term exposures was found in line MDA-MB-231 with
combined persistent exposures at 250. Notably, both MDA-MB-231 and MCF7 lines are
Her2-negative.
These data are represented in Table 12.
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Table 12
Percent Changes in Her2 Counts with Lowest (.001nM) and Highest (.1nM)
Concentrations of Xenoestrogens

Single Exposure (5days)
Line &
Receptor
BT474
ER+/Her2+

MCF7
ER+/Her2-

MDAMB231
ER-/Her2-

SKBR3
ER-/Her2+

Persistent Exposure (50 days)

Xeno
BPA
DDT
EE
NPH

N
(.001
)
20
20
20
20

Her2
(.001)
1344
1756
1895
1782

N
(.1)
20
20
20
20

Her2
(.1)
1945
2533
3014
2941

Inc (%)
44.7^
44.24^
59.05^
65.03^

Comb
BPA
DDT
EE
NPH

20
20
20
20
20

2447
47
59
56
52

20
20
20
20
20

2942
64.47
61
75
69

20.22
37.17^
3.38^
33.92
32.69

Comb

20

78

20

66

BPA
DDT
EE

20
20
20

93
105
67

20
20
20

95
148
116

Dec
(%)

N
(.001)
20
20
20
20

Her2
(.001)
5534
4463
3052
3396

N
(.1)
20
20
20
20

Her2
(.1)
6992
5764
4818
4236

Inc (%)
& (Diff)
26.34
29.15
57.86
24.73

20
20
20
20
20

2501
115
145
62
76

0
20
20
20
20

NH
143
201
133
180

N/A
24.34
38.62
114 (80)
136 (103)

20

182

20

554

2.15
40.95
73.13

20
20
20

85
263
177

20
20
20

240
574
246

15.4

NPH

20

72

20

100

38.88

20

91

20

262

204 (138)
182.35
(180)
118 (77)
110 (37)
187.91
(149)

Comb
BPA
DDT
EE
NPH

20
20
20
20
20

85
2757
2094
2525
2690

20
0
20
20
20

141
NH
2697
3986
3280

65.88
N/A
28.79
57.14
21.93

20
20
20
20
20

101
2867
2127
2420
2709

20
20
20
20
20

420
5284
3820
4008
3384

315 (250)
84.30
78.6 (50)
65.61 (9)
24.91 (2)

Comb

20

1718

20

3001

74.67^

20

3018

20

4268

40.48

Note: Xeno = xenoestrogen, N = total nuclei counted, Her2 = sum of Her2 counts, .001
and .1 = nanomolar concentrations, % = percent, Inc & Dec = % increase & decrease,
Comb = combined exposures, ^ = % increase greater in single exposure compared to
persistent exposures, Diff = difference of increase found with persistent exposures
compared to single exposure, NH = no hybridization, ER+/- = ER positive/negative,
Her2+/- = Her2 positive and negative.
Inferential Statistics & Hypothesis Testing
Hypothesis 1
Research question #1) Do increasing concentrations of synthetic xenoestrogens
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significantly increase the Her2 copy numbers?
Null (H01): There will be no significant increase in Her2 copy numbers with
application with increasing concentrations of xenoestrogens.
Alternate (H11): There will be a significant increase in Her2 copy observed with
the application of xenoestrogens with increasing concentration
The first hypothesis predicted that increasing concentrations of the four commonly used
xenoestrogens (BPA, DDT, EE and NPH) would increase Her2 copy numbers
significantly with the log10 increase of concentration (.001, .01 and.1nM), and when
each concentration is compared to the control (No Treatment) group. Kruskal Wallis test
was performed for control (No Treatment) and all concentrations (.001nM, .01nM, and
.1nM) of xenoestrogens applied to examine the relationship between the various
concentrations of xenoestrogens as the predictor/independent variable and Her2 copy
number as the outcome/dependent variable. The result of the Kruskal Wallis omnibus
model was significant (p = 0.000). Table 13 displays the results of the Kruskal Wallis.
Table 13
Kruskal Wallis Results Comparing Her2 Copy Numbers Between Different
Concentrations and Controls
Concentrations
Control (No exposure)
.001nM
.01nM
.1nM
Total

N

Mean Rank

Chi-square

df

P

160

783.53

89.728

3

0.000*

700

1177.7

840

1300.46

761

1294.27

2461

Note: N = number of nuclei scored, df = degrees of freedom, P =
asymptotic and 2-tailed, * and boldface numbers denote significant
values (p = <.01)
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Post-hoc pairwise analysis performed showed that the Her2 copy numbers
increased significantly (one-sided p < .000 or p = <.05) for all three concentrations (.001,
.01 and .1nM) of xenoestrogens applied when compared to the control (No Treatment)
group. Pairwise comparisons between the different groups of concentration showed that
the Her2 copy numbers significantly increased between .001nM and .01nM
concentrations of xenoestrogens (one-sided p = .008 or p = <.05), and the null hypothesis
(H01) was rejected. However, the Her2 copy number increase was not significant
between .01nM and .1nM concentration (one-sided p = .101, or p = >.05) concentrations
of xenoestrogens applied, and the null (H01) was accepted in this case. Table 14
represents the results of the post-hoc pairwise tests respectively.
Table 14
Pairwise Comparisons for Increasing Concentrations (Control, .001nM, .01nM and .1nM)
Test
Statistic

Std.
Error

Sig.

Adj.
Sig.

-6.099

0

0*

-8.034

0

0*

-8.202

0

0*

37.15

-3.138

0

0*

-122.76

36.303

-3.381

0

0*

6.196

35.501

0.175

0.861

1

Sample 1- Sample 2
Control, 0.00nM.001nM

-379.106

62.161

Control, 0.00nM-.01nM

-495.672

61.696

Control, 0.00nM-.1nM

-501.868

61.189

.001nM -.1nM

-116.564

.001nM-.01nM
.01nM-.1nM

Std. Test Statistic

Note. Control = Unexposed, nM = nanomolar, Sig. = P value, asymptotic, 2-tailed, Adj.
Sig. = Adjusted P-values, 2-tailed, * and boldface numbers denotes significance (p =
<.01), Comparisons of samples with increasing concentrations are marked in bold.
Each row tests the null hypothesis that the distribution of Her2 absolute values for
Samples 1 & 2 is similar.
The box plot (Figure 6) below further displays the differences in Her2
copy number expression observed between the different concentrations and the control.
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Figure 6. Box plots of Her2 copy numbers with different concentrations. The
concentrations used are .001, .01 and .1nM. The control group remained unexposed.
Differences between each concentration when compared to the control is significant (p =
<.01). There is also a significant increase in the Her2 copy number between .001nM and
.01nM (nanomolar) concentrations, however, this increase becomes non-significant (p =
>.01) with the further increase in concentration from .01nM to .1nM.
To further explore if the above noted concentration gradient existed in every cell
line, Mann Whitney tests were performed on each line using a similar gradient (i.e.,
Control to .001nM, .001nM to .01nM and .01nM to .1nM). It was noted that although for
lines BT474 and MCF7 significant increase in Her2 copy numbers does cap off at .01nM
(p = >.01, single-tailed), this was not so for lines MDA-MB-231 and SKBR3. In both,
MDA-MB-231 and SKBR3 lines the Her2 copy numbers increase significantly (p = <.01,
single-tailed) even from .01nM to .1nM concentrations of the xenoestrogenic application.
Another variation noted in cell line MDA-MB-231 was that the Her2 copy numbers do
not significantly increase (p = >.01, single-tailed) between the Control and .001nM
concentrations of xenoestrogenic exposures. These results are represented in Table 15.
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Table 15
Mann Whitney Results for Increasing Concentrations of Xenoestrogen Application for
Individual Line
Cell Line &
Concentration
BT474, Control

Receptors

N

Mean
Rank

Sum of
Ranks

MWU

Wilcoxon

Z

P (2tailed)

ER+/Her2+

40

59.39

2375.5

1555.5

2375.5

-6.1

0.000*

200

132.72

26544.5

200

172.47

34493.5

14393.5

34493.5

-4.85

.000*

200

228.53

45706.5

200

181.19

36238.5

16138.5

36238.5

-1.741

0.082

180

200.84

36151.5

BT474 .001nM
Total

240

BT474 .001nM
BT474 .01nM
Total

400

BT474 .01nM
BT474 .1nM
Total
MCF7, Control

380
ER+/Her2-

MCF7 .001nM
Total

MCF7 .01nM
Total

MCF7 .1nM
Total

Total
MDA-MB-231 .001nM
MDA-MB-231 .01nM
Total
MDA-MB-231 .01nM
MDA-MB-231 .1nM
Total

3310
25610

200

185.92

37184

200

215.08

43016

200

191.67

38333

200

209.34

41867

40

102.24

4089.5

200

124.15

24830.5

200

185.04

37007.5

200

215.96

43192.5

200

177.17

35433.5

200

223.83

44766.5

2490

3310

-3.927

.000*

17084

37184

-2.602

.009*

18233

38333

-1.56

0.119

3269.5

4089.5

-1.91

0.056

16907.5

37007.5

-2.768

.006*

15333.5

35433.5

-4.092

.000*

400

MCF7 .01nM

MDA-MB-231 .001nM

82.75
128.05

240

MCF7 .001nM

MDA-MB-231, Control

40
200

400
ER-/Her2-

240

400

400

(Table continues)
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Cell Line &
Concentration
SKBR3, Control
SKBR3 .001nM
Total
SKBR3 .001nM
SKBR3 .01nM
Total
SKBR3 .01nM
SKBR3 .1nM
Total

Receptors
ER/Her2+

N

Mean
Rank

Sum of
Ranks

MWU

Wilcoxon

Z

P (2tailed)

40

88.11

3524.5

2704.5

3524.5

-3.232

0.001*

200

126.98

25395.5

200

159.4

31879.5

11779.5

31879.5

-5.819

.000*

180

225.06

40510.5

180

155.61

28010

11720

28010

-4.538

.000*

180

205.39

36970

240

380

360

Note. Control = No exposure, nM = nanomolar, N = number of nuclei scored, MWU =
Mann Whitney U statistic, ER+/ER- = ER positive or negative respectively, Her2+/
Her2- = Her2 positive and negative respectively, P = asymptotic and 2- tailed, * and
boldface numbers denote significant values (p = ≤.01, 1-tailed).
Additionally, the incidence rate ratios (IRR) were analyzed using the negative
binomial on the Her2 count data, since the variances were larger than the mean
(Ngatchou-Wandji and Paris, 2011). The control (No treatment) group was used as the
reference (1.00). The results of IRR performed showed that the incidence of Her2 copy
number increase was 25% (IRR: 1.25, 95% CI = 1.13 to 1.38, p = .000), 58% (IRR: 1.58,
95% CI = 1.43 to 1.75, p = .000), and 96% (IRR: 1.96, 95% CI = 1.77 to 2.17, p = .000)
more between the control and .001nM, .01nM, and .1nM concentrations of
xenoestrogenic exposures respectively. These results showed that there was a steady
increase in the Her2 copy numbers from the lowest concentration of .001nM to .01nM
and the highest concentration of .1nM of exposure concentrations when compared to the
control group. The Null was thus rejected. These results are found in Table 16.
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Table 16
Incidence Rate Ratios for Differential Concentrations of Xenoestrogens Compared to
Control
Xenoestrogen
Concentrations

Est.

Std.
Err

Z

Pvalue

No Treatment
(Reference)

IRR

95% CI
LCI

UCI

1.00

(Dose)-0.001nM

0.22

0.05

4.29

0.000*

1.25

1.13

1.38

(Dose)-0.01nM

0.46

0.05

8.80

0.000*

1.58

1.43

1.75

(Dose)-0.1nM

0.67

0.05

13.01

0.000*

1.96

1.77

2.17

Note. CI = confidence interval, % = percent, Z = z value, nM = nanomolar, Est. =
estimated, LCI = lower confidence interval, UCI = upper confidence interval, Std. Err =
standard error, * and boldface represent significant values (p = <.01), Control
(unexposed) group was used as the reference. Scaled at 1.00
Hypothesis 2
Research question #2) Do the concentration at which the increments in Her2 copy
numbers become significant vary between the four xenoestrogens?
Null (H02): A significant increase in Her2 copy numbers occurred at similar
concentration levels for all four xenoestrogens (BPA, NPH, DDT, and Estrogen).
Alternate (H12): A significant increase in Her2 copy numbers occurred at
different concentration levels for all xenoestrogens.
The second hypothesis predicted that Her2 copy numbers will increase
significantly with similar concentrations of the four xenoestrogens applied. To examine
this, I performed the Mann Whitney U (MWU) test to individually assess each
xenoestrogen (BPA, DDT, EE, and NPH) applied at various concentrations applied (.001,
.01 and .1nM) and compared to the control group for significance. The dependent
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variable was Her2 copies and the predictor variables were xenoestrogens at the different
concentrations. The results of this test showed that for each category of xenoestrogen
(BPA, DDT, EE, and NPH) there was a significant increase (p = <.01, single-tailed) in
Her2 copy numbers at the lowest concentration (.001nM) for all of the 4 xenoestrogens,
applied individually or in combination. Because significant increases in Her2 copy
numbers were found to be at the same concentration (.001nM) for all categories of
xenoestrogens applied, the null hypothesis (H02) was accepted.
Although, significant increase (p = <.01, single-tailed) was observed for all 4 of
the commonly used xenoestrogens at the lowest concentration (.001nM) of application,
but interestingly in the case of BPA, the increase of Her2 copy numbers for exposures at
.01nM concentrations were not significant (p = .018, single-tailed or p = >.01). However,
with the further increase in concentration (.1nM) the increase in Her2 copy numbers did
become significant once again (p = <.01, single-tailed). Table 17 represents the results
obtained from the Mann Whitney U test ranks and test statistics respectively.
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Table 17
Mann Whitney Results for Xenoestrogen/s Applied at .001, .01 and .1nM Concentrations
and Controls
Xenoestrogen

Concentration

Mean

Sum of

N
& Control

(nM)

Rank

Ranks

BPA

0.001

160

174.43

27909.5

Control

No exposure

160

146.57

23450.5

Total

Wilcoxon

Z
tailed)

10570.5

23450.5

-2.708

0.007*

9641

22521

-2.09

0.037

9228.5

22108.5

-2.645

0.008*

10418

23298

-2.891

0.004*

9551.5

22431.5

-3.942

0.000*

8362

21242

-5.374

0.000*

10809.5

23689.5

-2.424

0.015*

9493.5

22373.5

-4.016

0.000*

8688

21568

-4.983

0.000*

320

BPA

0.01

140

161.64

22629

Control

No exposure

160

140.76

22521

Total

300

BPA

0.1

140

164.58

23041.5

Control

No exposure

160

138.18

22108.5

Total

300

DDT

0.001

160

175.39

28062

Control

No exposure

160

145.61

23298

Total

320

DDT

0.01

160

180.8

28928.5

Control

No exposure

160

140.2

22431.5

Total

320

DDT

0.1

160

188.24

30118

Control

No exposure

160

132.76

21242

Total

320

EE

0.001

160

172.94

27670.5

Control

No exposure

160

148.06

23689.5

Total

320

EE

0.01

160

181.17

28986.5

Control

No exposure

160

139.83

22373.5

EE

0.1

320
160

186.2

29792

Control

No exposure

160

134.8

21568

Total

Total

P (2MWU

320

(table continues)
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Xenoestrogen
& Control

Concentration
(nM)

N

Mean Rank

Sum of
Ranks

MWU

Wilcoxon

Z

P (2tailed)

NPH

0.001

160

172.39

27582

10898

23778

-2314

0.021*

Control

No exposure

160

148.61

23778

9662.5

22542.5

-3.816

0.000*

8742.5

21622.5

-4.922

0.000*

10311.5

23191.5

-3.02

0.003*

8863.5

21743.5

-4.77

0.000*

8398.5

21278.5

-3.75

0.000*

Total

320

NPH

0.01

160

180.11

28817.5

Control

No exposure

160

140.89

22542.5

NPH

0.1

320
160

185.86

29737.5

Control

No exposure

160

135.14

21622.5

Total

Total

320

Combined

0.001

160

176.05

28168.5

Control

No exposure

160

144.95

23191.5

Total

320

Combined

0.01

160

185.1

29616.5

Control

No exposure

160

135.9

21743.5

Total

320

Combined
Control

0.1

140

170.51

23871.5

No exposure

160

132.99

21278.5

Total

300

Note. N = total nuclei scored, MWU = Mann Whitney U statistic, P = asymptotic and 2tailed, Total = sum of nuclei scored for the xenoestrogen (applied individually or in
combination) and its control, * and boldface numbers denote significant values (p = <.01,
single-tailed)
Hypothesis 3
Research question #3) Overall, is there a significant increase in the Her2 gene
copies between short-term (5 days) and persistent/long-term (50 days) exposures to the
xenoestrogens?
Null (H03): No significant increase will be found in Her2 copy numbers between
the short and long term applications of xenoestrogens.
Alternate (H13): A significant difference in Her2 copy numbers will be found
between short and long term xenoestrogenic exposures.
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The third hypothesis predicted that there would be a significant increase in Her2
copy numbers between xenoestrogens applied for a single, short-term (5 days) exposure
when compared to persistent, and long-term (50 days) applications. To test this
hypothesis, I conducted the Mann Whitney U analysis for both durations of
xenoestrogenic application (single, short-term and persistent, long-term) as the
predictor/independent variables and Her2 copy number as the dependent variable. The
results of the analysis indicated that a significant increase of Her2 copy numbers had
occurred with the increasing durations of xenoestrogenic exposures (p = .000). Also,
since the Mann Whitney U test results are two-tailed, thus the significance values for a
single-tailed experiment can be divided by two. This would make the p-value even lower
than .000 (p = <.000). Thus, the alternate hypothesis (H13) was accepted. The results are
presented in Table 18, and Figure 7 shows the representative box plot.
Table 18
Mann Whitney U Results of Her2 Copies for Short & Long-term Xenoestrogenic
Exposures
N

Mean Rank

Sum of Ranks

MWU

Wilcoxon

Z

P (2tailed)

Single, short-term (5 days)

1240

1083.25

1343235.5

573815.5

1343235.5

-11.528

.000*

Persistent, long-term (50 days)

1260

1415.09

1783014.5

Total

2500

Exposure Type & Duration

Note. N = number of nuclei scored, MWU = Mann Whitney U statistic, P = asymptotic
and 2-tailed, * and boldface numbers denote significant value (p = <.01).
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Figure 7. Box plot of Her2 copies with short-term and long-term exposures. Significant
(p = <.000) in Her2 copies were observed with persistent, long-term (exposed daily for
50 days) when compared to single, short-term exposures (cultured for 5 days) with BPA,
DDT, EE and NPH.
Incident rate ratios (IRR) of Her2 copy numbers between single, short-term and
persistent, long-term exposures were also calculated using negative binomial (NgatchouWandji & Paris, 2011). Single, short-term exposure was used as the reference. These
results found an 86% increase (IRR: 1.86, LCI = 1.78 and UCI = 1.94, p = .000*) in the
incidence of Her2 copy numbers with persistent, long-term exposures compared to
single, short-term exposure durations.
To further explore whether the increase in Her2 copy numbers occurs in some or
all of the four xenoestrogens with their application duration, I conducted the Mann
Whitney U test for each individual xenoestrogen that compared the Her2 copy numbers
between single, short-term exposure duration and persistent, long-term exposure duration.
The results of the Mann Whitney U tests for each of the 4 commonly used xenoestrogens
further showed a significant increase in the Her2 copy numbers with increasing duration
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of their use (p = .000). Thus, the alternate hypothesis (H13) was accepted for each
individual xenoestrogen. The results of this research inquiry are presented in Table 19.
Table 19
Mann Whitney U Results of Her2 Copy Numbers for Single vs. Persistent Exposures of
the Four Commonly Used Xenoestrogens
Xenoestrogen &
Exposures

N

Mean
Rank

Sum of
Ranks

MWU

Wilcoxon
W

Z

P (2-tailed)

BPA, single exposure

200

165.71

33142.5

13042.5

33142.5

-8.284

0.000*

BPA, persistent
exposures

240

266.16

63877.5

Total

440

DDT, single exposure
DDT, persistent
exposures
Total

240

206.47

49552.5

20632.5

49552.5

-5.384

0.000*

240

274.53

65887.5

EE, single exposure

240

218.16

52358

23438

52358

-3.542

0.000*

EE, persistent exposures

240

262.84

63082

Total

480

NPH, single exposure
NPH, persistent
exposures
Total

240

217.02

52084

23164

52084

-3.727

0.000*

240

263.98

63356

240

207.11

49706.5

20786.5

49706.5

-3.948

0.000*

220

256.02

56323.5

Combinatorial, single
exposure
Combinatorial, persistent
exposures
Total

480

480

460

Note. N = number of nuclei scored, Single exposure = cells were exposed to
xeneoestrogen/s once and harvested on 5th day, Persistent exposure = cells were exposed
daily with xenoestrogen/s and harvested on the 50th day, MWU = Mann Whitney U
statistic, P = asymptotic and 2-tailed, * and boldface numbers denotes significant values
(p = ≤.01).
Hypothesis 4
Research question # 4) Overall, does Her2 gene expression vary significantly
with each specific receptor type (i.e., cell line) upon exposure to xenoestrogens?
Outcome/Dependent Variable: Her2 gene copy numbers
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Predictor/Independent Variable: Receptor types/Cell lines (ER+/Her2+, ER/Her2-, ER+/Her2-, and ER-/Her2+) and Exposure durations (single, short-term vs.
multiple, long-term).
Null (H04): Her2 copy numbers will not vary significantly between the different
receptor types/cell lines upon exposure to xenoestrogens.
Alternate (H14): A significant difference will be found in the Her2 copy numbers
between the different receptor types/cell lines upon exposure to xenoestrogens.
The fourth hypothesis predicted that the magnitude or amount increase of the
Her2 copy numbers noted between the different receptor types found in the 4 lines when
they are exposed to xenoestrogens would vary significantly. To test this hypothesis, I
performed the Kruskal Wallis test using the 4 cell lines as the predictor/independent
variables and Her2 copy number as the outcome/dependent variable. These results were
found to be significant for the receptor types found in the four cell lines (p = .000). The
results from the Kruskal Wallis omnibus are represented below in Table 20.
Table 20
Kruskal Wallis Test for Her2 Signals and Different Receptors
Cell Line

Receptors

N

BT474

(ER+/Her2+)

620

1894.38

MCF7

(ER+/Her2-)

640

578.08

MDA-MB-231

(ER-/Her2-)

640

705.03

SKBR3

(ER-/Her2+)

600

1884.23

Total

Mean Rank

Chi-Square

df

P (2-tailed)

1888.416

3

0.000*

2500

Note: N = number of nuclei scored, df = degrees of freedom, P = asymptotic and 2tailed, * and boldface numbers denote significant values (p = <.01).
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Because the results of the Kruskal-Wallis omnibus were significant, post-hoc
pairwise comparisons were conducted to check for similarities in Her2 copy numbers
between the different receptor types. The pairwise analyses found significant differences
(adjusted p = ≤.005 for one-sided test, or p = <.01) for Her2 copy numbers increments
observed between all of the different pairs of receptor types found in the various lines,
except for ER-/Her2+ (SKBR3) and ER+/Her2+ (BT474) lines where the distribution of
Her2 copies were similar (adjusted p = .5 for one-sided test, or p = >.01). The results
from the post-hoc pairwise analysis for this hypothesis are represented below in Table 21.
Table 21
Post-hoc Pairwise Comparison of the Different Receptor Types and Her2 Signals
Sample 1 - Sample 2

Test Statistic

Std. Error

Std. Test Statistic

Sig.

Adj. Sig.

-126.95

40.226

-3.156

0.002

0.010*

ER+/Her2- and ER-/Her2+

-1,306.15

40.891

-31.943

0

0.000*

(MCF7 – SKBR3)
ER+/Her2- and
ER+/Her2+

1,316.30

40.549

32.462

0

0.000*

-1,179.20

40.891

-28.838

0

0.000*

1,189.35

40.549

29.331

0

0.000*

10.152

41.208

0.246

0.805

1

ER+/Her2- and ER-/Her2(MCF7 – MDA-MB-231)

(MCF7 – BT474)
ER-/Her2- and ER-/Her2+
(MDA-MB-231 – SKBR3)
ER-/Her2- and ER+/Her2+
(MDA-MB-231 – BT474)
ER-/Her2+ and
ER+/Her2+
(SKBR3 – BT474)

Note: Sig = P-value, asymptotic significance (2-tailed), Std. Error = standard error, Adj.
Sig = Adjusted P-values (2-tailed), * and boldface numbers denotes significant values (p
= ≤.01 of adjusted significance).
Each row of the table tests the hypothesis that the distributions of sample 1 and 2 are
similar.
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To further elucidate the magnitude of increase found in the different receptor
types, the IRRs were examined using the negative binomial model. Since ER+/Her2(MCF7) line showed the lowest increase in its Her2 copy number changes with exposures
(single and persistent) to the various xenoestrogens; it was used as the reference line
(1.00). The IRR results indicated that the incident rates of Her2 copy number increase for
both of the Her2 positive lines regardless of their ER receptor status (BT474: ER+/Her2+
and SKBR3: ER-/Her2+) is 30 times greater than the reference which was Her2 negative
(95% CI, BT474: 28.81 to 32.59, and SKBR3: 27.88 to 31.58, p = .000). Additionally,
the incidence rates of Her2 for the line negative (or normal) for both ER and Her2
receptors (MDA-MB-231: ER-/Her2-), showed a 44% increase (IRR: 1.44, 95% CI =
1.35 to 1.54, p = .000) in its Her2 copy numbers when compared to the reference line.
Because significant differences found were significant for all receptor types, the null
(H04) was rejected. The IRR results are represented in Table 22.
Table 22
Incidence Rate Ratios (IRR) of Her2 Copy Numbers between the Receptor Types
Receptor Type (Cell Line)

Estimate

Std.
Error

Zvalue

P-value

IRR

95% CI
LCI

ER+/Her2- (MCF7)
(Reference)

UCI

1.00

ER-/Her2+ (SKBR3)

3.39

0.03

107.42

0.00000*

29.67

27.88

31.58

ER+/Her2+ (BT474)

3.42

0.03

108.99

0.00000*

30.64

28.81

32.59

ER-/Her2- (MDA-MB-231)

0.37

0.03

10.68

0.00000*

1.44

1.35

1.54

Note. CI = confidence interval, LCI = lower confidence interval, UCI = upper confidence
interval, * and boldface denotes significant values (p = <.01).
MCF7 line was used as the reference line (1.00), because the lowest levels of Her2
increments with single and persistent exposures to xenoestrogens were noted in this cell
line.
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To check whether the Her2 gene copy numbers increased significantly for each
line with increasing exposures durations to the 4 commonly used xenoestrogens,
comparisons between the single vs. persistent exposures were made for individual lines
using the Mann Whitney U test. Highly significant results (p = <.01) were observed
between the single vs. persistent exposures for all 4 lines, hence the alternate (H14) was
accepted for all of the lines in this case. The results of the Mann Whitney U tests
conducted for this hypothesis are displayed in Table 23 below.
Table 23
Comparison of Her2 Absolute Values for Single vs. Persistent Exposures in Individual
Line
Cell Line and
Exposures

Receptor
Status

N

Mean
Rank

Sum of
Ranks

Mann
Whitney
U

Wilcoxon
W

Z

BT474, Single

ER+/Her2+

300

174.59

52377.5

7227.5

52377.5

-17.244

0.000*

280

414.69

116112.5

300

205.25

61574

16424

61574

-13.812

0.000*

MCF7, Persistent

300

395.75

118726

Total

600
300

256.35

76904

31754

76904

-6.37

0.000*

300

344.65

103396

27374.5

61304.5

-6.088

0.000*

BT474, Persistent
Total
MCF7, Single

MDA-MB-231,
Single
MDA-MB-231,
Persistent

(2-tailed)

580
ER+/Her2-

ER-/Her2-

Total
SKBR3, Single

P

600
260

235.79

61304.5

SKBR3, Persistent

ER-/Her2+

300

319.25

95775.5

Total

560

Note. N = total nuclei scored, Single = cells exposed to xeneoestrogen/s once and
harvested on 5th day, Persistent = cells exposed daily with xenoestrogen/s and harvested
on the 50th day, ER+ = Estrogen receptor positive, ER- = Estrogen receptor negative,
Her2+ = Her2 receptor positive, Her2- = Her2 receptor negative, P = asymptotic and 2tailed, * and boldface numbers denotes significant values (p = ≤.01).
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Summary
Sample characteristics and data distribution using histograms, Q-Q plots and
Shapiro-Wilk’s tests of normality all showed non-normal distribution of the dependent
variable (i.e., Her2 signals) for all four cell lines. The data were also found to be highly
dispersed, leading to a greater standard deviation (SD) than the mean values in two of the
cell lines (MCF7 and MDA-MB-231). A Levene’s test was conducted that further
evaluated the similarity in the variances of the four lines which was non-significant. This
meant that the differences in the variances between the four lines were similar. Since the
assumptions for Kruskal Wallis analysis were cleared with the non-significant result of
Levene’s test, inferential statistics using this test were then performed.
The inferential analysis of this research study data supports hypothesis 3 and 4.
Significant increase in the Her2 copies were incurred with multiple, persistent exposures
consisting of daily exposures of the xenoestrogens for 7 weeks compared to the single,
short-term exposure cultured for five days. This held true for each categorical
xenoestrogen (BPA, DDT, EE and NPH) applied individually or in combination, and for
each receptor type (ER and Her2 positive and negative). The various receptor types were
found to be significantly different in their responses to the xenoestrogens and they were
all found to incur significant increases in their Her2 values compared to the reference line
(MCF7, ER+/Her2-) that had the least amount of Her2 copy number gain.
For hypothesis 1, a similar patterns of Her2 copy number gains were noted (i.e.,
from control (unexposed) to .001nM to .01nM) with both the cell lines with ER positive
status (BT474, ER+/Her2+; and MCF7, ER+/Her2-) as was found with the overall

174
exposures for all 4 lines. However, the patterns were dissimilar with respect to the other
two lines. Here, one line (SKBR3, ER-/Her2+), the alternate was accepted, as in this line
the Her2 copy numbers did increase significantly (p = .000) with the control and each
log10 increase in concentration (i.e., control to .001nM to .01nM to .1nM); whereas the
other line (MDA-MB-231, ER-/Her2-) did show a significant increase in Her2 copies (p
= .000) between each categorical exposure concentration (i.e., .001nM to .01nM to
.1nM), but a significant gain in Her2 copy numbers did not occur between the control
(unexposed) and .001nM exposure concentration. The alternate was accepted for line
SKBR3 (ER-/Her2+) for all concentration gradients. For lines BT474 and MCF7, the
alternate was accepted for concentration increase from control (unexposed) to .001nM to
.01nM of exposures. Lastly, for MDA-MB-231 (ER-/Her2-) line, the alternate was
accepted for concentration increase from .001nM to .01nM to .1nM of exposures.
With regards to hypothesis 2, although the alternate hypothesis supported a
significant increase in the Her2 copy numbers with dissimilar concentrations of the
various xenoestrogens due to their disparate nature, but interestingly all four of the
xenoestrogens studied (BPA, DDT, EE and NPH) were observed to significantly increase
in their Her2 values at the lowest nanomolar concentration of .001nM. This also held true
for individual as well as combinatorial exposures. Thus, the null hypothesis was accepted
in this case.
The following chapter has summarized the study, discussed social change
implications of the study findings; presented the limitations of the study, pointed out
future perspectives, and presented concluding remarks.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Xenoestrogens are substances with estrogenic properties, and repeated exposures
with synthetic xenoestyrogens could chemically modulate the promotion and progression
of breast cancer (Aube, Larochelle, & Ayotte, 2013; Brody & Rudel, 2003; Valeron,
Pestano, Luzardo, Zumbado, & Boada, 2009). Her2, a proto-oncogene, is found in two
copies in a normal mammary cell and is required for its normal development and
function. However, it can mutate by amplification and become oncogenic (i.e., cancercausing gene). Also for the normal functioning of the mammary cell, crosscommunications occur between the ER and Her2 receptors at the cell’s surface, which
further activates the Her2 gene within the cell’s nucleus (Her2 gene expression) (Stoica
et al., 2003; Yang, Barnes, & Kumar, 2004), and the nuclear ER (Jung et al., 2010;
Montemurro, Di Cosimo, & Arpino, 2013). Hence, the perturbations of the ER with
repeated extrinsic xenoestrogenic exposures could perturb the Her2 proto-oncogene,
thereby converting it to an oncogene. Animal models have demonstrated a connection
between xenoestrogenic exposures and Her2 gene activity; however, the carcinogenic
potential influencing the expression of the Her2 gene upon exposures to commonly used
xenoestrogens has not been systematically examined.
Using molecular genetics techniques (FISH) with a case-control study design, this
study assessed Her2 gene expression with differential exposures to 4 commonly used
household xenoestrogens (BPA, DDT, EE, and NPH) using 4 human breast cancer lines
that were ER- and Her2-positive or -negative providing mechanistic insights to the
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carcinogenicity of these xenoestrogens and evaluated their carcinogenic potential.
Additionally, the study discerned cellular phenotypes more susceptible to aggressive
disease with exposures to these xenoestrogens.
Summary and Interpretation of Findings
In a study conducted by Calfat et al. (2005) on 1,000 participants, the authors
observed that 95% and 51% had more than 0.1microgram/Liter (µg /L) urine
concentrations of BPA and NPH respectively, indicating that people are being exposed to
at least 0.1 µg/L concentrations of BPA and NPH. In another study by Calafat et al.
(2008) consisting of over 2,500 Americans, BPA concentrations ranging from 0.4 to 149
μg/L (mean=2.6 μg/L) were found in 92.6% of the study participants. The average levels
of total BPA in male and female urine was 1.63 and 1.12 ng/ml (nanograms/milliliter)
respectively. Additionally, Vandenburg, Maffini, Sonnenschein, & Soto (2009) estimated
that adult human exposures to BPA ranged from <1 µg/Kg/day to 5 µg/Kg/day.
Collectively, these data showed that human exposures to BPA ranged anywhere from
1.12 ng/ml to 5 µg /Kg/day.
In the current study, I applied xeneoestrogens in increasing log10 ratios of
nanomolar concentrations (i.e., .001nM, .01nM, and .1nM), and observed that even the
lowest concentrations (.001nM) of xenestrogenic applications significantly increased the
Her2 copy numbers when compared to the control (p = .000). Ad hoc pairwise
comparisons found significant increase (p = .000) in every concentration category applied
(.001nM, .01nM, and .1nM), when compared to the control group.
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The incidence rate ratio (IRR) values further showed that the Her2 copy number
increase was almost twice as much (1.96, or 96% greater) with the applications of .1nM
(highest) concentrations of xenoestrogen when compared to the control. The incidence of
Her2 increase was also found to have increased with increasing concentrations applied
compared to the control. An increase of 25% (IRR: 1.25, p = .000) of Her2 copy numbers
was found in the lowest concentration of xenoestrogenic application, which steadily
increased to 58% (IRR: 1.58, p = .000) at .01nM concentration of xenoestrogenic
exposures, and capped off at 96% (1.96, p = .000) with the highest concentration (.1nM)
of xenoestrogenic applications compared to the control. Comparing the three
concentrations to the control group, there was a 33% increase (from 25% to 58%) in Her2
copy numbers between .001 and .01nM concentrations, and a 38% increase (from 58% to
96%) observed in the Her2 copies between .01 and .1nM concentrations of
xenoestrogenic exposures. Thus, it can be inferred from Hypothesis 1 that Her2 oncogene
expression had increased even with nanomolar (nM) concentrations of xenoestrogenic
applications compared to the control.
Interestingly, when comparing within the three different concentration groups, the
pairwise comparisons found that that there was a significant increase (p = .008) in the
Her2 copy numbers ascending from .001nM to .01nM concentrations; however, a
significant increase in the Her2 copy numbers was not observed (p > .05) moving from
.01nM to .1nM concentration. This further implied that the lowest concentrations could
be more lethal in the case of Her2 gene copy number gains and mutations of this gene.
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Each line used in the study constituted of different types of receptors (ER and
Her2 positive or negative) and I further wanted to assess whether each line reacts
differently to xenoestrogenic exposures. Thus, Hypothesis 1 also examined whether the
increments in Her2 copy numbers were similar or not for each receptor type with
increasing concentrations of exposures to the 4 commonly used xenoestrogens.
Interestingly, different patterns emerged for these lines. Both lines that were ER+ (i.e.,
BT474 and MCF7) showed a similar pattern as was observed with the overall
concentrations; that is, Her2 copies increased significantly until .01nM exposure
concentrations to the 4 commonly used xenoestrogens and then they became nonsignificant (control to .001nM, and .001nM to .01nM, p = .000). However, for the lines
that were ER- (i.e., MDA-MB-231 and SKBR3), the values in Her2 copy numbers had
increased significantly (p = .000) even from .01nM to .1nM concentrations of exposures
to the 4 xenoestrogens. Also, for line MDA-MB-231, there was no significant increase in
the Her2 copy numbers found between the control and .001nM concentrations of
exposures to the xenoestrogens.
Previous research has indicated that some xenoestrogens are slow-activators while
others react quickly and are fast-activators of the cellular membrane (Bulaveya &
Watson, 2004; Payne, Rajapakse, Wilkins, & Kortenkamp, 2000). Nuclear transcriptional
assays performed that assessed their potency showed that some xenoestrogens were very
weak (e.g., DDE), while others were somewhat weak (e.g., BPA), yet others were quite
strong (e.g., DES) in their estrogenic activity (Silva, Scholze, & Kortenkamp, 2007).
Together, these studies provided that even though xenoestrogens are categorically
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grouped under one umbrella, they interacted differentially within biological systems.
Also, because the biochemical nature of xenoestrogens is disparate, it follows that the
carcinogenicity of xenoestrogens used individually as well as in combination may be
quite different.
In this study, one way carcinogenicity of these four (i.e., BPA, DDT, EE, and
NPH) commonly used household xenoestrogens was assessed was by examining the
concentrations at which significant increase in Her2 copy numbers initiated and when it
plateaus off for each xenoestrogen. Keeping in mind lessons from the past research
regarding the disparity of their biochemical nature, because some (e.g., DDT) are fast
activators, whereas others (e.g., BPA and NPH) are moderate and slow activators
respectively, it was proposed in Hypothesis 2 that the four xenoestrogens would
significantly increase Her2 copies at different concentrations of exposures when
compared to the control. Further, there would be differences in concentrations at which
individual vs. combinatorial exposures significantly increased in their Her2 copy
numbers.
Surprisingly, the Mann Whitney test statistics showed that not only did all four
(BPA, DDT, EE, NPH) commonly used household xenoestrogens incurred significant (p
= .000) increases in Her2 copies at similar concentration, but this held true for individual
as well as combinatorial xenoestrogenic exposures. Additionally, the significant increase
in Her2 copies was found at the lowest concentration (.001nM, p = .000) of application
for each xenoestrogen, whether applied individually or in combination.
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Studies conducted on xenoestrogens that assessed their carcinogenicity have been
performed using cellular proliferation, reporter gene assays (estrogen and androgen
receptor genes) and transcription arrays after short-term exposures (up to a week) with
OCs and their derivatives (Aube, Larochelle, & Ayotte, 2011; Valeron Pestano, Luzardo,
Zumbado, & Boada, 2009). However, breast cancer is observed to have a long latency
period (Nadler & Zurbenko, 2013; Olsson, Baldetorp, Ferno, & Perfekt, 2003; Paez et al.,
2012), but the aforementioned studies only studied short-term exposures ranging from 1
to 9 days.
In an effort to learn regarding the long-term effects of persistent applications of
the 4 common household xenoestrogens on Her2, I subjected the 4 lines to 50 days of
exposure with these xenoestrogens. Although the breast carcinogenesis latency period is
anywhere from 20 to 30 years (Marsden, Wright, Carrier, Moroz, & Rowan, 2012; Nadler
& Zurbenko, 2013), the breast cancer cell lines could only be treated for up to 50 days,
because as per the ATCC culturing instructions, these cells may start to die after 8 weeks
(56 days) of long-term culturing. Another caveat to long-term culturing of cells was the
threat of losing all of the cells to contamination with various microbes (e.g., bacteria,
mycoplasma, mold, yeasts, and viruses) (Life Technologies, n.d.). Due to these two
reasons, for persistent, long-term exposures the four breast cancer cell lines were treated
up to 50 days with the xenoestrogens. The results of the Mann Whitney test found that a
significant increase did occur in the Her2 copy numbers with persistent, long-term
exposures (50 daily exposures) to the 4 xenoestrogens compared to the single, short-term
(5 days) exposures (p = <.000).
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Because highly significant values (p = <.000) were observed between the single,
short-term exposures and persistent, long-term exposures, I next examined how much
difference in the Her2 copy number gains had occurred between these two exposure
durations. Incidence rate ratios (IRR) were performed to compare differences in the
magnitude of increase occurs between the single, short-term and persistent, long-term
exposure durations. Almost twice as much (86% increase, IRR: 1.86, p = 0.000) Her2
copy numbers were found with the persistent, long-term exposures with the 4 commonly
used xenoestrogens compared to their single, short-term exposures. It can be inferred
from this data that persistent low-level exposures occurring for even 7 weeks caused
significant (p = .000) amounts of amplifications to the Her2 oncogene. This finding is
important since most women worldwide are being exposed on a daily basis to these
common household xenoestrogens (Cohn, 2011; Darbre & Charles, 2010; Inifo-Nunez,
Herreros, Eucinas, and Gonzalez-Bulnes, 2010; Kuch, Metzer, & von der Trenck, 2010;
Qui, Suri, Bi, Sheng, & Fu, 2010).
Individual xenoestrogens have disparate characteristics even though they all have
estrogenic properties (Payne, Rajapakse, Wilkins, & Kortenkamp, 2000; Silva, Scholze,
& Kortenkamp, 2007; Aube, Larochelle, & Ayotte, 2008), therefore Hypothesis 3 of this
study further classified whether the differences in single vs. persistent exposures
significantly increased Her2 copies in some or all of the 4 commonly used xenoestrogens.
Mann Whitney tests were conducted with each xenoestrogen applied individually or in
combinatorial exposures compared the Her2 copy numbers between single, short-term
(single exposure cultured for 5 days) and multiple, persistent exposures (daily exposures
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cultured for 50 days). The results revealed that multiple, persistent exposures to all 4
commonly used xenoestrogens (BPA, DDT, EE and NPH) regardless of whether they
were applied individually or in combination had significantly (p = .000) increased the
Her2 copy numbers when compared to single, short-term exposures.
A sentinel population study by Gammon et al. (1999) has indicated that exposures
to contraceptive pills lead to aggressive breast cancer and that these women had an
increased Her2 receptor status. Additionally, patient data also demonstrated that when
there is amplification of the Her2 oncogene, then the patient prognosis related to a more
aggressive type of breast cancer with disease progression, tumor invasion, fewer diseasefree days, and worse survival outcomes lending to its poor prognostic value (Baselga &
Swain, 2009; Gutierrez & Schiff, 2011; Johnson et al., 2012; Lindemann et al., 2007;
Slamon et al., 2011).
The 4 cell lines used in this study were ER and Her2 positive or negative.
Pairwise analysis conducted on all of the different receptor types showed that the
distribution of Her2 copy numbers were significantly different for all of the lines except
those that already had a Her2 positive status (BT474 with ER+/Her2+ status, and
SKBR3 with ER-/Her2+ status). Comparing the 4 lines, it was noted that MCF7 line with
ER+/Her2- receptors had the least amount of Her2 copy number increase, and was used
as the reference. Both of the Her2+ lines regardless of the status of the ER receptor
(BT474 and SKBR3) showed a 30 times greater Her2 copy number increment compared
to the reference, implying that women with a Her2 positive status are highly susceptible
to cancer progression with exposures to even nanomolar concentrations of these four
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commonly used xenoestrogens. Importantly, even for the MDA-MB-231 line with ER/Her2- status, it was observed that a significant increase of 44% in the Her2 copy
numbers (IRR: 1.44, p = 0.000) occurred when compared to the MCF7 line with
ER+/Her2- status. Because the ER-/Her2- status is typically found on a normal mammary
cell, this statistic can have important mechanistic implications, since it can be inferred
from these results that the Her2 negative expression had mutated via amplification and
became Her2 positive with exposures to nanomolar concentrations of the 4 commonly
used xenoestrogens (BPA, DDT, EE, and NPH). Additionally, these results indicated that
the increase in Her2 oncogenic expression is multiplicative between the various receptors
found in these 4 cell lines.
I also performed Mann Whitney analysis on each line (ER and Her2 positive or
negative), that compared the Her2 copy numbers between single, short-term exposures
(cultured for 5 days) with the multiple, persistent exposures (daily exposures for 50 days)
for individual line. The increase in the Her2 copy numbers was found to highly
significant (p = .000) in each of the 4 lines regardless of their receptor status (i.e., ER and
Her2 positive or negative).
Breast carcinogenesis occurs with the activation of oncogenes or the inactivation
of TSGs (Lee & Muller, 2010; Pitot & Dragon, 1993). Exposures to chemicals and
hormones including xenoestrogens can trigger the activation of oncogenes (Brody,
Tickner, & Rudel, 2005; Davis et al., 1993; Montemurro, Cosimo & Arpino, 2013)
provided the theoretical construct of this study. All of the results of this study validated
that exposing human mammary cells to the 4 commonly used xenoestrogens (BPA, DDT,
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EE and NPH) leads to the mutation (i.e., copy number increase/amplification) of the Her2
gene located on the long-arm of chromosome 17 in the human genome.
A pathway to breast carcinogenesis (Davis et al., 1993; Soto & Sonnenschein,
2010) hypothesized that xenoestrogens increased the estrogenicity in a mammary cell
above normal levels and this led to mutation of genes located in 17q loci. Although, this
study did not check for increases in the estrogen in mammary cells after exposing them to
xenoestrogens used in the study, however, the results confirmed that xenoestrogenic
exposures mutated the Her2 gene located in 17q (17q11.2-17q12) via copy number
gains/amplification.
Implications for Social Change
Breast cancer is the main cause of death for women worldwide with mortality
rates reaching 522,000 women in 2012 (Ferlay et al., 2014; IARC, 2013). It is the second
leading cause of cancer-related deaths for women in the U.S. (ACS, 2015; SEER, n.d.).
Currently, an estimated 2.9 million women are living with a history of breast cancer in
the United States alone (ACS, 2014; SEER, n.d.). Breast cancer care ranks the highest
amongst all cancer care expenditures, accounting for $18.1 billion of annual healthcare
cost in the United States alone (NCI, 2015a).
Synthetic xenoestrogens are partially being blamed for increase in breast cancer
incidence (Aube, Larochelle, & Ayotte, 2011; Buteau-Lozano, Velasco, Cristofari,
Balaguer, & Perrot-Applanat, 2008; Davis et al., 1997). In the case of breast cancer,
synthetic xenoestrogenic exposures are now being researched as potential risk factors,
and are considered as a modifiable lifestyle factors (Aube, Larochelle, & Ayotte, 2011;
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Rudel, Attfield, Schifano, & Brody, 2007). Synthetic xenoestrogens are found in
commercial products, and are easily available (e.g., herbicides, plastics, pesticides,
contraceptives) to women in all societies worldwide (Cohn, 2011; Darbre and Charles,
2010; Inifo-Nunez, Herreros, Eucinas, & Gonzalez-Bulnes, 2010; Kuch, Metzer, & von
der Trenck, 2010; Qui, Suri, Bi, Sheng, & Fu, 2010; Vogel, 2009).
This research has provided a GEI model that predicts the carcinogenic potential of
4 commonly used synthetic xenoestrogens (BPA, DDT, EE, and NPH) and how
exposures to these xenoestrogens affected the Her2 oncogenic expression, a biomarker of
breast carcinogenesis. Using précis dosage analysis, this study clearly demonstrated that
exposures to all 4 xenoestrogens even at .001 nanomolar (nM) concentrations resulted in
significantly increasing the Her2 oncogenic expression, regardless of whether these 4
xenoestrogens were applied individually or in combination. Also, this study found that
with the increase in the concentrations from .001 to .1nM, the incidence of Her2 copy
number increase is almost twice as much (96% increase), indicating that even low-level
increase in concentrations of these 4 synthetic xenoestrogens greatly impacted the Her2
oncogenic expression levels.
The study further indicated that highly significant increase in Her2 copies
occurred not only with daily, persistent (chronic exposures) to all 4 xenoestrogens (BPA,
DDT, EE, NPH), but also with all 4 receptor types (ER and Her2 positive or negative).
Highly significant increments in Her2 oncogenic expression was found to occur (86%
more) with persistent exposures to the 4 synthetic xenoestrogens within 7 weeks
compared to a single exposure for five days. Although, these values are a little less than
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two fold, but these persistent exposures accounted for only 7 weeks; whereas due to their
ease of availability most women worldwide are constantly being exposed to these
commonly used xenoestrogens for all or most of their lives (Cohn, 2011; Darbre and
Charles, 2010; Inifo-Nunez, Herreros, Eucinas, & Gonzalez-Bulnes, 2010; Kuch, Metzer,
& von der Trenck, 2010; Qui, Suri, Bi, Sheng, & Fu, 2010; Vogel, 2009).
Additionally, this study provided direct biological evidence to the altercations of
the Her2 oncogene upon exposures with synthetic xenoestrogens. The study
demonstrated that the Her2 mutated by the amplification of its copy numbers with
exposures to the 4 commonly used synthetic xenoestrogens. Taken together, these results
established the 4 commonly used xenoestrogens as a risk factor for breast carcinogenesis,
and this information should be useful in making policy level decisions to curtail the sale
of these synthetic xenoestrogens and encourage the use of alternate chemicals. These
results have provided valuable information for advocacy groups to educate and empower
women regarding the ill health effects even with low-level exposures to these
xenoestrogens.
Because most women around the world are constantly exposed to these synthetic
xenoestrogens due to their omnipresence, modifying these risk factors should have a
great public health impact even though they only account for low levels (less than twice)
of risk (Aube, Larochelle, & Ayotte, 2011; Brody, Tickner, & Rudel, 2005; Johnson et
al., 2012). Reducing these risk factors of breast cancer would not only affect women
worldwide by reducing its incidence and mortality, but doing so would also translate in
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reducing the indirect costs that the disease incurs on family and extended family
members, such as lost work days and wages.
The cell line data showed that women with a Her2 positive (Her2+) status are at a
very high risk (~30 times greater than Her2- status) of cancer progression with
nanomolar levels of exposures to these synthetic xenoestrogens. If these results are
corroborated in human mammary tissue samples, these findings may have implications
for women with breast cancer with a greater risk for disease progression, especially since
added Her2 amplifications does lead to a more aggressive disease type, with disease
progression, poor prognosis, and lower survival rates (Baselga & Swain, 2009; Gutierrez
& Schiff, 2011; Johnson et al., 2012; Lindemann et al., 2007; Slamon et al., 2011).
For women with breast cancer under the age of 40 (young women), the Her2
expression (Her2+) has been found to be significantly higher compared to those that are
65 years or older (11.1 vs. 9.4 respectively; p = .0001) (Assi, Khoury, Dbouk, Khalil,
Mouhieddine, & ElSaghir, 2013). An increased proportion of ER-/HER2+ with high
tumor grade occur in younger women (Anders et al., Collins et al., 2012). Younger
women with breast cancer also had higher mortality rates compared those older than 40
years (18.3% vs. 12.1% respectively, p = .001). Although women with breast cancer
under the age of 40 years constituted a small proportion (worldwide 146,660 incident
cases in 2008) of the total, this was a significant burden not only on women but society as
well since they presented with a more aggressive disease (Assi et al., 2013). Azim et al.
(2012) demonstrated that there is an age-related differential in the gene expression
associated with MAPK and PI3K growth factor signaling found especially in younger
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women, thus heightening their risk for aggressive breast cancer. Xenoestrogens and Her2
are known to use these specific signaling pathways (Jung et al., 2010; Lemmon &
Schlesinger, 2010; Serra et al., 2011). This research study has also demonstrated that the
Her2 oncogenic expression increased even with nanomolar exposures to commonly used
xenoestrogens. Taken together, these results indicated that the risk associated for
aggressive breast cancer with low-level exposures to xenoestrogens would be far greater
for younger women compared to those that are over the age of 40 years. These findings
have implications for targeted advocacy, monitoring and early intervention/s for women
under the age of 40 years.
Importantly, this study demonstrated that even with ER and Her2 negative status
(MDA-MB-231 line) a significant increase (44% more) had occurred in their Her2 copy
numbers, marking a shift in their Her2 status from Her2 negative to Her2 positive
(Her2+) at nanomolar levels of exposures and with increasing concentrations (i.e.,
.001nM to .01nM to .1nM ) to commonly used synthetic xenoestrogens. Because, ER and
Her2 negative status is found in a normal mammary cell, these results indicate that even
in a cell that has normal Her2 gene expression, the expression can change or mutate via
Her2 gene amplification upon low-levels of exposures to these xenoestrogens and
become Her2 positive and oncogenic; which ultimately would lead to breast
carcinogenesis. These findings can be generalized to all women worldwide since normal
levels of Her2 or Her2 negative (Her2-) gene status is found in a normal mammary cell.
These findings further reiterate that even at nanomolar levels of exposures of these 4
commonly used synthetic xenoestrogens are risk factors for breast carcinogenesis. These
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findings further reiterated that even at nanomolar levels of exposures of these four
commonly used synthetic xenoestrogens they are indeed risk factors for breast
carcinogenesis, and that its population-attributable risk for breast cancer is significant.
This information can be used by public health and policy-makers to impose policies that
will curtail the ease of availability and use of these xenoestrogens. Additionally, breast
cancer advocacy groups, cancer agencies, public health nurses, cancer forums and
foundations should use this information to advocate, educate and inform women against
the use of these commonly found xenoestrogens due to their imposed risks even when
used in low concentration levels. Health educators should use this information to teach
the general public; especially young girls and women about the health risks with
exposures to these commonly used xenoestrogens, thereby making the consumers privy
to this information so they can make healthier choices when buying substances that
contain these xenoestrogens.
Limitations
Although this study provided précis measurements of each categorical
xenoestrogen and the durations of their exposures, however, due to ethical reasons this
study was conducted using breast cancer cell lines from ATCC, bioresource center.
Therefore, this study did not have any data on other risk factors (e.g., genetic
predisposition of BRCA1 and 2, parity, age at menarche, lactation, reproductive history,
smoking, breast-feeding, diet, and alcohol) involved in breast carcinogenesis (Aube,
Larochelle, & Ayotte, 2011; Buteau-Lozano, Velasco, Cristofari, Balaguer, & PerrotApplanat, Davis & Sieber, 1997). Including all of these risk factors and studying how

190
they interacted with exposures to some of the commonly used xenoestrogens would
further enhance our knowledge regarding risk factor assessment and interventions against
this disease.
Only ER and Her2 positive and negative cell lines were selected for studying the
effects of these xenoestrogens, mainly because xenoestrogens are thought to exert their
effects via the ER (Mercado-Feliciano & Bigsby, 2008; Stoica et al., 2003), then the ER
cross-communicate with Her2, and these two receptors are known to be the main drivers
of breast carcinogenesis (Gutierrez & Stoica, 2011). But, other receptors, such as the
insulin growth factor receptors, progesterone receptors, and androgenic receptors are also
found in the mammary cell. Thus, the generalizability of this study is limited to the
interactions of ER and Her2 receptors only with exposures to the 4 commonly used
xenoestrogens.
Lastly, because of the threat of losing the cell lines to either contamination or cell
death due to viability of cells in long-term culturing (ATCC; Gibco, Life Technologies),
this study was only be conducted for 7 weeks in order to study the long-term effects of
the 4 commonly used synthetic xenoestrogens. Because breast cancer has a long latency
period that could last up to 28 years (Marsden, Wright, Carrier, Moroz, & Rowan, 2012;
Nadler & Zurbenko, 2013; Paez et al., 2011), this study mimicked persistent long-term
exposures by daily exposing the cell lines to the four commonly used xenoestrogens for
50 days and examine their effects on Her2 gene expression.
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Future Perspectives
Based on the findings of this study, and due to the high reproducibility of FISH, it
would be beneficial to use FISH technology in the future to study direct gene expression
on fresh tissue samples using a hospital-based case-control design to study the effects of
commonly used xenoestrogens and incorporating other breast cancer risk factors (e.g.,
genetic predisposition, smoking, alcohol, diet, lactation, age at menarche). Here, the
patient exposures to the xenoestrogens can be assessed using gas chromatography or
mass spectrometry (Boada et al., 2012; Charlier et al., 2003; Cohn, Wolff, Cirillo, &
Scholtz, 2007; Hoyer, Jorgensen, Grandjean, & Hartvig, 2000, Hoyer et al; 2000; Hoyer,
Jorgensen, Rank, & Grandjean, 2001; Warner et al., 2002). Although Her2 is an
important biomarker of breast carcinogenesis, using FISH technology for future studies
would allow the incorporation of other genes in conjunction with Her2, such as p53, a
TSG also known to be involved in breast carcinogenesis and could be affected with
exposures to xenoestrogens (Davis et al., 1993; Soto and Sonnenschein, 2010)).
Because breast cancer is the main cause of death for women worldwide (IARC,
2013), and it is the second leading cause of death in women in the United States (CDC,
2014), using the aforementioned study design to perform survival analysis will also aid in
providing important data and insights regarding breast carcinogenesis and mortality due
to exposures to these xenoestrogens.
Conclusion
Breast cancer is still a public health concern (Aube, Larochelle, & Ayotte, 2011;
Valeron, Pestano, Luzardo, Zumbado, & Boada, 2009). This study has biological
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underpinnings and provides mechanistic insights that exposures to the 4 commonly used
xenoestrogens (BPA, DDT, EE and NPH) incur changes in the Her2 oncogene, a
biomarker of breast carcinogenesis and aggressive disease via its copy number
increase/gene amplification.
All the results of this study provide direct evidence of changes incurred to the
Her2 oncogene even with low-levels (nanomolar concentrations) of exposures to all 4
xenoestrogens, and that Her2 copies increase significantly with daily exposures within
short time span of 7 weeks (persistent, long-term exposures). A normal mammary cell
expresses only two copies of the Her2 gene and is Her2- (Grusko et al., 2002).
Importantly, this data also indicates that Her2 negative mammary cells can become Her2
positive with exposures to synthetic xenoestrogens. This phenomena was observed in the
lines that were Her2 negative (MDA-MB-231 and MCF7), but with xenoestrogenic
exposures their Her2 copy numbers increase significantly (p = <.000), thereby shifting
their Her2 status from Her2-negative to Her2-positive. As Her2 negative (Her2-) status
can be generalized to all women worldwide, this data should help regulatory agencies to
recognize the potential risk posed by even the low-levels of exposures to these
xenoestrogens and apply the precautionary principle, either by substituting these
chemicals with others that are not harmful to health or banning their sale to curtail their
usage.
The epidemiology of Her2 suggests that an increased proportion of ER-/Her2+
breast cancer with high tumor grade is found in younger women (<40 years) compared to
those that are older (Anders et al., Collins et al., 2012). This study also discerned that the
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women with a Her2 positive status are at the highest risk of disease progression to a more
aggressive disease type with exposures to these xenoestrogens. Cancer advocacy groups,
and public health nurses should inform and educate these women with the potential risks
with exposures to these 4 commonly used xenoestrogens and breast cancer progression.
Furthermore, because women with a Her2 positive status are at the greatest risk of
disease progression with exposures to these commonly used xenoestrogens, they should
regularly be monitored for their Her2 levels even if their Her2status changes with
therapy.
In all, this research improved our understanding of the molecular mechanisms
underlying breast cancer pathogenesis and progression with exposures to the 4 commonly
used xenoestrogens. Future breast cancer prevention efforts should benefit from this
study in the following ways; first, this study will bring about awareness of the importance
of avoiding or reducing exposures to the 4 commonly used xenoestrogens, and; second,
by increasing our understanding that some women due to their greater genetic based
sensitivity would need increased medical surveillance in order to intervene before the
occurrence of a more serious disease condition. Because these xenoestrogens are found
all over the world and the two receptor types incorporated in the study design are
common to all women around the globe, these findings would help not only our
immediate community in the fight against breast cancer, but our global community as
well.
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